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The 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) has 
remained at ~50% for over 50 years. HNSCC is categorised by multiple anatomical 
sites, but oral (oral SCC) and oropharyngeal squamous cell carcinoma (OPSCC) 
account for approximately 90% of all cases. At the time of writing, only one 
targeted agent, cetuximab (a monoclonal antibody targeting the epithelial 
growth factor receptor), has been approved for the treatment of 
recurrent/metastatic HNSCC. However, despite the high expression of EGFR in 
oral SCC tumour samples, the clinical benefit of cetuximab has been modest thus 
far. Using a phenotypic screening approach, I sought to identify putative 
therapeutic targets. 
A whole genome siRNA screen carried out using an aggressive patient-derived 
cell line (‘Liv7k’) in normoxic and hypoxic conditions provided the foundation for 
this project. In addition, a drug-repurposing screen tested the efficacy of 1,351 
compounds, approved for cancer and non-cancer indications. A number of 
approaches were used to identify potential targets, including a whole genome 
siRNA screen in normoxic and hypoxic conditions, a drug-repurposing screen, and 
a data multiplexing approach combining the two screens with pathway analysis 
and datasets from The Cancer Genome Atlas and the International Cancer 
Genome Consortium.  
Genomic characterisation of oral cancer cell lines confirmed the importance of a 
previously identified frequently amplified region of chromosome three, which 
contains a number of driver genes in HNSCC. In addition, a differential 
susceptibility of oral SCC cells in hypoxia formed the basis of a line of inquiry 
centred on triglyceride and ether lipid metabolism. Finally, compound screening 
identified a dependence of oral SCCs on cysteinyl leukotriene signalling, which is 
involved in inflammatory conditions such as asthma.  
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Chapter 1 Introduction 
Head and neck cancer is the sixth most common cancer in the world with more 
than 11,000 new cases in the UK in 2014[1, 2]. More than 90% of head and neck 
cancers are squamous cell carcinomas (head and neck squamous cell carcinoma; 
HNSCC)[3], and these are further categorised by biological subsite, HPV status 
and TNM stage. Current five-year survival rates have lingered at approximately 
50% for decades in patients where spread to regional lymph nodes has 
occurred[4]. Metastasis, abetted by late presentation and detection, is the 
major factor leading to the failure of treatment in head and neck patients[5, 6], 
and in contrast to other solid tumours, head and neck tumours spread almost 
exclusively lymphatically[7].  
The mainstay treatment for HNSCC remains (often disfiguring) surgery with 
adjuvant chemo/radiotherapy. At the time of writing, only one targeted therapy 
has been approved for the treatment of local recurrent/metastatic HNSCC. In 
2006, cetuximab (Erbitux; Bristol-Myers Squibb, NY, USA) a humanised 
monoclonal antibody targeting epithelial growth factor receptor (EGFR) was 
approved. However, given the strong evidence for the importance of EGFR in 
HNSCC progression, the overall improvement in patient survival upon cetuximab 
treatment has been modest. Overexpression of the protein occurs in more than 
90% of cases and is predictive of a poor prognosis[8], however combined 
cetuximab and radiotherapy led to only a 10% overall survival benefit versus 
radiotherapy alone[9-11].  
Pembrolizumab (Keytruda; Merck & Co. Inc, Kenilworth, NJ, USA), is an immune 
modifying therapy which has been approved for use in unresectable, metastatic 
melanoma (2014)[12], non-small cell lung cancer (2014)[13] and in HNSCC 
(2016)[14]. The humanised monoclonal antibody binds programmed cell death 
protein 1 (PD-1) receptor on the surface of T cells and prevents their binding to 
PD-L1 and PD-L2 on tumour cells, thus stimulating T-cell mediated tumour cell 
destruction[12]. Its approval in recurrent and/or metastatic HNSCC was 
accelerated based on early results of the phase 1b KEYNOTE-012 trial, which 
showed an overall response rate (ORR) of 18%[14]. A later phase II clinical trial 
(KEYNOTE-055) which sought to assess the efficacy of pembrolizumab in patients 
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who were refectory to cetuximab treatment showed an ORR of 16%[15]. More 
recently, its use has extended to cover any solid tumour with mismatch repair 
deficiency or high microsatellite instability. This is because tumours with high 
mutation rates have increased levels of abnormal antigens and are therefore 
more responsive to immune modulation[16]. Another immune checkpoint 
inhibitor, nivolumab (Opvido), was approved later in 2016 following on from the 
successful phase III CheckMate-141 trial[17]. Ongoing phase III trials are 
encouraging but further studies are required to understand the full potential of 
immunotherapy in HNSCC. 
1.1 Disease Characterisation 
1.1.1 Anatomic Definition 
The primary focus of this body of work is oral squamous cell carcinoma (oral 
SCC), which represents 38% of head and neck cancers in males and 50% in 
females[2]. The disease encompasses multiple anatomic sites, including the lip, 
buccal mucosa, anterior two thirds of the tongue, upper and lower gingiva, the 
floor of the mouth and the hard palate (ICD-10: C00-06)[18]. The base of the 
tongue, the squamous-lined tonsils (palatine and lingual), the side and back 
walls of throat and the soft palate are classified as oropharyngeal cancer (ICD-
10: C09-10) and were not investigated in this study. Individual subsites have 
varying degrees of access to local venous and lymphatic systems, and are 
therefore accompanied by different risk factors and treatment options. While 
these classifications serve as a useful guide, there is no internationally agreed 
anatomical definition of oral SCC in the wider literature and data from multiple 
sites are often combined. Where possible, it has been specified whether a 
referenced study focused specifically on squamous cell carcinomas of the oral 
cavity or HNSCCs in general. 
1.1.2 Epidemiology 
Although the highest prevalence of oral SCC is seen in the over 65 age bracket, 
there has been a dramatic rise in younger populations (<45 years) in recent 
years[19]. Socio-economic factors weigh heavily on these statistics, with alcohol 
and smoking cooperatively exacerbating risk[20]. However, the increased 
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incidence largely reflects an atypical younger population who have minimal 
exposure to the classic risk factors[21-24]. HPV has an established role in 
oropharyngeal cancer, with up to 70% of these patients testing positive for the 
virus[25, 26]. However, HPV is predominantly absent in oral SCC. Moreover, 
those patients presenting with HPV-positive tumours generally have a more 
favourable prognosis, even in recurrence[27-29], suggesting a distinct disease 
aetiology. Despite this, current evidence suggests that cetuximab and 
pembrolizumab benefit patients with either HPV status[30]. 
The complexity of HNSCC is further compounded by the intrinsic heterogeneity 
of the disease, as revealed by molecular analyses[31-34]. The last decade has 
seen the release of an unprecedented amount of genomic characterisation, 
thanks to projects such as The Cancer Genome Atlas (TCGA) and the 
International Cancer Genome Consortium (ICGC). This freely available data has 
vastly improved the understanding of disease processes and opened the door to a 
number of innovative personalised therapeutic strategies. To date, HNSCC has 
not truly benefitted from this wealth of information, when compared to the 
leaps made in the molecular subtyping of other cancer types[35, 36]. This 
project capitalises on large sequencing datasets in order to help identify novel 
molecular subtypes. 
1.1.3 TNM Staging 
Oral SCCs are defined clinically by the TNM (Tumour, Node and Metastasis) 
system, which allows for the successful management of disease prognosis. The 
three factors relate to: (1) the primary tumour, including size and location; (2) 
the extent of nodal involvement; and (3) the presence of distant metastasis. 
Tumour and nodal status are staged from 1-4, with sub-classifications a, b or c 
(Table 1.1). For example, T4aN2aM0 indicates a moderately advanced tumour 
with local invasion into tongue muscle or mandible and involving more than one 
lymph node. The oral cavity is one of the most common sites of SCC incidence, 
owing to its exposure to external carcinogens. Primary treatment for most 
tumours is surgery, often in combination with radiotherapy with postoperative 
chemotherapy to improve local disease control. Platinum-based therapies such 
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as 5-flurouracil and cisplatin have a modest impact on patient survival and 
decrease time to recurrence[37].  
Primary Tumour (T) 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour <2cm in greatest dimension 
T2 Tumour 2-4cm in greatest dimension 
T3 Tumour >4cm in greatest dimension 
T4a Moderately advanced local disease, with invasion into cortical bone, deep extrinsic muscle of the tongue, maxillary sinus, or skin of face 
T4b Very advanced local disease, with invasion into masticator space, pterygoid plates, or skull base and/or encases internal carotid artery 
Regional Lymph Nodes (N) 
Nx Nodal involvement cannot be assessed 
N1 No regional lymph node involvement 
N2 Metastasis in a single ipsilateral lymph node, <3cm in greatest 
dimension 
N2a 
Metastasis in a single ipsilateral lymph node 3-6cm in greatest 
dimension; or in multiple ipsilateral nodes, none >6cm; or in bilateral 
or contralateral nodes, none >6cm 
N2b Metastasis in a single ipsilateral lymph node 3-6cm in greatest 
dimension 
N2c Metastasis in a multiple ipsilateral lymph nodes, none >6cm in 
greatest dimension 
N3 Metastasis in a bilateral/contralateral lymph nodes, none >6cm in 
greatest dimension 
Distant Metastasis (M) 
Mx Distant metastasis cannot be assessed 
M0 No evidence of distant metastasis 
M1 Distant metastasis 
Table 1.1 TNM Staging (American Joint Committee on Cancer, AJCC). 
 
Lymph node metastasis is estimated to occur in approximately 40% of oral cancer 
patients[38]. The proximity of the oral SCCs to regional lymph nodes has a major 
impact on rate of recurrence and distant metastasis of tumour cells, with one 
study finding cervical lymph node metastasis in ~62% of T3/T4 tumours[39]. 
Extracapsular spread (ECS) is another major prognostic factor in oral SCC. Its 
significance is widely recognised in the prognosis of oral cancer, with average 5-
year survival dropping to 24% in patients with ECS in cervical lymph nodes[40]. 
So far, ECS has not been shown to predict worse disease-free survival in HPV-
positive or negative oral SCCs[41]. There are approximately 300 lymph nodes in 
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the neck, which are classified by their location. These are the submental and 
submandibular group, the upper jugular group, the middle jugular group, the 
lower jugular group, the posterior triangle group and the anterior compartment 
[42](Figure 1.1). 
 




1.2 Hallmarks of Head and Cancer 
Hanahan and Weinberg’s “Hallmarks of Cancer” (Figure 1.2) describe the eight 
defining features of all cancers, which are enabled by genome instability and 
inflammation[43]. These hallmarks underpin the development and progression of 
HNSCC, which remains a major therapeutic challenge. This introduction touches 
on many of these defining characteristics but focuses primarily on three key 
hallmarks: genomic instability, deregulated metabolism and inflammation. 
HNSCC is a highly heterogeneous cancer, characterised by mutations and somatic 
copy number alterations[44]. This is an underlying reason for treatment failure, 
and explains why so many targeted therapies fail to bring wide-reaching benefit, 
despite success in pre-clinical studies[45].  
Genomic instability is exaggerated by another defining feature of solid tumours 
such as HNSCC. Hypoxia, which occurs when tumour growth outpaces that of 
oxygen and nutrient supplying blood vessels, brings about a strong selective 
pressure on cells[46]. Hypoxia promotes a more aggressive phenotype that is 
associated with resistance to chemo/radiotherapy[47]. Lack of oxygen also 
perturbs cellular metabolism, which forms the second major theme of this 
thesis. These changes in energy utilisation are a direct result of successive 
genetic alterations and limited availability of nutrients and include a shift to a 
glycolytic phenotype and increased production of lipids[48]. Herein, a subset of 
genes involved in triglyceride metabolism was identified as part of an unbiased 
genomic screen. Maintaining a steady supply of lipids is essential to the survival 
of rapidly proliferating cells. Lipids exist in a wide variety of forms owing to 
different lengths of fatty acid chains and the position and number of double 
bonds. This multiplicity allows lipids to play a range of roles within the cell, 
including as cell membrane constituents, second messengers in signalling and 
storage of energy[49]. 
Finally, an FDA-approved compound screen led to the identification of a class of 
non-steroidal anti-inflammatory drugs (NSAIDs), which caused >90% growth 
inhibition in oral SCC cell lines. Tumour growth is dependent on the surrounding 
extracellular matrix and the ancillary processes that occur within it[50]. 
Infiltrating immune cells can facilitate tumour development through the release 
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of cytokines and growth factors that promote tumour growth and promote 
invasion[51]. Moreover, it has been shown that NSAIDs can impair the growth and 
development of HNSCCs[52]. This introduction reviews the known roles of 
inflammation in HNSCC and presents novel findings from in vivo work targeting a 
major inflammatory pathway. 
  




1.3 Molecular Landscape 
Head and neck cancer is a highly heterogeneous disease, with genetic variation 
between patient tumour samples and within the tumour itself, and accounts for 
approximately 550,000 cases and 380,000 deaths every year[53]. However, at 
present, complete and standardised genomic profiles exist for just 522 patients 
in TCGA dataset – a snapshot of the overall situation. Like most solid tumours, 
HNSCC occurs through a series of genetic alterations, which occur over an 
individual’s lifetime. Epigenetic mechanisms also play a key role (although have 
not been investigated further here). There are two functional classes of genetic 
alteration: somatic mutation and structural variation. 
1.3.1 Somatic Mutation 
Several key alterations in HNSCC had been discovered before the widespread 
implementation of high throughput platforms for gene expression analysis, with 
the most frequent being those found in TP53 (17p13), a tumour suppressor gene 
in which activating mutations are known to play an important role in the 
pathogenesis of HPV-negative HNSCC[44]. Loss-of-function mutations in TP53 are 
almost universal and are recognised as one of the earliest genetic alterations in 
HNSCC[54].  
Also common are inactivating deletions or mutations in CDKN2A (9p21), which 
occur in >50% of HNSCC tumours, and amplification of CCND1 (11q13), found in 
approximately one third of HPV-negative HNSCCs[55, 56]. In addition, up to one 
third of HNSCCs harbour activating mutations in the oncogenic PI3K pathway, 
with the largest percentage occurring in the PIK3CA gene (3q26)[57]. PTEN, a 
negative regulator of the PI3K pathway and tumour suppressor gene is also 
frequently lost or downregulated in aggressive HNSCC[54, 58, 59].  
As a result of sequencing data, inactivating mutations in NOTCH1 have been 
confirmed in 10-15% of HNSCCs[44, 60, 61], suggesting a tumour suppressor role, 
a function validated in several studies[62-64]. However, NOTCH1 dysregulation is 
more complicated than mere loss-of-function. Increased NOTCH pathway 
signalling occurs in approximately one third of HNSCCs, and is accompanied by 
an oncogenic phenotype[65-67].  
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The NOTCH1 gene encodes a transmembrane receptor which belongs to a family 
of interrelated signalling molecules which can regulate many aspects of cell 
biology, including stem cell renewal[68], proliferation and cell survival[69]. In 
oral SCC tumours, NOTCH1 is localised at the invasive edge where its expression 
is positively correlated with lymph node metastasis and depth of local 
invasion[69-71]. Furthermore, inhibition or knockdown of NOTCH1 reduces cell 
proliferation and invasion[69, 72]. The conflicting roles of NOTCH1 are likely 
influenced by the presence of other genetic alterations and the surrounding 
microenvironment[73, 74]. 
1.3.2 Structural Variations 
HNSCCs exhibit a high degree of chromosomal instability, which contributes to 
the vast heterogeneity of the disease and represents a major clinical challenge. 
Structural variations occur frequently through mutational mechanisms, including 
errors in DNA recombination, replication and repair processes[75]. These include 
insertions, deletions, duplications, translocations and inversions, all of which 
can lead to changes in gene copy number. Originally, structural variation was 
defined as a genomic alteration involving a segment of DNA larger than 1 Kb; 
however improvements in detection have led to a revision of this definition to 
include changes involving more than 50 base pairs[76]. In contrast, insertions 
and deletions (INDELs) normally involve only a few base pairs. 
Copy number alteration (CNA) refers to copy number changes occurring in 
somatic cells and should not to be confused with copy number variation (CNV) 
which is germline in origin. A recent analysis of 3,299 tumour samples spanning 
12 cancer types revealed two major classes of genetic alteration in cancer that 
are characterised by recurrent somatic mutation (M class) or copy number 
alteration (C class), with HNSCC primarily falling under the latter category[77]. 
Using various techniques, a high incidence of LOH/deletion on chromosomes 3p, 
5q, 8p, 9p and 18q[78-80] and high levels of gain/amplification on 3q, 5p, 7p, 8q 
and 11q have been identified in HNSCC, many of which have been confirmed in 
recent years utilising high-throughput sequencing methods. 
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1.3.2.1 Epithelial Growth Factor Receptor (EGFR) 
Focal amplification of 7p11.2 occurs in approximately 31% of HNSCCs[81]. The 
region is home to the gene encoding EGFR, a receptor tyrosine kinase which is 
expressed in over 90% of HNSCCs[82]. Increased protein expression of EGFR is 
observed early in carcinogenesis, and increases with the degree of dysplasia[83]. 
Protein overexpression has been shown to occur in a similar percentage of oral 
SCC samples[84-86]. Moreover, EGFR has been repeatedly verified as a negative 
prognostic indicator in HNSCC with its overexpression correlating with 
significantly decreased overall and disease-free survival in addition to high rates 
of loco-regional relapse[87]. Similar findings are found in patients with tumours 
with increased EGFR copy number[88, 89].  Activation of EGFR signalling brings 
about a malignant phenotype which is characterised by enhanced angiogenesis, 
decreased apoptosis and a propensity to metastasize to local and distant 
sites[90]. This is achieved through activation of downstream signalling pathways 
such as AKT, STAT3 and MAPK[91-94]. Despite a solid biological rationale to 
target EGFR, inhibitors of the receptor have met with limited success as a 
monotherapy, indicating a requirement for additional therapeutics in this 
disease.  
1.3.3 Summary 
A number of studies have sought to capitalise on recent technological advances 
in order to associate key molecular alterations to specific pathological traits. 
Overall, a complex pattern of chromosomal alteration has emerged in which the 
gains and losses commonly observed in HNSCC translates into clinically relevant 
prognoses, and correlates with poorer survival in patients[95]. While some of 
these regions contain key oncogenes and tumour suppressor genes, the 
importance of other regions to disease progression is currently unknown[96].  
Distinguishing driver mutations from randomly occurring passenger mutations 
(which result from a higher basal rate of alteration in tumour cells), remains a 
challenge[97]. A driver mutation has a causal role in oncogenesis and confers a 
growth advantage to the tumour cell that is passed on to daughter cells, 
allowing it to alter core processes, overcome cell cycle restriction and activate 
survival and invasion pathways[43]. In contrast, passenger mutations are not 
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selected for and generally do not confer a growth advantage. These somatic 
mutations are passed on with no functional consequence[98]. In addition, 
facilitator mutation events, which are not oncogenic by themselves, often 
promote the genetic diversity that enables tumour cells to overcome restrictions 
on their growth. The difficulty is in distinguishing the types of mutation, which 
relies largely on measuring how randomly they are distributed. Inevitably, a 
number of mutations will be falsely classified and should be interpreted with 
caution. Consolidation of driver mutations is achieved by investigating their 
phenotypic consequence. 
1.4 Genetic Progression  
1.4.1 Precursor Lesions 
Genetic alterations occur in a stepwise progression, accompanied by 
macroscopic changes in the oral mucosa known as precursor lesions. The most 
common of these is the appearance of a white patch on the mucosal lining 
termed oral leukoplakia. These lesions occur in approximately 1.5% of the 
population and are associated with an increased risk of malignant 
transformation[99]. The rate of development into invasive carcinoma differs 
depending on population cohort and variation in assessment, but it is currently 
thought that ~1% of leukoplakia make the transition into oral SCC[99]. 
By the time leukoplakias are visible to the naked eye, the cells will have 
undergone a number of histological and genetic alterations. The first genetic 
multi-step progression model of HNSCC was proposed in 1996 (updated in Figure 
1.3). The model provides a link between instances of chromosomal loss and 
histopathological observations in early and late stage tumours.   
1.4.2 Field cancerisation 
Early genetic changes can also be present in the macroscopically normal 
epithelium surrounding lesions[100]. ‘Field Cancerisation’ describes the 
existence of a pre-neoplastic field of epithelium outside the surgical margins 
defined by macroscopically visible lesions[101]. The field arises from a single 
cell which develops a genetic alteration and clonally expands, later giving rise to 
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a secondary invasive carcinoma[102, 103]. Slaughter et al. was the first to link 
the existence of such fields to the high propensity of HNSCCs to recur in 
patients[104]. An analysis of macroscopically normal mucosa surrounding HNSCC 
revealed genetic alteration in 36% of patients[105]. HNSCCs have the second 
highest percentage of multiple primary tumours (15%) of all cancer types[106].   
However, fixed linear models of progression, such as that in Figure 1.3, do not 
fully capture the heterogeneous nature of HNSCC, which has been shown to 
involve multiple molecular routes to a metastatic endpoint.   
 
 
Figure 1.3 Genetic progression model of HNSCC. Chromosomal regions with frequent copy 
number alterations are presented, along with associated oncogenes or tumour suppressors. 
NOTCH1 has been reported as both an oncogene and tumour suppressor gene in HNSCC, 





1.4.2 Major Copy Number Events in HNSCC 
Somatic copy number alterations affect a larger proportion of the cancer 
genome than any other type of genetic alteration[108]. Much like somatic 
mutations, it is important to distinguish driver events that contribute to cancer 
progression from passenger events that are acquired throughout the lifetime of a 
tumour, but do not impart a phenologic change[109]. Driver CNAs that provide a 
growth advantage occur more often and similar patterns of alteration are seen in 
cancers of similar tissue types[110]. Copy number alterations can be divided into 
“arm-level” events encompassing entire arms or smaller “focal” events, which 
occur within a specific region[111]. Additional copies of certain genes can lead 
to over activity of the protein product. Oncogenes are often activated in this 
way and lead to cellular transformation. Figure 1.4 shows the most significant 
chromosomal alteration events in HNSCC, according to GISTIC 2.0 analysis[112]. 
Amplification of chromosome 3q26-29 is a defining feature of squamous type 
cancers and is estimated to occur in up to 75% of HNSCCs[113]. The region 
contains a number of established and prospective oncogenes, including PIK3CA, 
TP63 and SOX2[114-116]. Furthermore, it has a demonstrated ability to enhance 
migration and invasion and is consistently associated with a poor prognosis in 
HNSCC patients[117-119]. The 3q26-29 amplicon forms a major part of this 
project and will be discussed further in chapters four, five and six. In particular, 






Figure 1.4 Major arm-level and focal copy number alterations in HNSCC. (A) Graphical 
representation of significant chromosomal alterations in HNSCC in TCGA dataset, as determined 
by GISTIC 2.0, n = 279 samples (green = amplification; red = deletion, yellow, both). Vertical lines 
represent arm level events and rectangles depict focal alterations with significance set at a q-value 
= 0.25. (B) Major focal copy number alterations in HNSCC. GISTIC 2.0 analysis reveals 36 
significantly recurring deletion events and 26 amplification events, ranked by descending residual 






1.5 IGF Signalling in HNSCC 
3q26-29 copy number amplification is the most frequent genomic alteration in 
HNSCC and is universally associated with a poor prognosis[113]. Whole exome 
sequencing revealed the presence of this amplicon in a number of oral SCC cell 
lines used in this project. Subsequent analysis of the region identified a number 
of genes, which are highly significant for survival in patients (TCGA HNSCC 
dataset). The most significant gene in terms of overall survival was insulin-like 
growth factor 2 binding protein 2 (IGF2BP2). In the cell, IGF2BP2 binds to and 
stabilises specific gene transcripts, thus regulating their translation. One of the 
confirmed targets of the gene is insulin-like growth factor 2 (IGF2), which acts 
through the IGF1 receptor (IGF1R) to activate downstream growth and survival 
pathways. A central aim of this project was to determine if IGF2BP2 acts as a 
key driver gene in HNSCC progression. 
1.5.1 Overview 
The IGF signalling pathway represents a very attractive target in cancer therapy, 
however effective inhibition of the network has proven challenging. To date, 
most inhibitors have IGF1R, a heterodimeric transmembrane receptor that is 
associated with poorer survival in advanced stage oral SCC [120] and is 
preferentially overexpressed in HPV-negative HNSCC[121]. IGF1R was found to 
be significantly expressed in a series of oral cancer biopsies taken from patients 
prior to treatment[122]. Moreover, it has been shown that elevated expression 
of IGF1R, in combination with its binding protein, IGFBP3, correlates with a 
significantly shorter time to progression in HNSCC[123]. In vivo studies also 
support a role for IGF1R in tumour progression. Constitutive activity of IGF1R led 
to the rapid induction of tumours in a transgenic mice model, while a small-
molecule inhibitor of the receptor reduced the tumour burden[124]. Conversely, 
deletion of IGF1R or genetic reduction of circulating IGF1 has been shown to 
negate tumour progression[125, 126]. 
The IGF1R receptor is composed of two extracellular α subunits which mediate 
ligand binding and two transmembrane β subunits with tyrosine kinase activity 
(Figure 1.5)[127]. There is a 60% amino acid sequence homology between the 
IGF1R receptor and the insulin receptor (IR)[128], which allows the formation of 
33 
 
hybrid receptors which can bind both IGF ligands[129]. Ligand binding of IGF1 or 
IGF2 to IGF1R (or hybrid/insulin receptors) leads to autophosphorylation of the 
receptor and activation of insulin receptor substrate (IRS)[130]. There are six 
distinct IRS proteins but IRS-1/2 mediate most of the downstream 
signalling[131]. Phosphorylation of IRS-1 at Tyr612 activates the p85 regulatory 
subunit of PI3K and subsequently AKT[132, 133], while phosphorylation at Tyr896 
promotes binding of Grb2 and activation of the MAPK pathway[134]. AKT 
activation frees mTOR from tuberous sclerosis complex 2 (TSC2)-driven 
inhibition, thus promoting cell growth and survival[135]. PI3K activity is 
negatively regulated through PTEN-mediated dephosphorisation of PIP3[136], 
however the PTEN tumour suppressor gene is commonly mutated/deleted in 
HNSCC (8-23% of cases)[44, 137]. 
 
Figure 1.5 Insulin Signalling in HNSCC. An overview of the insulin signalling pathway, depicting 
the interaction of IGF-binding proteins with IGF ligands, IGF ligand-receptor binding and targeted 




1.5.2 Clinical Trials 
Despite promising pre-clinical results, IGF1R inhibitors and monoclonal 
antibodies have lacked efficacy in human trials. One such monoclonal therapy, 
figitumumab, provided no benefit to patients with palliative HNSCC in a phase II 
clinical study[138].  Another phase II trial assessing cixutumumab (IMC-A12) in 
combination with cetuximab is ongoing in HNSCC patients (ClinicalTrials.gov 
identifier: NCT00957853), however the same regimen held no benefit for 
colorectal cancer patients[139]. In fact, lack of efficiency has led to early 
termination in some trials and one phase II study comparing cetuximab 
with/without the dual IGF1R/IR inhibitor OSI-906 (ClinicalTrials.gov 
identifier:NCT01427205) was withdrawn prior to enrolment. 
A possible reason for the failure of IGF1R inhibition is the compensatory action 
of homologous receptors, such as IR or hybrid receptors. High IR to IGF1R ratios 
have been associated with IGF1R inhibitor resistance[140, 141]. Indeed, the 
stimulation of IR can maintain cellular proliferation in the absence of 
IGF1R[142]. Furthermore, downregulation of IR in LCC6 cells was shown to 
reduce the growth rate of xenografts in athymic mice independently of 
IGF1R[143]. Dual blockade of IGF1R and IR tyrosine kinase activity is a feasible 
therapeutic option[144] and has been shown to synergise with approved 
cytotoxic agents as well as targeted Src-kinase inhibition and hormonal 
modulation[145-147].  
Crosstalk with other growth factor receptors can also contribute to treatment 
failure. Upregulation of EGFR is associated with resistance to IGF1R inhibition in 
vitro and vice versa[148, 149]. Barnes et al. showed that stimulation with either 
IGF or EGF resulted in heterodimerisation of both IGF1R and EGFR and that 
simultaneous blockade of the receptors lead to a greater reduction in cellular 
proliferation and migration than single receptor inhibition[150]. In support of 
this resistance mechanism, EGF-EGFR binding was shown to directly 
phosphorylate IRS and activate AKT and MAPK pathways, independently of 
IGF1R[151]. However, other studies have found that dual inhibition of IGF1R and 
EGFR provided no added benefit[152].  
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Combination with other forms of therapy has also yielded positive results. 
Concurrent administration of ganitumab (AMG-479) and panitumumab with 
radiation resulted in significantly higher rates of success than the use of either 
given alone with radiotherapy[153]. 
1.5.3 IGF binding proteins 
IGF2BP2 belongs to a conserved family of three mRNA-binding proteins, IGF2BP1, 
IGF2BP2 and IGF2BP3 (also known as IMP1, IMP2 and IMP3), which bind multiple 
gene transcripts with unique and overlapping functions[154]. Expression of the 
gene family is predominantly embryonic, but is often upregulated in aggressive 
cancer[155]. IGF2BP2 is the most divergent family member with moderate to 
high expression in a wide range of adult tissues, including the testis, colon and 
kidneys[156].  
Alternative translational initiation gives rise to two isoforms of IGF2BP2 with 
molecular weights of 62 and 66kDa[157]. IGF2BPs contain four C-terminal K-
homology (KH) domains which bind RNA transcripts[158] and two N-terminal RNA 
recognition motifs (RRMs) which stabilise the interaction[159]. The process 
involves the formation of large, granular complexes called ribonucleoprotein 
(RNPs) which facilitate the transport of transcripts to their target destination, 
while maintaining the integrity of mRNA molecules[160]. 
1.5.4 Regulation of IGF2BP2 
While a comprehensive network of IGF2BP2 interactions has yet to be 
completed, recent studies suggest an important role for high-mobility-group A2 
(HMGA2). HMGA2 is a transcription factor which exhibits a very similar 
expression pattern to IGF2BP2 and is correlated with decreased overall survival 
in HNSCC[161]. Embryonic HMGA2 has been shown to regulate the level of 
IGF2BP2 mRNA in the cell, and promote its transcription in cooperation with 
NFKB1[162, 163]. Furthermore, IGF2BP2 is significantly downregulated in HMGA2 
knockout mice, which exhibit impaired skeletal muscle development and 
reduced myoblast proliferation. Rescuing of this phenotype was partially 
achieved by overexpressing IGF2BP2 in knockout myocytes[164]. The study also 
found that knockdown of IGF2BP2 led to reduced protein expression of c-MYC 
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and IGF1R but did not alter mRNA expression of these genes. This suggests that 
IGF2BP2 alters the rate at which mRNAs are translated without affecting overall 
mRNA levels. 
In the last decade, microRNAs (miRNAs) have garnered increasing interest in 
cancer research stemming from their role as regulators of gene expression[165]. 
Luciferase gene reporting revealed that miR-1193 directly targets the 3’UTR of 
IGF2BP2 and reduces its expression in breast cancer. miR-1193 mediated 
suppression of IGF2BP2 led to deactivation of the PI3K and ERK signalling 
pathways and a significant diminution of proliferative and invasive 
capacity[166]. 
A recent global miRNA profiling analysis of 51 locally advanced HNSCC tumour 
samples reported consistent downregulation of Let-7 miRNA family members, 
Let-7a and Let-7c[167]. In line with this, Let-7 miRNAs have been shown to 
negatively regulate the expression of IGF2BP2, HMGA2, CCND1 and IGF1R[168]. 
The study also showed that the RNA binding protein, Lin28bc can inhibit Let-7, 
thus upregulating the expression of its target genes, including IGF2BP2. 
Importantly, the expression of Lin28b, IGF2BP2 and IGF2 are significantly 
correlated with high rates of disease relapse[168]. 
The same Lin28b/Let-7 axis was later shown to drive oncogenic SOX2 expression 
in HNSCC, where it reprograms cells to a stem-like state[169, 170]. Stem cells 
are capable of initiating and sustaining tumour growth, thus they represent a 
valuable therapeutic target in HNSCC[171]. This supports previous findings that 
Let-7 negatively regulates expression of stemness genes[172]. Interestingly, 
stemness is maintained in Let-7 expressing primary GBM cultures in the absence 
of Lin28b, suggesting other mechanisms must exist to preserve tumour cell 
stemness[173]. IGF2BP2 has been shown to protect Let-7 target transcripts 
(including HMGA2) from gene silencing. Loss of tumour-initiating capacity 
incurred by IGF2BP2 depletion was restored by overexpressing Lin28b[173, 174]. 
Disruption of this reciprocal relationship between Let-7 miRNA and IGF2BP2 
could be important in the promotion of HNSCC tumour progression. 
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1.5.5 Target Transcripts of IGF2BP2 
At present, little has been confirmed about the role of IGF2BP2 in cancer, but 
there is mounting evidence that it facilitates oncogene expression[175-177]. As 
one of 422 predicted RNA-binding proteins in mammalian cells, IGF2BP2 could 
potentially regulate the translation of numerous gene transcripts with wide 
ranging cellular functions[178]. The range of roles carried out by an RNA-binding 
protein is include pre-mRNA splicing, post-transcriptional modification, and 
regulation of translation. The key question is what its target transcripts within a 
cell are, and following on from this, does IGF2BP2 bind different targets in 
different cancer types? 
Janiszewska et al. employed a RIP-CHIP microarray in glioblastoma spheroid 
cultures and found approximately 400 transcripts that were bound to the 
IGF2BP2-RNP complex with a significant overrepresentation of genes involved in 
mitochondrial metabolism[179]. A number of IGF2BP2 binding partners have also 
been identified in mouse myoblasts, including MYC, SP1, IGF1R, CCNG1, 
NOTCH2, CDK6, AKT3, MDM2, KI67, ARF1, and MAPK1[164]. Surprisingly, no 
strong IGF2BP2-IGF2 binding was observed in these cells. A similar study in 
colorectal cancer revealed IGF2BP2 binding of MAPK1, EFF2F, RAF1, SP1, CCNB1, 
CCNA2, NUCKS1 and importantly, IGF2. However, IGF2 was the least enriched of 
the aforementioned gene transcripts[175]. 
IGF2BP2 binds to and stabilises IGF2 mRNA within the cell, positively regulating 
its translation[180]. Like IGF1, IGF2 is a major growth factor involved in 
development as evidenced by growth retardation in mice lacking it[181]. Mature 
IGF2 is a 7.5 kDa peptide growth factor produced mainly in the liver, but it can 
be secreted by most tissues where it acts in an autocrine or paracrine 
manner[182]. Like IGF2BP2, it is highly expressed in the embryonic tissue where 
it promotes foetal growth, and its expression declines rapidly after birth[183]. 
While IGF2 is a major growth factor in the prenatal state, IGF1 takes over during 
post-natal development and remains until puberty[184].  
The growth factor is able to exert its effects through binding and activating 
either the IGF1 receptor (IGF1R), insulin receptor A (IR-A) or heterodimeric 
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IGF1R/IR-A[185-187]. IGF2R specifically binds IGF2, but lacks an intracellular 
tyrosine kinase domain required for signalling. IGF2R is responsible for regulating 
IGF2 levels in the extracellular matrix, thus acting as a negative regulator of its 
mitogenic activity[188, 189]. Circulating levels of IGF2 are regulated by 
interactions with secreted IGFBPs, which stabilise the growth factor and limit its 
bioavailability for other receptors as unbound IGF2 has a half-life of only a few 
minutes[190, 191]. The majority of circulating IGF2 is bound to IGFBP3 and a 
glycoprotein called acid-labile subunit (ALS), and to a smaller extent, 
IGFBP5[192, 193]. IGFBPs and IGF2BPs interact widely with IGF-independent 
ligands and thus are capable of both promoting and suppressing tumour 
progression[194]. 
1.5.6 IGF2BP2 in cancer 
While re-expression of IGF2BP1 and IGF2BP3 has been observed in a number of 
aggressive malignancies[195-197], studies on IGF2BP2 have mainly focused on its 
putative role in type II diabetes[198, 199] and an unrelated role in the regulation 
of smooth muscle cell adhesion and motility[200]. Since the original discovery 
that the p62 splice variant of IGF2BP2 elicits an auto-antibody response in 
hepatocellular carcinoma (HCC)[201], other immune responses have been 
documented in oesophageal adenocarcinoma (ESCC) and breast cancer[202, 
203]. Elevated expression of IGF2BP2 has also been correlated with higher rates 
of metastasis and shorter survival in oesophageal adenocarcinoma[176]. In 
addition, IGF2BP2 was recently shown to promote colorectal cancer cell 
proliferation by protecting RAF1 mRNA from miR-195 mediated 
degradation[175]. RAF1 is an essential component of the mitogen-activated 
protein kinase (MAPK) pathway, where it phosphorylates and activates the 
mitogen-activated protein kinase (MEK)-1/2, which in turn phosphorylate and 
activate extracellular-related kinase (ERK)-1/2[204, 205]. 
The gene is frequently overexpressed in glioblastoma multiforme (GBM)[206, 
207] where it has been shown to control oxidative phosphorylation in stem cells 
through stabilisation of gene transcripts involved in the mitochondrial 
respiratory chain[179]. Further evidence suggests that IGF2BP2 modulates GBM 
progression through an IGF2-IGF1R-PI3K axis[177]. Interestingly, IGF2BP2 also 
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inhibits translation of the mitochondrial transport protein, uncoupling protein-1 
(UCP1), in breast cancer[208]. This preferential interaction of IGF2BP2 with 
mRNA components of mitochondrial complex could provide the metabolic link 
between its involvements in cancer, obesity and type-II diabetes[209]. 
Enhanced invasion is a key hallmark of cancer, and is often a precursor to full-
blown metastasis. Epithelial to mesenchymal transition (EMT) describes a 
process in which an adherent epithelial cell acquires a more motile phenotype 
and is underwritten by a series of molecular alterations[210]. The loss of E-
cadherin (encoded by CDH1) is one such alteration and is driven by 
transcriptional repressors such as Snail (SNAI1) and Slug (SNAI2)[211, 212].  
IGF2BP2 is implicated in the EMT process in breast cancer[213] and its 
overexpression has been shown to enhance the invasive phenotype of GBM 
through modulation of EMT components[177]. Moreover, knockdown of IGF2BP2 
led to a reduced ability of cells to migrate and invade. A key upstream regulator 
of IGF2BP2, HMGA2, was recently shown to be essential for TGFβ-mediated EMT 
in breast cancer where it localises at the invasive front of tumour cells and 
regulates Snail expression[214, 215]. In addition, overexpression of HMGA2 has 
been strongly correlated with HNSCC progression and survival where it 
upregulates Snail and promotes EMT[216]. 
1.5.7 Summary 
It is clear that IGF2BP2 is not merely a passive reservoir of IGFs, but exerts 
control over a multitude of genes with wide-reaching consequences throughout 
the cell. Expression analyses have revealed elevated expression of IGF2BP2 in 
tumour compared to normal tissue and a carcinogenic role has already been 
established in certain cancer types. Through its regulation of IGF2 and 
subsequent activation of downstream oncogenic signalling nodes, IGF2BP2 has 
been shown to promote cell growth and survival in addition to maintaining 
metabolic integrity. However, a role in head and neck cancer has yet to be 
assessed. Herein, the process of IGF2BP2 identification from a comprehensive 
analysis of patient data combined with genomic screening, and validation of its 
phenologic influence in a series of patient-derived HNSCC cell lines is described.  
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1.6 The Significance of Hypoxia 
One of the primary aims of this thesis was to identify genes that were selectively 
essential in hypoxia. To this end, a whole genome siRNA screen was carried out 
to determine genes, which are selectively essential in hypoxia. These genes 
represented ~10% of the total 18,075 genes knocked down. However, a more 
manageable number of hits were needed to follow up so the results of the siRNA 
screen were combined with pathway analysis to determine if these genes had 
common functions in the cell. The top hit returned a subset of genes involved in 
the metabolism of fatty acids and cholesterol biosynthesis. The importance of 
hypoxia and lipid metabolism in HNSCC is discussed in the remainder of the 
introduction. 
1.6.1 Clinical Definition 
Hypoxia results from the tumour mass growing faster than the vascular supply, 
leading to regions with a decreased supply of nutrients and oxygen[217, 218]. 
Hypoxia is a defining feature of solid tumours, including head and neck 
cancers[219, 220]. There is a strong correlation between tumour volume and the 
degree of hypoxia in HNSCC tumours and hypoxic tumour volume is an 
independent prognostic factor for survival in patients [221]. Approximately two 
thirds of TCGA primary HNSCC tumours are stage 3 or 4, which suggests that at 
least this many tumour samples are hypoxic to some degree[54]. 
Well-oxygenated peripheral tissue generally has an oxygen tension of 
approximately 40 mmHg (5% O2)[222]. Tumours are considered to be hypoxic 
when the oxygen tension within the tumour falls below that of the surrounding 
tissue and is generally accepted to be ≤8 mmHg (1% O2), however a cellular 
response to hypoxia can be activated anywhere below 5% O2, and the exact 
value will vary between different tumours[223]. The diffusion limit of oxygen 
falls between 70-200µm from the nearest blood vessel[223]. This diffusion limit 
also applies to anti-cancer drugs, which often fail to penetrate the tumour mass 
and reach internal cells at a lethal concentration (Figure 1.6). In addition, 





Figure 1.6 Oxygen diffusion gradient in a solid tumour. (A) Diagram shows tumour cells in 
relation to the nearest blood vessel and the extracellular matrix (ECM). Anti-cancer drugs fail to 
reach isolated tumour cells furthest from blood supply. (B) The partial oxygen pressure (pO2) drops 
from 40 mmHg in peripheral tissue to less than 5 mmHg in tumours and is accompanied by a drop 






1.6.2 Transcriptional Regulation by HIF-1A 
Hypoxia exerts a strong selective pressure on tumour cells, promoting genomic 
instability and increasing rates of mutation[225]. This in turn drives a more 
aggressive phenotype with enhanced proliferative, invasive and metastatic 
potential[226]. Hypoxia-responsive genes are estimated to make up about 1.5% 
of the human genome and effect wide-ranging adaptive changes to aid cells in 
their survival of a low oxygen environment[227]. Genetic changes occur 
predominantly, but not exclusively through hypoxia inducible factor-1α (HIF-
1α)[228]. 
HIF-1α is the master regulator of hypoxia. It exists as a dimer with HIF-1β (not 
induced by hypoxia) and acts as a transcription factor, which binds to hypoxia 
response elements (HREs) in the promoter region of target genes. At normal 
oxygen tension, HIF-1α is kept under a constant state of hydroxylation and is 
marked for destruction by the von Hippel-Lindau protein (VHL)[229, 230]. This 
hydroxylation cannot occur in low oxygen, leading to stabilisation of HIF-1α and 
increased transcription of genes containing a HRE (Figure 1.7)[46].  
 
Figure 1.7 The fate of HIF-1α in the cell. (A) HIF-1α is rapidly degraded in normoxic conditions 
via hydroxylation by prolyl hydroxylase-domain enzymes (PHDs), recruitment of VHL and 
subsequent ubiquitination/proteasomal degradation. (B) In hypoxia, HIF-1A binds hypoxia-





In addition, the activation of HNSCC oncogenes such as PIK3CA, and loss of 
tumour suppressors such as PTEN, can compensate for the degradation of HIF-1α 
in oxygenated environments by increasing its translation[231]. This highlights the 
tumour cell’s dependence on HIF-1α to maintain an aggressive phenotype under 
conditions of stress. To date, no HIF-1α inhibitors have been approved for use in 
cancer due to their lack of efficacy or low tolerability. The tumour 
microenvironment produces discrepancies between in vitro and in vivo efficacy 
studies, often resulting in clinical failure. In addition to the challenge of 
delivery, no robust hypoxic marker exists for the preselection of patients with 
high HIF-1α activity[232]. 
The significance of low oxygen has been well documented within a metabolic 
context where it exerts great physiological stress on tumour cells, requiring 
adaptation in order to best utilise the limited oxygen available[233, 234]. One of 
the outcomes of this is an increased reliance on glycolysis as the primary means 
of ATP production rather than (the more efficient) oxidative phosphorylation. 
Interestingly, this preference is also observed in areas of tumours which are not 
oxygen limited, in a process termed “aerobic glycolysis”[235]. This has led to 
the conclusion that the glycolytic phenotype confers a survival advantage to 
tumour cells, despite the lower output of ATP and the acidification of the 
surrounding extracellular matrix (ECM)[236].  
The evolutionary drive to survive in these low oxygen/ATP/pH conditions occurs 
in the early stages of tumour formation, when the tumour epithelial boundary 
expands beyond the oxygen diffusion limit (>70-200µm) [236, 237]. The scarce 
resources drives the selection of cells favouring those less sensitive to growth 
restraints and therefore more capable of survival in low oxygen, acidic 
environments[238]. This is supported by the upregulation of H+ transporters in 
cancer cells[239], in addition to increased expression of high performance 
glucose transporters (e.g. GLUT1)[240]. Lactate production and the resulting 
acidification of the surrounding ECM have also been shown to enhance invasion 
and stimulate the activation of tumour-associated macrophages[241, 242].  
To date, two major hypoxic gene signatures have been developed. Winters et al. 
developed a 99-gene set that was shown to be a significant prognostic factor for 
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recurrence-free survival in HNSCC patients[243]. Toustrup et al. developed a 15-
gene hypoxic classifier set in HNSCC (Table 1.2), based on the gene expression 
profiles of cell lines exposed in vitro to different oxygen and pH levels, and 
followed up with in vivo xenograft studies[244, 245]. The list predominantly 
comprises genes involved in cell metabolism, stress response and apoptosis. 
ALDOA, which codes for a glycolytic enzyme and catalyses the conversion of 
fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate, is frequently upregulated in oral SCC [246] but has not as yet been 
linked to patient outcome. Higher expression of SLC2A1 (GLUT1) is consistently 
associated with a poor prognosis in patients with oral SCC [240, 247] while 
HNSCC cells treated with a GLUT1 inhibitor demonstrate enhanced 
chemosensitivity to cisplatin[248]. 
Hypoxia Responsive Genes 
ADM C3orf28 P4HA1 
ALDOA EGLN3 P4HA2 
ANKRD37 KCTD11 PDK1 
BNIP3 LOX PFKFB3 
BNIP3L NDRG1 SLC2A1 
Table 1.2 Hypoxia gene classifier set. Gene set developed by Toustrup et al. [244]. 
 
1.6.3 Hypoxia and Clinical Failure 
Tumour hypoxia is consistently correlated with poorer prognosis in HNSCC, and is 
a major determinant of resistance to chemo/radiotherapy[249]. A large multi-
centre study of 397 patients with HNSCC found that overall survival was 
significantly impaired in tumours with pre-treatment oxygen tensions of less 
than 2.5 mmHg[250]. Concomitant chemo/radiotherapy is the cornerstone 
postoperative treatment for HNSCC patients, and despite improving the 
prognosis of patients with locally advanced disease[251], recurrence occurs in 
>50% of patients with stage 3/4 tumours, in which the median survival is <12 
months[252]. In normoxic tissue, the high oxygen tension acts as a 
radiosensitising agent by prolonging the lifespan of the highly reactive hydroxyl 
radicals produced when tightly bound electrons are removed from water in the 
sheath surrounding DNA (radiolysis)[253]. These free radicals cause damage to 
DNA in the form of double strand breaks (DSBs), single strand breaks (SSBs), DNA 
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base damage and DNA-DNA/DNA-protein crosslinking[254]. In hypoxic tissue, 
fewer hydroxyl radicals are produced, thus decreasing the frequency of DNA 
damaging events. 
Rapidly dividing tumour cells are more vulnerable to DNA damage than normal 
cells with their lower turnover. Radioresistance arises when oxygen tension 
drops to ≤5 mmHg in HNSCC tumours[253], although less severe oxygen levels are 
sufficient to cause a multitude of gene expression changes[255, 256]. It has been 
demonstrated in head and neck cancer that hypoxic radioresistance can be 
counteracted by hypoxia modifying approaches, such as treating with 
nitroimidazoles (which mimic oxygen during irradiation) [257] or by increasing 
oxygen delivery to the affected area, potentially via the ARCON (accelerated 
fractionated radiotherapy with carbogen and nicotinamide) strategy[258]. The 
high cytotoxicity of the drugs has hampered their implementation at a clinically 
relevant dose[259], but there has been a small, but significant improvement in 
locoregional control over radiotherapy alone[260]. 
Cells in hypoxic conditions can exhibit resistance to drugs, primarily owing to 
their distance from blood vessels, which can decrease the effective 
concentration to which they are exposed [261], depending on the structure and 
metabolic stability of the drug. In addition, some drugs require oxygen in order 
to be maximally cytotoxic (e.g. bleomycin)[262]. A study by Yoshiba et al. 
showed that hypoxia was able to induce resistance to 5-flurouracil in oral cancer 
cells by inducing cell cycle arrest at the G1/S transition phase[263]. Similarly, 
knockdown of GLUT1 in a panel of oral cancer cell lines sensitised hypoxic cells 
to cisplatin-mediated apoptosis[264]. Cells in a hypoxic environment exhibit a 
slower cell cycle progression, which enhances their resistance to anticancer 
drugs[265]. Furthermore, the selection pressure exerted by hypoxia favours cells 
expressing mutant p53, as p53-dependent apoptosis will eliminate susceptible 
cells with wild-type p53[225], thus decreasing sensitivity to treatment. In this 





Hypoxia is one of the defining characteristics of head and neck squamous  cell 
carcinoma, and one of the major causes of the chemo/radioresistance and the 
resulting poor prognosis. Identifying pathways involved the hypoxic response 
(HIF-1α dependent or not) and how they influence the behaviour of tumour cells 
and the surrounding extracellular matrix, is essential if the efficacy of therapies 
are to be improved. To some extent, hypoxia underpins every hallmark of cancer 
by promoting genomic instability. This, in turn, drives the selection of cells with 
an aggressive phenotype that are highly adapted to their harsh environment. The 
role of hypoxia in HNSCC has been extensively studied and this has shown that it 
carries a consistently negative prognosis. This is compounded by the lack of a 
robust biomarker in the clinic, which will impede the implementation of 
targeted therapies. To this end, hypoxic gene signatures have been developed 
that can successfully predict treatment outcome. However, this approach is 
limited by highly heterogenous tumours such as HNSCCs. This study seeks to 
identify genes that are not only highly expressed in hypoxia, but are also 




1.7 Lipid Metabolism 
Hypoxia creates an environment in which a tumour cell must adapt in order to 
survive. Immediate changes occur in cellular metabolism in order to compensate 
for the loss of ATP resulting from decreased oxidative phosphorylation[267]. To 
date, most metabolism studies in cancer have focused on changes in glucose and 
glutamine; however, the roles of lipids in tumour progression are increasingly 
recognised. Implementation of an unbiased genomic screen has identified a 
subset of genes involved in triglyceride metabolism, with potential importance 
in HNSCC progression. In addition, the role of a class of lipids known as ether 
lipids (plasmalogens), which are present at higher levels in tumours than normal 
tissue[268], is investigated in a panel of oral SCC cell lines. 
1.7.1 Fatty Acid Metabolism 
A number of metabolic changes occur in cells undergoing malignant 
transformation, including a switch to a glycolytic energy profile, heightened 
glutaminolysis and an increase in de novo fatty synthesis[269-271]. 
Reprogramming of lipid metabolism is increasingly recognised as a hallmark of 
cancer and involves the fining-tuning of synthesis, storage and degradation of 
triglycerides (TGs), phospholipids (PLs), cholesterols (CLs) and cholesterol esters 
(CEs)[272]. Figure 1.8 provides a graphical overview of the key events in lipid 
metabolism. Free fatty acids (FAs) are the essential building blocks for the 
synthesis of membrane lipids and lipid second messengers such as 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), as well as acting as substrates 
for energy production[273]. FAs can come from exogenous sources in the diet or 
can be synthesised de novo in the cytoplasm. 
 
              
Figure 1.8 Overview of lipid metabolism. 
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1.7.2 Fatty Acid Synthesis 
Sterol regulatory element-binding proteins (SREBPs) are transcription factors 
which act as master regulators of lipid metabolism by controlling the synthesis of 
FAs, TGs and CLs[274]. Three isoforms exist in mammalian cells (SREBP-1a, -1c 
and -2), with distinct but overlapping roles, and encoded by SREBP-1a/1c and 
SREBP2, respectively[275]. Fatty acids are primarily synthesized from 
tricarboxylic acid (TCA) cycle-derived citrate, which is converted to 
oxaloacetate and acetyl-CoA by ATP citrate lyase (ACLY). Acetyl-CoA is then 
carboxylated to malonyl-CoA by acetyl-CoA carboxylase (ACC) and condensed to 
palmitate by fatty acid synthase (FASN). This basic, 16-carbon FA can be 
elongated and desaturated to various degrees, generating a wide range of FAs 
with different functionalities[276]. In order to become biologically active, a FA 
must gain one molecule of coenzyme A in a two-step reaction catalysed by acyl-
CoA synthetase (ACS). In this form, FAs can be further modified to triglycerides 
through esterification with glycerol and stored in lipid droplets for future use. 
There are currently 26 genes encoding ACS enzymes, which are categorised 
according to the length of the acyl chain they generate[277].  
At this stage, fatty acid chains are completely saturated and must gain at least 
one double bond in order to perform their complete range of functions. The 
insertion of a cis double bond at the delta-9 position of short chain fatty acids 
(C-16, C-18) is catalysed by stearoyl-CoA desaturase (SCD) and significantly 
alters the physical properties of FAs[278]. There are two SCD isoforms in 
mammalian cells - SCD1 and SCD5. The former is the most extensively studied 
and its overexpression has been implicated in a number of human cancers[279]. 
Limiting the supply of fatty acids by blocking their synthesis or decreasing their 
release from storage could prove to be an effective strategy for slowing tumour 
cell proliferation. Inhibition of enzymes required for the synthesis of fatty acids 
should theoretically limit tumour cell growth while having a negligible effect on 
normal cells. 
Indeed, knockdown or inhibition of ACLY in cancer cell lines has been shown to 
limit in vitro proliferation and survival as well as in vivo xenograft growth[280, 
281]. Similarly, ACC1 knockdown induced apoptosis in prostate and breast 
cancer, but not in non-malignant control cells[282, 283]. However, knockdown 
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of either of the two ACC isoforms, ACC1 and ACC2, was shown to accelerate 
proliferation in lung cancer cells by maintaining NAPDH generation in the 
absence of AMP-activated protein kinase (AMPK)[284]. Increased FASN expression 
has been reported in HNSCC[285, 286] and its expression is linked with tumour 
metastasis and recurrence[287]. Likewise, high levels of phosphorylated ACC is 
correlated with decreased overall survival in HNSCC patients[288]. FASN has 
been the focus of a number of drug discovery efforts leading to the generation of 
specific inhibitors (e.g. C75) which has been shown to have an effect on cancer 
cell proliferation and viability[289-291]. In HNSCC, inhibition of FASN sensitises 
cells to radiotherapy[292] . However, their development has been plagued by 
poor pharmacokinetics and off-target toxicities[293, 294].  
SCD1 inhibition or knockdown has been shown to induce apoptosis in malignant 
cell lines of the lung and hypopharynx when cultured in reduced serum in a 
response attributed to the ER stress pathway[295]. A similar study found that 
SCD1 inhibition caused apoptosis in colorectal cancer cells via stimulation of the 
ceramide synthesis pathway[296]. Endogenous levels of ceramide (a sphingosine 
attached to a fatty acid chain) are increased under stresses such as hypoxia or 
radio/chemotherapy[297, 298]. Ceramide expression is consistently lower in 
HNSCCs compared to normal or pre-malignant keratinocytes and is inversely 
correlated with rates of nodal metastasis[299, 300]. Moreover, treatment with 
ceramide enhanced the cell killing effect of paclitaxel and knockdown of 
ceramide synthase led to apoptotic resistance in HNSCC cells[301, 302]. 
1.7.3 Dynamic Lipid Storage 
De novo lipogenesis is essential for the dynamic remodelling of lipid membranes 
required for rapidly proliferating cells. Cancer cells, with their rapid 
proliferation rates are heavily dependent on de novo synthesis, favouring this 
method over extracellular scavenging of fatty acids[303]. However, cancer cells 
retain their dynamism through a complementary lipolytic pathway that can 
liberate free fatty acids from neutral and phospholipid stores (lipid droplets) 
when needed for lipid-mediated intracellular signalling[49]. Elevated numbers of 
lipid droplets are commonly observed in tumour cells and have been correlated 
to the malignant potential of cancers[304-307]. The stepwise synthesis of 
triglycerides is catalysed by monoacylglycerol and diacylglycerol acyltransferases 
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(MGATs and DGATs) of which a number of isoforms exist depending on cellular 
context[308, 309]. An alternative pathway, the glycerol-3-phosphate pathway 
(G-3-P), exists, but both pathways converge on the final step to generate 
TGs[310].  
The breakdown of TGs is mediated by an antagonistically acting set of enzymes, 
including hormone-sensitive lipase (LIPE), adipose triglyceride lipase (ATGL)[311] 
and monoacylglycerol lipase (MGLL), which governs the final step in the lipolytic 
cascade resulting in the generation of FAs and glycerol. The enzyme has been 
shown to be tumourigenic in ovarian, breast and melanoma by liberating FAs to 
serve as building blocks for lipid signalling molecules such as lysophosphatidic 
acid (LPA) and prostaglandins (e.g. PGE2), which effect a diverse lipid signalling 
network thus stimulating survival, migration and invasion[312]. The authors of 
this study also showed that inhibition of MGLL simultaneously stimulates anti-
tumourigenic cannabinoid pathways and depresses pro-tumourigenic lipid 
signalling in aggressive prostate cancer[313].  
Other studies have shown the blockade of MGLL inhibits the proliferation of 
colorectal cancer cells in vitro[314, 315] and attenuate the growth of colorectal 
and hepatocellular carcinoma xenografts in vivo[316, 317]. Furthermore, MGLL is 
able to promote a more invasive phenotype in nasopharyngeal carcinoma 
through positive regulation of EMT proteins[318]. Conversely, a tumour 
suppressive role for MGLL was reported in colorectal cancer, where it negatively 
regulates PI3K/AKT signalling[319], which serves to highlight the complexity of 
the signalling networks involved. While current evidence strongly favours an 
oncogenic role, it is possible that MGLL has dual roles in cell growth regulation 
depending on cellular context. Clearly, more work is needed to affirm its role in 
cancer progression. 
1.7.4 The Role of Hypoxia in Lipid Metabolism 
Fluctuations in oxygen levels may drive the selection of cells that are able to 
switch between anabolic and catabolic processes[320, 321]. Hypoxia increases 
fatty acid synthesis and FASN expression through the activation of AKT and 
SREBP1. FASN protein was recently shown to localise to hypoxic regions in breast 
cancer xenografts[322]. Increasingly, evidence suggests that aggressive tumours 
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are highly reliant on acetate as a carbon source in the generation of lipids. A 
recent study showed that a short chain variant of ACS, cytoplasmic acetyl-CoA 
synthetase (ACSS2), becomes essential under metabolically limiting conditions 
such as hypoxia.  
In the absence of oxygen, entry of pyruvate into the TCA cycle is inhibited and 
acetyl-CoA must be generated from other sources. An alternative source is the 
condensation of acetate by ACSS2, which is stimulated in hypoxia-induced 
metabolic stress[323, 324]. Furthermore, its expression is positively correlated 
with tumour stage and patient survival and it was recently identified as a critical 
enzyme for the growth and survival of breast cancer cells screened in low 
oxygen and low serum[325]. A follow up study found that knockout of ACSS2 
inhibited growth of breast cancer xenografts inhibited in mice[325]. Loss of 
ACCS2 was also shown to reduce tumour burden in a genetic mouse model of 
hepatocellular carcinoma[326]. Additional compensation of lipogenesis comes 
from increased uptake of exogenous lipids in hypoxia and the promotion of lipid 
droplet formation[327]. Lipids stored in droplets can also be deployed as an 
antioxidant buffer if there is a sudden increase in available oxygen[328]. 
Cancer cells thrive on an abundance of fatty acids, which they use for membrane 
building, energy storage and production of signalling molecules[329]. Various 
competing mechanisms exist to regulate the synthesis, storage and release of 
fatty acids from lipid storage droplets[330]. The correct functioning of this 
system revolves around the action of enzymes, which are vulnerable to hijacking 
by aberrant signalling processes in cancer. However, this dependence on 
enzymes to catalyse rate-limiting steps in lipid metabolism also leaves cancer 
cells vulnerable to targeted therapeutics, which selectively target highly 
proliferative cells. As ever, the vast heterogeneity of cancers may undermine 
this approach through differential expression of various isoforms, crosstalk with 
other signalling networks and other compensatory measures including the 
development of resistance. Successful application will require studying the 
specific metabolic dysregulations of any given tumour. 
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1.7.5 Lipid Rafts and Metastasis 
Cell membranes consist of a variety of lipid structures, the proportions of which 
influence the fluidity of the membrane[331]. Lipid rafts are low-density 
membrane domains, which consist of tightly packed saturated fatty acids in the 
form of sphingolipids and cholesterol (Figure 1.9). Lipid rafts also act as 
platforms for signalling molecules and facilitate the transduction of cell death 
and/or survival signals throughout the cell[332]. These include the insulin and 
EGF receptors, which play a major role in HNSCC progression[333]. 
 
Figure 1.9 Structure of a lipid raft. Lipid rafts are membrane domains that are rich in certain lipid 
species such as sphingosine, cholesterol and gangliosides. Lipids within the structure are very 
tightly packed, leading to the formation of distinct “floating” rafts that can diffuse freely throughout 
the plasma membrane. Lipid rafts are dynamic structures, capable of rapid assembly and 
disassembly, and contain a number of transmembrane proteins (TMP) and 
glycosylphosphatidylinositols (GPI). PC, phosphatidylcholine; PE, phosphatidylethanolamine; GA, 
gangliosides; PS, phosphatidylserine; CL, cholesterol; PI, phosphatidylinositol; SP, sphingomyelin. 
 
Dynamic reorganisation of lipid raft domains in cell membranes has been shown 
to influence the response of HNSCC cells to radiation treatment[334]. Radiation 
and other cellular insults such as cisplatin stimulate the reorganisation of these 
domains, and the recruitment of receptors such as FasR/CD95 or EGFR[335]. 
Moreover, elevated levels of cholesterol have been observed in oral SCC tumour 
compared to normal tissue[336], while elevated levels of sphingosine kinase 1 
(SPHK1), which catalyses the phosphorylation of sphingosine, have been 
implicated in HNSCC invasion through positive regulation of EGFR and 
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STAT3[337]. The metabolism of the major sphingolipid component, ceramide, 
has been shown to play an important part in HNSCC pathogenesis[338]. The 
levels of C18-ceramide were significantly decreased in advanced HNSCCs 
compared to normal tissue and correlated with increased nodal invasion and 
metastasis[300]. Ceramide is a potent inducer of apoptosis and has been shown 
to enhance the growth inhibition effect of paclitaxel in in vitro HNSCC 
assays[301, 339]. 
1.7.6 Summary 
Lipids represent an important source of energy for the cell, and are an essential 
biosynthetic resource. The structural variation of fatty acids gives rise to a 
number of lipid species with different characteristics. The relative ratios of 
these lipids dictate membrane fluidity and function and can influence tumour 
cell migration and invasion[340]. De novo lipid synthesis is an essential process in 
tumour development and generates up to 95% of the lipids required by the 
rapidly dividing cells[341]. Neutral lipids such as triglycerides are stored in lipid 
droplets, which are vital for survival under energy stress and are frequently 
found in higher numbers in tumour cells[305]. Recently, it was shown that 
cancer stem cells have a higher ratio of unsaturated versus saturated fatty acids 
and that this ratio is essential for the maintenance of stemness[342]. Interfering 
with the lipogenic process was shown to impair stemness and tumour initiation 
capacity in ovarian cancer stem cells[343]. A complete picture of how metabolic 
alterations sustain an aggressive phenotype in HNSCC has yet to emerge, as 
research in this field is limited. However, an increased requirement for lipids is 
common to all cancer cells, including those of the head and neck. A better 
understanding of deregulated metabolic pathways could lead to novel 




1.8 Cysteinyl Leukotrienes and Inflammation 
Inflammation is an important micro-environmental factor in the progression of 
cancer[344]. The innate immune response is responsible for the clearing of 
infection from affected areas, but it is also advantageous for the tumour to 
recruit inflammatory mediators. Tumour cells release chemical signals to lure 
macrophages and granulocytes to the site of tumour growth and stimulate them 
to release cytokines, which drive angiogenesis and aid in the restructuring of 
surrounding stroma[344]. A drug-repurposing screen (conducted as part of this 
project) identified a family of compounds involved in the regulation of 
inflammation, which significantly inhibited the growth of an aggressive, patient-
derived oral cancer cell line. 
The oral cavity is the first point of contact with exogenous carcinogens, such as 
alcohol, tobacco and betel quid. Prolonged exposure to these agents damages 
the mucosal lining and leads to the accumulation of mutations over a 
lifetime[345]. Cigarette smoke in particular has a significant effect on the innate 
immune system through the generation of reactive oxygen species, which 
activate pro-inflammatory signalling cascades in oral epithelial cells[346].  
The NF-κβ transcription factor is the primary regulator of genes involved in the 
inflammatory response and is the central hub through which inflammatory 
agents act[347]. Inactive NF-κβ exists in a sequestered state in all mammalian 
cells; it is only upon translocation to the nucleus that it becomes an active 
inflammatory mediator. Constitutive activation of NF-κβ is detected in head and 
neck cancer cells and its expression is positively correlated with tumour 
stage[348, 349]. NF-κβ upregulates the expression of pro-inflammatory cytokines 
interleukin-8 (IL-8) and tumour necrosis factor-α (TNFα)[350]. The latter has 
been shown to regulate the activity of a group of lipid inflammation mediators 
called eicosanoids[351]. 
1.8.1 Eicosanoids 
The eicosanoid (greek: eicosa, 20) family of lipophilic signalling molecules are 
important regulators of inflammation[352]. In response to stimulation, cysteinyl 
leukotrienes are rapidly generated from arachidonic acid (AA), a 20-carbon, 
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polyunsaturated fatty acid which is esterified to glycerol in cell membrane 
phospholipids[353]. AA is released directly into the cytosol through activation of 
calcium-dependent cytosolic phospholipase A2 (cPLA2) which catalyses the 
hydrolysis of phospholipid molecules. Phospholipase C and D can also liberate AA 
indirectly by generating diacylglycerol and phosphatidic acid, (intermediate lipid 
products from which fatty acids can be released by the action of diacylglycerol 
and monoacylglycerol lipases)[354]. Free AA that does not diffuse into the 
extracellular matrix is metabolised within the cell via three major 
pathways[355], giving rise to lipid molecules with overlapping and distinct roles 
in inflammation (Figure 1.10). This project focuses specifically on the role of 
the lipoxygenase pathway in oral cancer. 
 
Figure 1.10 Pathways of arachidonic acid metabolism. 
 
 
1.8.2 Lipoxygenases (LOX pathway) 
Liberated AA can be converted to a group of lipid molecules known as 
leukotrienes, which play a pivotal role in the inflammatory response and feature 
predominantly in asthma[356]. The first step in the synthesis of leukotrienes is 
the translocation of cytosolic AA to the phospholipid membranes of the nucleus, 
endoplasmic reticulum and Golgi apparatus[357]. Here, 5-LOX activating protein 
(FLAP) presents AA to 5-lipoxygenase (5-LOX) which catalyses the sequential 
oxidation at the C-5 position to generate 5-hydroxyperoxyeicosatetraenoic acid 
(5-HPETE), and dehydration to form the unstable intermediate, leukotriene A4 
(LTRA4)[358].  
The pathway branches off at this point to produce either LTB4, which acts as a 
chemotactic for neutrophils or the cysteinyl leukotrienes (CysLTs) - LTC4, LTD4 
ARACHINDONIC ACID 
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and LTE4[359, 360]. CysLTs get their name from the presence of a conserved 
cysteine residue and are the primary lipid mediators of inflammatory disease 
and are mainly produced by eosinophils, mast cells and macrophages[361]. 
Despite structural similarities, the CysLTs are functionally diverse. LTRA4 is 
processed into the intermediate metabolite, 5-HETE, which is hydrolysed by 
LTRA4 synthase to form LTB4. LTC4 is generated through the enzymatic activity 
of LTC4 synthase exported from cells where it is sequentially metabolised to 
LTD4 and LTE4 (Figure 1.11). Small molecule inhibitors, which target the 5-LOX 
pathway, have been approved for the treatment of asthma. 
 
Figure 1.11 Overview of cysteinyl leukotriene metabolism. CysLT1R has been shown to 
activate downstream pathways including PI3K[362], ERK[363] and GSK3β[364]. Inhibitors act on 
various points in this pathway (purple boxes). LTRA4, C4, D4, leukotriene A4, C4, D4; FLAP, 5-
lipoxygenase-activating protein; 5-LO, 5-lipoxygenase; 5-HPETE, 5-hydroperoxyeicosatetraenoic 
acid; GSK3β, glycogen synthase kinase 3 beta; PI3K, phosphoinositide 3-kinase; PKCα, protein 
kinase C α; ERK, extracellular signal-related kinase; MEK, mitogen-activated protein kinase kinase; 




LTB4 binds its cognate GPCRs, BLT1 and BLT2, with a high and low affinity, 
respectively[365, 366]. BLT1 expression is confined mainly to peripheral 
leukocytes, whereas BLT2 is fairly ubiquitous with peak expression in the spleen, 
liver and lymphocytes[367]. LTD4 has the highest in vivo activity of the terminal 
CysLTs and can act through two GPCRs termed CysLT1R and CysLT2R. The 
receptors exhibit different affinities for their respective ligands, with CysLT1R 
selectively binding LTD4 and CysLT2R having a lower but equal affinity for LTC4 
and LTD4[368, 369].  
At the site of inflammation, CysLTs can be produced by leukocytes alone, which 
produce all of the enzymes required for their synthesis. However, the situation 
in vivo is often more complex and involves a degree of cellular cooperation. On 
one hand, epithelial and endothelial cells expressing LTRA4 hydrolase can 
generate leukotrienes from LTRA4, which is released from neutrophils; 
conversely, leukocytes can utilise AA released from these cells as fuel to 
generate leukotrienes[370, 371]. This transcellular metabolism highlights the 
shortcomings of simple 2D in vitro assays in determining the role of leukotrienes 
in inflammation and cancer. 
1.8.3 Leukotrienes and Cancer 
To date, the majority of work exploring the role of leukotrienes in a disease 
setting has centred on pre-existing inflammatory conditions. Inflammatory bowel 
disease (IBD) such as ulcerative colitis and Crohn’s disease are known risk factors 
of colorectal (bowel) cancer (CRC)[372], the fourth most common cancer and 
the second most common cause of cancer death in the UK[373]. A recent meta-
analysis showed that the risk of bowel cancer was 70% higher in people with IBD 
compared to the general population[374]. IBD is characterised by high levels of 
AA-derived pro-inflammatory metabolites such as CysLTs and prostaglandins in 
the intestinal wall, which are produced by infiltrating leukocytes. 
Correspondingly, high levels of LTE4 have been detected in the urine of IBD 
sufferers[375].  
Overexpression of CysLT1R has been found in a number of cancer types, 
including those of the bladder, prostate, breast and bowel, and are associated 
with decreased patient survival[376-379]. On the other hand, high CysLT2R 
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expression is predictive of a favourable prognosis in CRC[380]. This expression 
pattern may be explained by the counteracting role of the CysLT2R which keeps 
CysLT1R locked in a heterodimer under basal conditions in intestinal epithelial 
cells[381, 382]. Upon LTC4 stimulation, CysLT2R induces internalisation of the 
heterodimeric complex, negatively regulating the plasma membrane expression 
of CysLT1R[382].  
LTD4 stimulation of CysLT1R leads to enhanced cell survival signalling in 
intestinal epithelial cells with a concomitant increase in proteins such as COX-2, 
β-catenin and Bcl-2[383], as well as increased proliferation and migration via the 
ERK1/2-p90RSK and PI3K-Rac pathway, respectively[362, 384]. The anti-
tumourigenic signalling protein IFN-α has been shown to induce CysLT2R 
promoter activity, whereas mitogenic EGF suppresses it. Furthermore, EGF-
induced cell migration in the colon cancer cell line, Caco-2, was mitigated by 
LTC4 stimulation of CysLT2R[385]. At the time of writing, no studies have 
established a role for CysLTs in oral cancer, although one study found 
significantly elevated levels of LTB4 in oral SCC compared to normal control 
tissue[386]. 
A number of CysLT1R antagonists (montelukast, pranlukast, zafirlukast) have 
been approved for the treatment of asthma[387] and drug-repurposing studies 
have shown that the compounds can induce apoptosis in cancer cell lines in 
vitro[376, 378, 388, 389]. Antagonism of CysLT1R in colon cancer cell lines has 
been shown to reduce proliferation and combination treatments of the COX-2 
inhibitor (celecoxib) with either a 5-LOX inhibitor (MK-886) or CysLT1R 
antagonist (LY171883) produced an additive effect[390, 391]. Subsequent in vivo 
work has shown that CysLT1R antagonists negatively regulate VEGF expression in 
mice and reduce vascular permeability[392]. Furthermore, in a murine Lewis 
lung carcinoma model, pranlukast and montelukast prevented tumour metastasis 
by inhibiting capillary permeability[393]. In line with these findings, Savari et al. 
showed that Montelukast treatment successfully inhibited the growth of human 




The crosstalk of the host’s immune system with tumour cells is highlighted by 
the recent approval of pembrolizumab for the treatment of 
recurrent/metastatic HNSCC[14]. It is increasingly evident that chronic 
inflammation contributes to the development and progression of cancer. 
Repeated inflammatory insults, such as those experienced by smokers or IBD 
sufferers, predispose to the development of dysplasia. The recruitment of pro-
inflammatory cytokines and growth factors promote the growth and survival of 
tumour cells and facilitate their invasion through the extracellular matrix. 
Further evidence for the tumour-promoting role of inflammation stems from the 
success of non-steroidal anti-inflammatory drugs (NSAIDs) in preventing 
carcinogenesis[395].  
Cysteinyl leukotrienes have been less well studied than their COX pathway 
counterparts, but early evidence suggests an equally important role in tumour 
progression. By promoting the transcription of oncogenic genes[396], 
leukotrienes have been shown to sustain proliferation and enhance migration 
and invasion in colon cancer cells[397]. Through its interaction with VEGF, they 
can also induce angiogenesis[398], while inhibition of the CysLT1R inhibited the 
growth of tumours in a xenograft model[394]. CysLT1R signalling is linked with a 
number of cancer hallmarks and targeting the receptor shows promise as a 
therapeutic strategy.  
Herein, a drug-repurposing screen reveals a group of CysLT1R inhibitors that are 
highly effective at inhibiting the growth of oral SCC cell lines. This study sought 




1.9 Thesis Aims and Objectives 
HNSCC survival rates have remained stagnant for decades in the absence of 
effective targeted therapies. This project sought to identify novel driver genes 
in the disease through the application of large-scale genomic and compound 
screening. Hypoxia was chosen as the differential in these screens, owing to its 
prognostic significance in solid tumours. Following on from this, potential targets 
were followed up using a combination of bioinformatic and functionality-based 
approaches. Three major themes emerged from this work: (1) the amplification 
of chromosome 3q36-29, (2) the role of hypoxia in lipid metabolism and (3) 
tumour-related inflammation. Chapter 3 will give a brief overview of the screen 
results, while chapters 4, 5 and 6 will focus on the identification and validation 
of 3q26-29 genes that are frequently overexpressed in HNSCC and significant for 
patient survival. Chapter 7 will investigate the destabilising effect of hypoxia on 
the HNSCC genome and the importance of lipid metabolism genes. Chapter 8 




Chapter 2 Materials and Methods 
2.1 Cell lines 
The patient-derived epithelial cell lines used in this thesis are listed in Table 
2.1. All cell lines were adherent and HPV-negative. Cell lines were grown in 
keratinocyte serum free medium supplemented with 25µg/mL bovine pituitary 
extract (BPE) and 2.5ng/mL epithelial growth factor (EGF), unless otherwise 
stated. 
# Cell Line Tissue Gender/Age TNM Stage Disease Ref 
1 Liv7k Tongue ? / ? T3N2b SCC R. Shaw 
2 Liv37k FoM M / 57 T3N2b SCC R. Shaw 
3 Liv52k Tongue M / 30 T2N0 SCC R. Shaw 
4 Liv72k Tongue F / 79 T3N2c SCC R. Shaw 
5 KR19 Tongue F / 19 T4aN2b SCC In-house 





Gingiva ? / 27 - - [400] 
Table 2.1 Cell lines used in this thesis. Details include the tissue of origin, patient details and 
TNM stage. FoM, floor of mouth; TrigRE, retromolar trigone. 
 
The “Liv” series of cell lines were generously gifted by Professor Richard Shaw 
(University of Liverpool, UK) and the OKF4 and OKG4 lines were purchased from 
the Rheinwald Lab (Boston, USA). The KR19 cell line was extracted from primary 
patient tissue by Dr Lynn McGarry (CRUK Beatson Institute, UK). 
2.2 Reagents and Vendors 
Reagents were purchased from various companies for use in this work. Reagents 
and company details are listed in Table 2.2. 
Product Catalog Number 
Thermo Fisher Scientific 
NuPAGE™ Transfer Buffer NP0006 
NuPAGE™ Tris-Acetate SDS Running Buffer LA0041 
NuPAGE™ MOPS SDS Running Buffer NP000102 
NuPAGE™ MES SDS Running Buffer NP000202 




Halt™ Phosphatase Inhibitor Cocktail 78420 
Keratinocyte-SFM Medium (Kit) with L-
glutamine, EGF, and BPE 17005075 
DMEM, high glucose, pyruvate, no glutamine 21969035 
DMEM/F-12, no glutamine 21331020 
MEM α, nucleosides 22571020 
RPMI 1640 Medium, no glutamine 31870074 
Foetal Bovine Serum, qualified, E.U.-approved, 
South America origin 10270106 
Lipofectamine™ RNAiMAX Transfection Reagent 13778500 
Lipofectamine™ 2000 Transfection Reagent 11668019 
NuPAGE™ LDS Sample Buffer NP0007 
NuPAGE™ Sample Reducing Agent NP0004 
NuPAGE™ Antioxidant NP0005 
Trypan Blue Stain (0.4%) for use with the 
Countess™ Automated Cell Counter T10282 
RNaseZap™ RNase Decontamination Solution AM9780 
High-Capacity cDNA Reverse Transcription Kit 4368814 
RNaseOUT™ Recombinant Ribonuclease 
Inhibitor 10777019 
Pierce™ BCA Protein Assay Kit 23225 
NuPAGE™ 4-12% Bis-Tris Protein Gels, 1.0 mm, 
12-well NP0322PK2 
PageRuler™ Prestained Protein Ladder, 10 to 
180 kDa 26617 
PVDF Transfer Membrane, 0.45 µm 88518 
FastDigest NheI FD0973 
FastDigest BamHI FD0054 
FastDigest SalI FD0644 
FastDigest Esp3I (BamHI) FD0454 
FastDigest Buffer B64 
Orange DNA Loading Dye R0631 
MAX Efficiency™ DH5α™ Competent Cells 18258012 
GeneRuler 1 kb DNA Ladder SM0312 
T4 Polynucleotide Kinase (10 U/µL) EK0031 
T4 DNA Ligase Buffer 46300018 
TaqMan™ Gene Expression Master Mix 4369016 
TaqMan™ RNase P Detection Reagents Kit 4316831 
GE Healthcare (Dharmacon) 
5X siRNA Buffer B-002000-UB-100 
Sigma-Aldrich Company 
DAPI, dilactate D9564 
Triton™ X-100 X100 
Zafirlukast Z4152 
Staurosporine from Streptomyces sp. S4400 
Doxycycline Hydrochloride D3072 
RNase-Free Water W3513 
Rapid DNA Ligation Kit 11635379001 
cOmplete™, Mini Protease Inhibitor Cocktail 04693124001 
Bovine Serum Albumin Fraction V 10735086001 





RNeasy Mini Kit 74104 
QIAprep Spin Miniprep Kit 27104 
AllPrep DNA/RNA Mini Kit 80204 








Lenti-X™ Concentrator 631231 
In-Fusion® HD EcoDry™ Cloning Plus 638912 
Stellar™ Competent Cells 636763 
Macherey-Nagel™ NucleoSpin™ Gel and PCR 
Clean-up Kit 12303368 




Montelukast (sodium salt) 10008318 
Table 2.2 List of reagents. 
 
2.3 Cell Culture Methods 
2.3.1 General Maintenance 
The media for cell lines used in this thesis are detailed in section 2.1. Stocks 
were maintained to keep a good stock of low passage cells. All procedures were 
carried out using aseptic techniques in a class II laminar flow hood with HEPA 
filtration. Cells were centrifuged at 300 x g for 5 minutes using a Beckman 
Coulter Allegra X-22R benchtop centrifuge. Cells were incubated at 37°C / 5% 
CO2, unless otherwise stated. 
2.3.2 Thawing stocks 
Cells were thawed from liquid nitrogen stocks in 37°C water bath and 
resuspended in pre-warmed culture medium. The cell suspension was pelleted 
by centrifugation, medium removed and the cells resuspended in fresh medium 
for seeding in an appropriate flask. 
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2.3.3 Passage of cell cultures 
Cell lines were split upon reaching confluence to continue growing stocks or seed 
for experiments. Spent medium was removed by aspiration and cells were 
washed once in sterile 1 x PBS. This was removed and a small volume of trypsin 
was added to the cell layer (3mL for T175, 2mL for T75 and 1mL for T25). Gentle 
rocking of flasks ensured even coverage of the cell layer. Flasks were incubated 
at 37°C for 5-10 minutes to maximise enzyme activity. Once cell detachment 
was confirmed under a light microscope, 10mL of serum-containing media was 
added to inactivate the trypsin. This suspension was centrifuged to pellet, the 
supernatant was removed and the pellet was resuspended in fresh medium and 
the cells seeded into a new flask. 
2.3.4 Cell Counting 
An aliquot of live cell suspension was mixed 1:1 with trypan blue stock solution 
(0.4%) and pipetted into a Countess chamber slide. Cells were counted using a 
Countess™ automated cell counter (Thermo Scientific). Dead cells were 
subtracted from total cell count and live cell counts were used. 
2.3.5 Creation of frozen cell stocks 
Stocks of early passage cells were generated for all cell lines used in this thesis. 
Cells were pelleted as in section 2.5.3 and resuspended in freezing solution. 
This solution consisted of 70% culture medium, 20% FBS and 10% DMSO. Cells in 
this solution were aliquoted into labelled and barcoded 2mL cryo-vials, scanned 
into the cell stock spreadsheet and placed into a freezing container (Mr Frosty, 
Nalgene) to allow gradual cooling. This was stored at -80°C overnight and frozen 
cells were transferred to liquid nitrogen stores the next day. 
2.4 Plasmid Manipulation 
A number of cell lines were modified by plasmid integration in order to achieve 
gene knockdown. SnapGene software (GSL Biotech LLC) and free-to-use ApE 
software (M. Wayne Davis, University of Utah, USA) were used to design plasmids 
in this project. 
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2.4.1 pTRIPZ_IGF2BP2 (tet-inducible) 
Glycerol stocks of five custom-made pTRIPZ plasmids, three containing a unique 
shRNA sequence targeting IGF2BP2, one positive GAPDH shRNA control and one 
non-targeting shRNA control, were ordered from Dharmacon. The plasmid 
contains a tetracycline-inducible promoter, so gene expression can be switched 
on and off. Glycerol stock were thawed on wet ice and grown in AMP-containing 
LB-broth. Plasmid DNA was extracted and purified by maxiprep. 
 
Figure 2.1 pTRIPZ lentiviral vector map, provided by Dharmacon. The empty vector is 
13,362bp in size. 
 
The plasmid DNA was subsequently digested using Fast Digest SalI (Thermo Fisher 
Scientific) as a quality control check. This was incubated for 5 minutes at 37° 
and run on a 1% agarose gel to generate bands of approximately 7104bp, 4028bp, 




2.5 Bacterial Transformation 
Either DH5α™ (Thermo Fisher Life Technologies) or Stellar™ competent cells 
(Clontech) were used for transformation reactions, depending on RecA status 
required. Competent cells were thawed on wet ice prior to use and mixed gently 
to ensure even distribution. 50µL of competent cells were transferred to a 14mL 
round-bottomed falcon tube and 1µL of ligated DNA was added. The cells were 
kept on ice for 25 minutes and then heat shocked for 45 seconds at 42°C. Tubes 
were then placed on ice for 2 minutes and 500µL of pre-warmed (37°C) SOC 
medium was added. Cells were incubated with shaking at for 45 minutes at 37°C 
and 100µL of neat and diluted transformation reaction was plated onto agar 
plates containing appropriate antibiotic. Plates were incubated overnight at 
37°C. 
2.6 Plasmid cloning, purification and sequencing 
Colonies were picked from agar plates using sterile pipette tips and placed into 
14mL round-bottomed falcon tubes containing 5mL of LB broth, supplemented 
with antibiotic. Tubes were incubated overnight at 37°C with constant shaking. 
The following day, bacterial cells were pelleted by centrifugation, the 
supernatant was removed and a QIAprep Spin Miniprep Kit (Qiagen) was used to 
purify plasmid DNA according to manufacturer’s instructions. The eluted DNA 
was sequenced with appropriate primer(s) and compared to the plasmid map. 
Following this, correct sequences were transformed into competent cells again 
and grown up for maxiprep by a Genomic-tip 500/G kit (Qiagen). Maxiprep was 
performed as directed by manufacturer. Minipreps and maxipreps were carried 
out by Andrew Keith (CRUK Beatson Institute). DNA was sequenced using the 
Applied Biosystems 3130xl Genetic Analyser, according to manufacturer 
instructions. 
2.7 Lentiviral transfection of mammalian cells 
2.7.1 Packaging and envelope system 
Plasmids with the correct sequence were transfected into 293T cells using the 
psPAX2 lentiviral packaging and pCMV-VSV-G envelope plasmids in order to 
generate lentiviral particles. psPAX2 is a 2nd generation lentiviral packaging 
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plasmid and contains Gag, Pol, Rev and Tat HIV-1 genes. psSPAX2 and pCMV-VSV-
G are available from Addgene (plasmid #12260 and #8454) and were kindly gifted 
by Loic Fort (Laura Machesky Lab). They were originally deposited by Didier 
Trono and Bob Weinberg, respectively. 
2.7.2 Puromycin kill curves and selection 
To generate stable cell lines expressing the plasmid, a dose response curve of 
puromycin was applied to determine the minimum amount of antibiotic required 
to kill 100% of non-transfected cells. Cells of interest were seeded in a 24 well 
plate and incubated overnight. The next day, the media was replaced with 
media containing puromycin at concentrations ranging from 0-2µg/mL. Cells 
were examined daily to identify the minimal concentration of antibiotic that 
efficiently kills all non-transfected cells between 4-7 days after addition. Media 
was changed as necessary. 
2.7.3 Lentiviral transfection into 293T cells 
Briefly, 2.5x106  293T cells were seeded in a 10cm dish in 10mL of full growth 
medium (DMEM, 10% FBS, 2mM L-glut) and incubated overnight at 37°C / 5%CO2. 
The next day, 15µg psPAX2, 5µg pCMV-VSV-G and 10µg target plasmid were 
added to 1mL of serum-free medium in a 1.5mL eppendorf and mixed well. In a 
separate tube, 30µL Lipofectamine 2000 (Thermo Fisher Scientific) was added to 
1mL of serum-free medium and mixed. The packaging mix was combined with 
the transfection mixed by gentle inversion. The mixture was incubated at room 
temperature for 15 minutes and added dropwise to 293T cells. Gentle rocking of 
the dish ensured even coverage of the plasmid mix and cells were then 
incubated overnight at 37°C / 5%CO2. *Containment Level II procedure from this 
point*. The next day, the virus containing media was removed from 293T cells 
and discarded in a 1% virkon solution. New growth media was added gently to 
293T cells to avoid detachment of cells. 
2.7.4 Concentration of lentivirus 
Virus-containing media was harvested from 293T cells into a sterile 50mL falcon 
tube. Virus containing media was centrifuged briefly at 500 x g for 10 minutes at 
4°C and filtered through a 0.45 polyethersulfone (PES) filter into a new sterile 
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50mL falcon (do not use nitrocellulose – it binds surface proteins on the lentiviral 
envelope).  One volume of Lenti-X concentrator (Clontech) was added to 3 
volumes of clarified supernatant, and mixed by gentle inversion. This solution 
was incubated overnight at 4°C. The next day, the solution was centrifuged at 
1,500 x g for 45 minutes at 4°C to pellet the virus and the supernatant was 
discarded in a 1% virkon solution. Next, the pellet was gently resuspended in 
1/10 the original volume of keratinocyte serum-free media. The concentrated 
virus was used immediately for titration or stored at -80°C. Repeat the next day. 
2.7.5 Lentiviral transduction of Liv7k cells 
Liv7k cells were seeded at 1.5x106 per 10cm dish and incubated overnight at 
37°C / 5%CO2. The next day, concentrated virus was added dropwise to cells and 
the plate was gently rocked to ensure even distribution. Cells were incubated 
overnight and fresh media containing virus was added to target cells. After 
another overnight incubation, virus-containing media was removed and cells 
were allowed recover for 24-48 hours in full growth media. 
2.7.6 Determination of viral titer 
This was carried out on the cell line of interest, in order to determine the 
optimal multiplicity of infection (MOI), which is defined as the number of 
transducing units per cell. Cells of interest were seeded at 25,000 cells/well in a 
24-well plate. Cells should be 40-50% confluence the next day. A five-fold 
dilution series of concentrated viral stock was created in a sterile V-bottomed 96 
well plate using serum free medium, and mixed well by pipetting up and down 
at each dilution stage. Media was removed from target cells and 225µL of serum-
free medium was added to each well. Then, 25uL was transferred from the viral 
source plate to the cell plate and incubated for 4 hours at 37°C / 5%CO2. Virus 
containing medium was removed from cells followed by a gently rinse with 1x 
PBS. Full medium containing 1 µg/mL of doxycycline was added and incubated 
for a further 72 hours. Then, the number of turbo-RFP expressing cells was 
counted and the number of transducing units per mL was calculated: 




2.7.7 Puromycin selection of stably expressing cells 
Target cells were allowed to recover for 24-48 hours after lentiviral infection 
and passaged if necessary. Following this, a pre-determined concentration of 
puromycin was added to cells in full growth medium and incubated for up to 7 
days, until only stably transduced cells remained. These cells were expanded 
and frozen down as stocks. 
2.8 Molecular Biology Techniques: RNA 
2.8.1 Isolation of RNA from mammalian cell lines 
Extraction of total RNA was performed using RNase-free reagents and plastic 
ware. Surfaces and pipettes were cleaned with RNaseZap™ RNase 
Decontamination Solution (Thermo Fisher Scientific) prior to work. RNA was 
isolated from cells using an RNeasy® Mini Kit (Qiagen), according to 
manufacturer’s instructions. A QIAshredder spin column (Qiagen) was used to 
homogenise the cell pellet. DNase digestion was performed using an RNase-Free 
DNase Kit (Qiagen) for every RNA sample used within this body of work. RNA 
concentration was measured and assessed for purity using a NanoDrop 
spectrophotometer. RNA was stored at -80°C until use. 
2.8.2 Normalisation and reverse transcription of RNA 
Each RNA sample was normalised to 100ng/µL and reverse transcribed using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™), according 
to manufacturer’s instructions. RNase Out (Thermo Fisher Scientific) solution 




2.8.3 Generation of cDNA standard curves 
A four-point standard curve was created for each experiment. First, the neat 
cDNA samples were diluted 1:1 in RNase-free water. Next, a pool of all cDNA 
samples was created and diluted 1:4 in RNase-free water, with careful mixing at 
each step. Individual samples were diluted 1:24 in RNase-free water and mixed 
well (Figure 2.2). 
 
Figure 2.2 Generation of a standard curve for RTq-PCR experiments. 
 
 
2.8.4 Real time quantitative PCR (RTq-PCR) 
RT-qPCR was primarily used to measure knockdown efficiency of RNAi 
transfections but was also used to quantify gene expression in panels of cell lines 
grown in different oxygen conditions. 2 x qPCR Mastermix was ordered from 
Primer Design and all primers were either designed using NCBI primer blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) or ordered from Qiagen. 
Melt curves were generated to assess primer specificity. The optimal reference 
gene was determined on an experiment-to-experiment basis. RTq-PCR was 
performed using an Applied Biosystems 7500 Fast system.  
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2.8.5 Primer Design 
Standard parameters were used to design forward and reverse primers which 
covered a region of 100-300bp in length, and spanned an exon-exon junction 
(Table 2.3). Both primers were assessed for off-target binding using BLAST. 
Primers are listed in Table 2.4. 
Primer Attribute Optimal Range 
Sequence Length 18-23 bp 
PCR Product Size 100-300 bp 
GC Content 40-60% 
Melting Temp 57-63°C (max 3°C diff) 
Max Self-Complementarity 2 
Max 3’ Self-Complementarity 1 
Table 2.3 Optimal primer attributes. 
 
Target 
Gene Primer Sequence 
Amplicon Length 
(bp) 
IGF2BP2 For 5’-GGCTTGACCATAAAGAACATCAC-3’ Rev 5’-GGAATCTCTTCGGCTAGTTTGG-3’ 190 
CDH1 For 5’-GTCAGTTCAGACTCCAGCCC-3’ Rev 5’-AAATTCACTCTGCCCAGGACG-3’ 295 
SNAI1 For 5’-ACTCTAATCCAGAGTTTACCTTCC-3’ Rev 5’-CAGGACAGAGTCCCAGATGAG-3’ 124 
SNAI2 For 5’-TCAAGGACACATTAGAACTCACAC-3’ Rev 5’-CTACACAGCAGCCAGATTCC-3’ 199 
CDH1 For 5’-CGAACTATATTCTTCTGTGAGAGG-3’ Rev 5’-ATGATAGATTCTTGGGTTGGGTC-3’ 160 
VIM For 5’-CTTAAAGGAACCAATGAGTCCCT-3’ Rev 5’-GCAGGTCTTGGTATTCACGA-3’ 162 
HIF1A For 5’-TTTTTCAAGCAGTAGGAATTGGA-3’ Rev 5’-GTGATGTAGTAGCTGCATGATCG-3’ 66 
ARNT For 5’-CTACCCGCTCAGGCTTTTC-3’ Rev 5’-CACCAAACTGGGAAGTACGAG-3’ 75 
18S For 5’-GTAACCCGTTGAACCCCATT-3’ Rev 5’-CCATCCAATCGGTAGTAGCG-3’ 151 
GAPDH For 5’-GAAGGTGAAGGTCGGAGTC-3’ Rev 5’-GAAGATGGTGATGGGATTTC-3’ 226 
ACTB For 5’-CCAACCGCGAGAAGATGA-3’ Rev 5’-CCAGAGGCGTACAGGGATAG-3’ 97 
Target 





PSME4 Hs_PSME4_1_SG 203776661 12/13 107 
CYSLTR1 Hs_CYSLTR1_1_SG 197629900 1/2/3 126/209/186 
PSMC2 Hs_PSMC2_2_SG 197629899 N/A 106 
PSMD6 Hs_PSMD6_1_SG 197629898 5/6 91 
PSMD2 Hs_PSMD2_1_SG 187169669 3/4 120 
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IGF2BP Hs_IGF2BP2_1_SG 187163099 9/10 87 
MGLL Hs_MGLL_1_SG 172785459 5/6 64 
DGAT2 Hs_DGAT2_1_SG 172757566 2/3 95 
GNPAT Hs_GNPAT_1_SG 180726532 4/5 84 
FAR2 Hs_FAR2_1_SG 180726539 8/9 103 
FAR1 Hs_FAR1_1_SG 180726538 5/6/7 106 
SCD Hs_SCD_1_SG 174465809 2/3 66 
DGAT1 Hs_DGAT1_1_SG 174465808 2/3/4 67 
LIPE Hs_LIPE_1_SG 174464740 6/7 120 
DAGLA Hs_DAGLA_1_SG 174464739 15/16/17 130 
AGPS Hs_AGPS_1_SG 174465765 15/16/17 140 
PNPLA2 Hs_PNPLA2_1_SG 174465764 4/5 80 
Table 2.4 Primers used in this thesis, custom made and off the shelf 
 
2.9 Molecular Biology Techniques: Protein 
2.9.1 Cell Lysis (6 well plate) 
Cell plates were placed on wet ice and medium aspirated. Cells were then 
washed once with cold PBS and 80µL of cold RIPA buffer (50mM Tris HCl (pH 8, 
150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1x protease 
inhibitor, 2x phosphatase inhibitor) was added to each well, after which the cell 
layer was scraped and transferred to a 1.5mL eppendorf tube. Samples were 
mixed by vortexing and kept on wet ice for 30 minutes, with further vortexing 
every 10 minutes. Samples were passed through a 0.5mm diameter needle five 
times and centrifuged for 10 minutes at 10,000 x g at 4°C. The supernatant was 
transferred to a new eppendorf tube and stored at -20°C. 
2.9.2 Protein Quantification (BCA Assay) 
Protein samples were quantified using a Pierce™ BCA assay kit (Thermo Fisher 
Scientific), according to the manufacturer’s instructions. Samples were 
normalised to equivalent concentrations. 
2.9.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Samples were mixed 1:3 with NuPAGE® 4x LDS Sample Buffer and 1:9 with 
NuPAGE® 10x Reducing Agent (Thermo Fisher Scientific) and heated at 70°C for 
10 minutes. 10-30µg of protein was pipetted into each lane of a pre-cast 
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NuPAGE™ 4-12% Bis-Tris Protein Gel held in an XCell SureLock™ Mini-Cell gel 
electrophoresis tank (Thermo Fisher Scientific). 10µL of PageRuler™ Prestained 
Protein Ladder (10 to 180 kDa) was run alongside samples for size estimation. 
Electrophoresis was performed at 120V for 80 minutes or until the running front 
reached the bottom of the gel. 
2.9.4 Western Blotting 
Gels were transferred onto 0.45µm polyvinyl difluoride (PVDF) membrane using a 
Bio-Rad Mini-Protean Tetra Cell at 70V for 120 minutes. The membrane was then 
stained with 0.1% Ponceau S solution (diluted in 5% acetic acid) for 10 minutes to 
ensure complete transfer. The membrane was rinsed for 15 minutes in 1 x TBST 
to remove the stain and then blocked for 1 hour at room temperature in 5% 
BSA/TBST. After blocking, the membrane was placed in a 50mL falcon containing 
5mL of primary antibody/5% BSA/TBST. The membrane was incubated overnight 
at 4°C with constant rolling. The following day, the membrane was washed 3 
times for 10 minutes with 1 x TBST and incubated with secondary antibody in 5% 
BSA/TBST for 1 hour at room temperature. The membrane was washed three 
more times and imaged on a LI-COR CLx (LI-COR Biosciences).  
A full list of antibodies used for western blotting in this body of work is detailed 
in Table 2.5. Secondary antibodies were used at a 1:2000 dilution in 5% 
BSA/TBST (either goat anti-rabbit IgG (H+L) Cross Adsorbed Secondary Antibody, 
DyLight 800 or goat anti-mouse IgG (H+L) Cross Adsorbed Secondary Antibody, 




Target protein Company Catalog # Species/ isotype Dilution 
AGPS Atlas HPA030210 Rb IgG 1:500 
Akt (p) Ser473 Cell Signalling 4060 Rb IgG 1:1000 
Akt (pan) Cell Signalling 2920 Ms IgG1κ 1:1000 
GAPDH Cell Signalling 2118 Rb IgG 1:1000 
IMP2 Cell Signalling 14672 Rb IgG 1:1000 
MAPK (p) 
Thr202/Tyr204 Cell Signalling 
9101 
Rb IgG 1:1000 
MGLL ProteinTech 14986-1-AP Rb IgG 1:1000 
p70 S6K Cell Signalling 2708 Rb IgG 1:1000 
p70 S6K Cell Signalling 9206 Ms IgG 1:1000 
p70 S6K (p) 
Thr389 Cell Signalling 
9206 
Ms IgG2a 1:1000 
PSMD2 Cell Signalling 14141 Rb IgG 1:1000 
PSMD6 Bethyl Labs A303-827A Rb IgG 1:1000 
PSME4 Bethyl Labs A303-880A Rb IgG 1:1000 
α-tubulin Cell Signalling 3873 Ms IgG1 1:1000 
β-Actin Cell Signalling 3700 Ms IgG2b 1:1000 
Table 2.5 List of antibodies. (p) phospho. 
 
2.10 Statistical Analysis 
Data was analysed for significance using GraphPad Prism (San Diego, CA, USA). 
Statistical significance was set at p<0.05 unless otherwise stated. 
2.11 RNA Sequencing 
RNA was extracted as described in section 2.8. Library generation and 
sequencing was carried out by William Clark (CRUK Beatson Institute). The 
quality of RNA was assessed using a RNA ScreenTape assay with the 2200 
Tapestation system (Agilent Technologies). RNA-seq libraries were generated 
using the TruSeq Stranded mRNA LT Kit (Illumina), according to an adapted 
version of manufacturer’s instructions from Fisher et al.[401]. cDNA synthesis 
and adaptor ligation was performed as in Bailey et al.[402]. The quality and 
quantity of the DNA libraries was assessed using a DNA D1000 ScreenTape assay 
with the 2200 Tapestation system (Agilent Technologies) and Qubit Fluorometric 
Quantitation system (Thermo Fisher Life Technologies), respectively. All libraries 
were sequenced using the Illumina NextSeq 500 system with the High Output Kit 
v2 (75 cycles) to generate 2x36 paired-end reads. 
RNA sequencing analysis was carried out by Ann Hedley and Gabriela Kalna 
(CRUK Beatson Institute). Quality checks on the raw RNASeq data files were done 
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using fastqc: (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 
and fastq_screen: 
(http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). RNASeq 
reads were aligned to the GRCh38[403] version of the human genome using 
TopHat2 version 2.0.10[404] with Bowtie version 2.1.0[405]. Expression levels 
were determined and statistically analysed by a combination of HTSeq version 
0.5.4p3: (http://htseq.readthedocs.io/en/release_0.9.1/), the R 3.1.1 
environment, utilizing packages from the Bioconductor data analysis suite and 
differential gene expression analysis based on the negative binomial distribution 
using the DESeq2[406]. Pathway analysis of genes with a fold change >2.0 and an 
adjusted P value <0.05 was performed using GeneGo Pathways Software 




2.12 High Throughput Screening: siRNA 
Two high throughput screens were performed in this project, including a whole 
genome siRNA screen and an FDA-approved compound screen. Both screens were 
carried out on the Liv7k cell line in normoxic and hypoxic conditions and 
included three replicates per condition. Automated liquid handling machinery 
was used in order to reduce variability between batches and minimise human 
error (Table 2.6). Sterile technique was maintained throughout the screen. All 
surfaces and plastic ware were sprayed with 70% ethanol before work and gloves 
and PPE were worn at all times. The automated machines were used inside 
laminar flow hoods to maintain sterility. All screening plastic ware used in the 
course of this project are listed in Table 2.7. 
Equipment 
Janus Varispan and MDT automated workstation (Perkin Elmer) 
Matrix WellMate® liquid dispenser (Thermo Fisher Scientific) 
Envision 2102 plate reader (Perkin Elmer) 
ALPS 3000 plate sealer (Thermo Fisher) 
Operetta high content microscope (Perkin Elmer) 
Opera high content confocal microscope (Perkin Elmer) 
Table 2.6 List of automated equipment used in the screens. 
 
Greiner Bio One 
Product Catalog # 
Cell culture microplate, 96 well, polystyrene, flat-bottom 
(chimney well), µclear®, black, CellStar®, tissue culture, 
lid with condensation rings, sterile, 8 pcs/bag 
655090 
Cell culture microplate, 384 well, polystyrene, flat-
bottom, µclear®, black, CellStar®, tissue culture, lid, 
sterile, 8 pcs/bag 
781091 
Microplate, 96 well, polypropylene, V-bottom, chimney 
well, natural, 10pcs/bag 
651201 
Microplate, 384 well, polypropylene, flat-bottom, 
natural, 10pcs/bag 
781201 
Cell culture microplate, 96 well, polystyrene, flat-
bottom, chimney well, µclear®, white, CellStar®, tissue 
culture, lid with condensation rings, sterile, 8pcs/bag 
655098 





2.12.1 Liquid Handling Quality Control 
To ensure even dispensing throughout plates, a quality control check of the 
automated workstation was performed prior to the screen. A 96 well V-bottomed 
plate containing 50µL 2.5mM Orange G dye was used in place of the siRNA source 
plate. 2.5µL of Orange G was transferred to every well of a black, clear-
bottomed 384 well plate. Then, a WellMate was used to dispense 47.5µL of 
sterile ddH2O to each well containing Orange G. The plate was shaken for 15 
minutes at room temperature, and absorbance was measured at 460nm on an 
Envision plate reader. The mean, standard deviation and the coefficient of 
variation (CV) was calculated for each plate. A CV of <10% was deemed within 
acceptable limits.  





2.12.2 Preparation of source plates 
96-well source plates containing “siGENOME” pooled siRNA were purchased from 
Dharmacon (GE Healthcare) and diluted to a concentration of 500nM. On the day 
of screening, source plates were removed from -20°C storage and allowed to 
thaw at room temperature. While the source plates were thawing, control plates 
were prepared containing All Stars® cell death control (Qiagen) (LO control) and 
non-targeting negative control (Dharmacon “On-Target Plus”) (HI control) in the 
relevant wells. The percentage growth inhibition caused by target siRNAs will be 
normalised to that of the non-targeting control siRNA. All Stars siRNA will be 
used as a positive control to confirm successful transfection. See plate layout in 
Figure 2.3.The concentration of siRNA in the control plate was also 500nM. Once 
thawed, plates were spun down for one minute at 2000rpm in batches of six and 
placed inside the laminar airflow hood. Plate seals were peeled off and plates 










2.12.3 Experimental Design 
Prior to beginning the screen, a number of transfection reagents were tested at 
a range of concentrations in the Liv7k cell line. RNAiMax was chosen because it 
had the highest on-target effect with minimal toxicity. 
The classes of siRNA target are detailed in Table 2.8, and contained siRNAs to 
18,075 genes in total. The screen was designed to include three replicates per 
oxygen condition and was carried out in 10 batches. Each batch consisted of 24 x 
96-well siRNA source plates being stamped into 36 x 384-well experimental 
plates. Six “cells only” plates were also included to assess edge effects (Figure 
2.4). In total, 231 source plates were stamped into 342 experimental plates, 
with an additional 60 cell only plates (total 402 x 384-well plates).  
The Janus automated workstation was used to stamp each experimental plate 
with 2.5µL of control and target siRNA. 7.5µL of RNAiMAX transfection reagent 
(diluted in serum-free media) was then added to the siRNA using the WellMate 
and placed on a plate shaker at 600rpm for 15 minutes. Following this, 40µL of 
cell suspension was added using the WellMate and plates were incubated at 37°C 
/ 5% CO2 in either normoxic or hypoxic conditions for 72 hours. 
Class Number of source plates 
Kinase 9 
G-Protein Coupled Receptor 5 
Phosphatase 4 
Ion Channel 5 
Drug Target 60 
Protease 6 
Ubiquitin 9 
Rest of Genome 133 
Total 231 





Figure 2.4 Experimental design of a screen batch. 
 
2.12.4 Fixation and Staining 
At the 72-hour time point, cells were fixed with 4% formaldehyde for 15 minutes 
followed by a PBS wash. Then, cells were permeabilised with 0.1% TX-100 and 
stained with 1µg/mL DAPI for 2 hours. Cells were washed once more with PBS 
and plates were sealed for imaging on the Operetta high content microscope 
(Perkin Elmer). A nuclei count was carried out using Harmony software, and 
analysed with Dotmatics browser. 
2.12.5 Hit Selection 
The percentage growth inhibition of each siRNA was normalised to negative 
control values from the same plate. The mean, median and standard deviation 
were calculated from three technical replicates. To identify hypoxia-specific 
hits, the difference between the median of the normoxic condition was 
subtracted from the median of the hypoxic condition. A threshold of minimum 
growth inhibition of 10% in hypoxia and a window of 20% between the two 
conditions was applied. Genes that met these criteria were selected for 
rescreen. In addition, a number of plate-level calculations were performed.  
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2.12.5.1 Signal to Background Ratio (S2B) 
The signal to background ratio is the difference between the mean of the 
positive and negative control samples. As it does not take standard deviation in 
to account, it does not provide any information about data variability. Xp and Xn 
represent the sample mean of the positive and negative controls, respectively. 
𝑆2𝐵 =  𝑋𝑒
𝑋𝑒
 
2.12.5.2 Z-factor (Z’) 
The Z-factor (or Z prime, Z’) accounts for variability in the positive and negative 
controls and involves four parameters: 
Z′ = (𝑋𝑒 − 𝑋𝑒) − 3(𝑆𝑒 − 𝑆𝑒)(𝑋𝑒 − 𝑋𝑒)  
where Xp and Xn represent the mean of the positive and negative control 
samples while Sp and Sn denote standard deviations of the same. The constant 
in the equation is based on three standard deviations from the mean, assuming a 
normal distribution. The Z’ gives an indication of how difference the positive 
and negative controls are and thus the quality of the experiment (Table 2.9). 
Z’ Category Interpretation 
Z’ = 1 Ideal A perfect assay - Z factors cannot exceed 1 
1 > Z’ ≥ 0.5 Excellent There is a large difference between positive and negative controls 
0.5 > Z’ ≥ 0.3 Marginal There is a moderate difference between positive and negative controls 
0.3 > Z’ > 0 Poor There is too much overlap between positive and negative controls 
Z’ < 0 Failed There is no difference between positive and negative controls - redesign assay 






2.12.5.3 Coefficient of Variation (CV) 
A CV was calculated for both the positive and negative controls: 
% CV = 𝑒𝑠
𝑚𝑒𝑣𝑒
∗ 100 
2.12.5.4 Strictly Standardised Mean Difference (SSMD) 
The inclusion of three replicates allowed for an accurate estimation of siRNA 
variability. To this end, the uniformly minimal variance unbiased estimate of 
strictly standardised mean difference (umvue SSMD) was calculated to assess the 
size of siRNA effects: 
𝑆𝑆𝑆𝐷 =   Г �(𝑒 − 1)2 �
Г �(𝑒 − 2)2 �  � 2𝑒 − 1𝑠𝑒𝑒𝑒   
where n is the number of replicates, di and si are the sample mean and standard 
deviation of the difference between the ith siRNA and the negative control and 
Г() is a gamma function (i represents a specific siRNA). Table 2.10 provides a 




Positive SSMD thresholds 
(activation) 
Extremely Strong SSMD ≥ 5 SSMD ≤ -5 
Very Strong 5 > SSMD ≥ 3 -5 < SSMD ≤ -3 
Strong 3 > SSMD ≥ 2 -3 < SSMD ≤ -2 
Fairly Strong 2 > SSMD ≥ 1.645 -2 < SSMD ≤ -1.645 
Moderate 1.645 > SSMD ≥ 1.28 -1.645 < SSMD ≤ -1.28 
Fairly Moderate 1.28 > SSMD ≥ 1 -1.28 < SSMD ≤ -1 
Fairly Weak 1 > SSMD ≥ 0.75 -1 < SSMD ≤ -0.75 
Weak 0.75 > SSMD > 0.5 -0.75 < SSMD < -0.5 
Very weak 0.5 ≥ SSMD > 0.25 -0.5 ≤ SSMD < -0.25 
Extremely Weak 0.25 ≥ SSMD > 0 -0.25 ≤ SSMD < 0 
Zero SSMD = 0 SSMD = 0 




2.13 High Throughput Screening: Drug-Repurposing 
The Liv7k cell line was subjected to 1,351 FDA-approved compounds for oncology 
and non-oncology indications in normoxic and hypoxic conditions. The library 
was tested at a single concentration of 10µM. Candidates were prioritised based 
on three criteria: (1) drugs which were maximally effective (≥90% kill); (2) 
selectivity in the hypoxic condition; and (3) selectivity for Liv7k cells. The latter 
criterion was based on comparisons from previous drug screens carried out 
within the Screening Facility. Drug libraries are listed in Table 2.11. 
Library Name Number of Compounds 
NIH Evotec Clinical Collection 1 281 
NIH Evotec Clinical Collection 2 446 
LOPAC Pfizer (Sigma Aldrich) 90 
Selleck FDA-Approved Library 420 
Developmental Therapeutics Program 
(DTP) FDA-Approved Oncology Set 114 
Table 2.11 Details of compound libraries used in the drug-repurposing screen. 
 
The drug screen was performed in normoxic and hypoxic conditions with three 
replicate plates per condition. Similar to the siRNA screen, automated liquid 
handling machinery was used. On day 0, Liv7k cells were seeded in 190µL of K-
SFM at 5000 cells per well in black, clear bottomed 96-well plates. The cells 
were incubated overnight at 37°C / 5% CO2. The next day, drug source plates 
(stock concentration 10mM in DMSO) were removed from -20°C storage and 
allowed to thaw. Plates were centrifuged at 2000 rpm for 1 minute.  
In a laminar airflow hood, plate seals were removed and replaced with a sterile 
plastic lid. For every compound source plate, an intermediate dilution plate was 
created. 98µL of serum-free media was dispensed into a PP V-bottomed plate 
using the WellMate and covered with a sterile lid. Relevant controls were then 
added to the intermediate plate. Staurosporine (stock 1mM, final concentration 
1µM) was used as a positive control to confirm successful stamping of drugs and 
DMSO was used a negative control at a concentration of 0.1%.  
Using the Janus, 2µL of drug stock was transferred from the source plate to the 
intermediate dilution plate to create a 1 in 50 dilution. The intermediate plates 
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were placed on a plate shaker for 30 minutes at 750 rpm to ensure complete 
mixing. After 30 minutes, 10µL of drug-containing media from the intermediate 
plates was stamped into six cell plates to create a further 1:20 dilution. The 
final concentration in the well was 10µM of compound.  
Cell plates were incubated at the relevant oxygen condition for 72 hours, after 
which the cells were fixed and stained as for the siRNA screen. A nuclei count 
was performed using the Operetta high content microscope. 
2.14 RNAi transfection (96 well plate) 
Stock siRNA was diluted to a working concentration of 500nM. 10µL of diluted 
siRNA was dispensed into each well and 30µL of diluted RNAiMax transfection 
reagent was added on top. Incubation for 15 minutes at room temperature with 
shaking ensured complex formation. Cells are a concentration of 5000/well were 
seeded in a 160µL of full media. The final concentration of siRNA in each well 
was 25nM and the final volume of transfection reagent was 0.125µL/well. Cells 
were incubated at 37°C / 5% CO2 for 72 hours unless otherwise stated. At 
experiment end-point, cells were fixed and stained as in the siRNA screen. A list 
of siRNAs used in transfections is provided in Table 2.12. 
siRNA ID Sequence(s) Catalog # 
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2.15 Functional Assays: Incucyte Zoom3® 
2.15.1 Propagation 
On day 0, cells were seeded at a range of concentrations in black, clear-
bottomed 96-well plates in 200µL of K-SFM. Cells were incubated overnight at 
37°C / 5% CO2. The next day, plates were added to the Incucyte and imaged 
every 3 hours for 72-96 hours. Propagation was calculated from the confluence 
mask generated by the device’s software. 
2.15.2 Migration (Wound Assay) 
Cells were seeded in 100µL K-SFM at 30,000 cells per well in Essen Imagelock™ 
96-well plates and incubated overnight at 37°C / 5% CO2. The next day, a 
scratch was made using a woundmaker tool™ (Essen Bioscience), according to 
manufacturer’s instructions. The cell layer was checked to ensure a good scratch 
was made and washed once with 1 x PBS. 200µL of full media was added 
carefully to avoid disturbing the cells around the wound. Plates were added to 
the Incucyte and imaged every 3 hours for 72-96 hours until complete wound 
closure. Migration is quantified using device software using relative wound 
density (RWD). RWD is calculated as the cell density in the wound area relative 
to the cell density outside of the wound area over time. 
2.15.3 Invasion (Wound Assay) 
The day before making the wound, growth factor reduced matrigel (stock 
9mg/mL) was placed in a fridge on wet ice and allowed to thaw. On the same 
say, cells were seeded in 100µL K-SFM at 30,000 cells per well in Essen 
Imagelock 96-well plates and incubated overnight at 37°C / 5% CO2. The next 
day, matrigel was diluted 1:1 in full media to a concentration of 4.5mg/mL, and 
kept on wet ice. A scratch was made as for migration, and the cell layer was 
washed once with 1 x PBS. PBS was tipped into a container containing 1% virkon 
solution and the cell plate was placed in a coolbox to ensure the matrigel 
remains between 4-8°C.100µL of diluted matrigel was added to each well using a 
multichannel pipette and the plates were incubated at 37°C / 5% CO2 for one 
hour to allow matrigel to set. 100µL of full media (plus 2 x compound if 
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required) was added on top of the matrigel and added to the Incucyte. RWD was 
the primary readout for this assay. 
2.15.4 Inverse Invasion Assay (Transwell®) 
Matrigel (9mg/mL) was allowed to thaw slowly on ice and diluted 1:1 in full 
media. 100µL of diluted matrigel was carefully pipetted into the centre of each 
transwell insert (6.5mm Transwell® with 8.0µm Pore Polycarbonate Membrane 
Insert, Corning) and incubated for one hour at 37°C / 5% CO2. During this time, a 
cell suspension was prepared containing 5x106 cells per mL in full media. When 
the matrigel had set, the Transwell inserts were inverted and 100µL of the cell 
suspension was pipetted onto the underside of the filter (which is now 
uppermost). Transwell inserts were covered using the base of the 24-well culture 
plate, which was carefully lowered until it contacted the droplet of cell 
suspension. The inverted plate was incubated for 4 hours to allow the cells to 
attach. After 4 hours, the plate was turned upright again. Transwell inserts were 
dipped sequentially in 3 x 1 ml serum free medium to wash and left in wash 3 for 
incubation. 100µl of full media plus extra growth factor (insulin/IGF1) was gently 
pipetted into the insert on top of the matrigel/media. The plates were 
incubated at 37°C / 5% CO2 for 5 days.  
Cells were live stained with 4µM Calcein AM and 2µM Hoechst 33342 for one hour 
and the lower side of the insert was imaged on an Olympus FLUOVIEW FV1000 
confocal laser-scanning microscope. The experiment is carried out in three sets 
of technical duplicates with five fields imaged in Z-stacks ranging from 0µm 
(base) up to 120µm into the membrane. Quantification was performed using 
ImageJ. 
2.15.5 3D Spheroid Formation 
Spheroids were created using Cultrex® 3D Spheroid Cell Invasion Assay (Trevigen 
catalog # 3500-096-K), according to manufacturer instructions. A seeding density 




2.15.6 Neutral Lipid Staining 
Cells were fixed in 4% formaldehyde for 15 minutes, followed by 
permeabilisation with 0.1% TX-100 in 1 x PBS for 1 hour. Cells were then washed 
once with 1 x PBS and sequentially stained with 1µg/mL DAPI (sigma # D9564, 
0.5µg/mL Deep Red Cell Mask (Thermo Fisher #H32721) and 2µg/mL BODIPY 
493/503 neutral lipid stain (Thermo Fisher # D3922). Cells were imaged using the 
Operetta high content microscope (Perkin Elmer). 
2.15.7 MitoStress Assay (Seahorse, Agilent) 
The day before the assay, cells were plated at 5000 cells/well in a Seahorse 
XF96 cell culture microplate (Agilent). The next day, Seahorse XF media was 
modified to have the same concentration of L-glutamine, D-glucose and pyruvate 
as keratinocyte serum free media, and 1M NaOH was added until a pH of 7.4 was 
achieved. Next, oligomycin, FCCP, rotenone and antimycin-A were diluted in 
seahorse media in order to give a final concentration of 1μM in the cell plate. 
One hour before the assay, the media in the cell plate was exchanged for 
seahorse media and incubated at 37°C. The assay was performed according to 
manufacturer’s instructions and oxygen consumption rate/extracellular 
acidification rate was normalised to cellular nuclei count. 
2.15.8 Proteasome Activity Kit  
Proteasome activity was measured according to manufacturer’s instructions 
(Promega #G8660). 
2.16 Liquid Chromatography Mass Spectrometry (LCMS) 
2.16.1 Lipid Extraction 
Cells were seeded into a 6 well plate and siRNA/TR mix was added. After a 72-
hour knockdown, the cell layer was washed once with ice-cold PBS. Lipids were 
extracted by adding 0.75mL of ice-cold methanol:PBS (1:1) to each well and 
scraping cells into a 1.5mL eppendorf. At this point, internal standard controls 
were spiked into each sample (pos-mode, PC 170/170; neg-mode, PE 170/170). 
0.5mL of ice-cold chloroform was added and the tubes were vortexed for 1 
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minute, followed by centrifugation (14000rpm) at 4°C for 10 minutes. Carefully, 
the lower layer of chloroform containing dissolved lipids was moved into a glass 
autosampler vial. Butylated hydroxytoluene (BHT) was added to each sample and 
the lipid-containing chloroform was evaporated using nitrogen gas. Dried lipids 
were sealed in the glass autosampler vials and stored at -20°C until 
reconstitution in chloroform:methanol:water (1:1:0.3) (pos-mode) or isopropyl 
alcohol:chloroform:methanol (90:5:5) (neg-mode). 
2.16.2 LCMS 
Lipidomic analysis was performed by Gillian Mackay and Sergey Tumanov (CRUK 
Beatson Institute) using Q Exactive orbitrap mass spectrometer coupled to 
Dionex UltiMate 3000 LC system (Thermo Scientific). The LC parameters were as 
follows: 3 µL of sample was injected onto a 1.7 µm particle 100 x 2.1mm ID 
Waters Acquity CSH C18 column (Waters) which was kept at 50°C. A gradient of 
(A) water/acetonitrile (40:60, v/v) with 10 mM ammonium formate and (B) 
acetonitrile/2-propanol (10:90, v/v) with 10 mM ammonium formate at a flow 
rate of 0.3 mL/min was used. The gradient ran from 0% to 40 % B over 6 min, 
then from 40% to 100% B in the next 24 min, followed by 100% B for 4 min, and 
then returned to 0% B in 2 min where it was kept for 4 min (40 min total). Lipids 
were analysed in both positive and negative mode. The electrospray and mass 
spec settings were as follows: spray voltage 3 kV (positive mode) and 3.5 kV 
(negative mode), capillary temperature 300°C, sheath gas flow 50 (arbitrary 
units), auxiliary gas flow 7 (arbitrary units) and sweep gas flow 5 (arbitrary 
units). The mass spec analysis was performed in a full MS and data dependent 
MS2 (Top 10) mode, with a full scan range of 300-1200 m/z, resolution 70,000, 
automatic gain control at 1 x106 and a maximum injection time of 250 ms. MS2 
parameters were: resolution 17,500, automatic gain control was set at 1 x105 
with a maximum injection time of 120 ms. 
2.17 In vivo xenografts 
Animal handling in this project was carried out by Susan Mason (Karen Blyth lab, 
CRUK Beatson Institute). Project license number: PPL70/8645. 5x106 Liv7k cells 
were subcutaneously injected into NOD/SCID mice (n=20). Mice were split into 
treatment or control groups by cage assignment (n=10 per group). Montelukast (5 
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mg/kg) or vehicle control were administered daily by oral gavage once tumours 
were palpable and had reached a predetermined size (~5 mm). Tumour volume 
was calculated as (length x width2) / 2, and statistical significance between the 
two groups was determined by unpaired t-test. Thereafter, measurements were 
taken using calipers three times weekly until tumour size reached 15mm in any 
direction, as per licence conditions. Mice were taken at this point and survival 
curves were plotted. Statistical significance of survival was determined using 
Log-rank test. 
2.18 Immunohistochemistry 
Immunohistochemistry (IHC) was carried out by Colin Nixon and the Beatson 
histology department. Tumour xenografts were fixed in 4% formaldehyde for 24-
36 hours and embedded in paraffin. Slices were adhered to glass slides for 
staining. Prior to staining, slides were washed twice in 1 x PBST and blocked for 
six minutes in peroxidase-blocking solution (Dako #S2023). Staining was 
performed using the Dako Autostainer. Sections were washed twice in 1 x PBST 
and blocked for 30 minutes in 2.5% normal horse serum (Vector #MP-6401-15) or 
Mouse on Mouse Blocking Reagent (Vector #MKB-2213). Primary antibodies and 
their dilutions used are listed in Table 2.13. Secondary antibodies, HRP 
conjugated goat anti-mouse (Dako #K4001), and horse anti-rabbit (Vector #MP-
6401-15) were used as appropriate. After further washing 1 x PBST, 3,3’-
diaminobenzidine tetrahydrochloride (Dako #K3468) was added and slides were 
counterstained with haematoxylin Z solution, and mounted with DPX (Sigma 
#44581). Tissue sections were scanned and images uploaded into Halo (Indica 
Labs) for staining analysis. 
Target Species Supplier Catalog # Dilution 
Ki67 Rabbit Thermo Fisher RM-9106 1:500 
AKT (phospho) Rabbit Cell Signalling 4060 1:250 
ERK1/2 (phospho) Rabbit Cell Signalling 9101 1:250 
ERK1/2 Rabbit Cell Signalling 9102 1:250 
MTOR (phospho) Rabbit Cell Signalling 2976 1:100 
HLA Mouse Abcam ab70328 1:100 
F4/80 Rat Abcam ab6640 1:250 
NIMP Rat Abcam ab2557 1:100 




2.19 Patient sample acquisition and processing 
Patient samples were acquired from the NHS Queen Elizabeth University Hospital 
in Glasgow and were restricted to HPV- negative primary tumours with evidence 
of lymph node involvement. Processing of samples involved either snap freezing 
for RNA/DNA extraction, fixation in formaldehyde for immunohistochemical 
staining or culturing of fresh tissue for the generation of primary cell lines. 
Frozen samples were processed as in Biankin[407] et al., 2012. 
Chapter 3 Results – High Throughput Screening 
The over-arching aim of this project was to identify novel driver genes in oral 
squamous cell carcinoma. We chose to approach this using an aggressive (T42Nb) 
patient derived cell line (Liv7k), 
utilising hypoxic conditions to mimic 
the common feature of HNSCC 
tumours. As such, siRNA and drug-
repurposing screens were performed 
in both hypoxia (0.1% O2) and 
normoxic (21% O2) conditions. This 
allowed for the selection of genes or 
drugs based on their response in 
each condition. A complete protocol 
for both screens can be found in 
chapter 2, but a brief summary of 
the process is provided in Figure 
3.1.  
Percentage growth inhibition was 
the primary output in both the siRNA 
and drug screens, and was 
calculated relative to the non-
targeting control siRNA and DMSO 
vehicle control, respectively. The 
negative controls were also used to 
Mycoplasma tesing, banking of cell 
stocks 
Determine optimal cell density, assess 
edge effects 
Lipid-based transfection reagent 
assessment, efficacy vs toxicity 
Mock screen under experimental 
conditions, postive control spiked 
randomly throughout plates to mimic 
hits, determination of plate statistics 
Primary screen (n=3 per condition), 
output: growth inhibition (nuclei count) 
 
Confirmed hits validated using multiple 
molecular / phenotypic assays, and in 
vivo evaluation 
  
Figure 3.1 Screening workflow summary. 
The process applies to both compound and 




monitor data variability across all plates throughout the screen. The positive 
control (siAllStars in the siRNA screen and staurosporine in the drug screen) was 
used to monitor the consistency of data produced and aid in the selection of 
hits. This chapter provides an overview of the quality assessment of the siRNA 
and drug screens. 
3.1 siRNA Screen 
The primary screen was performed in normoxic and hypoxic (0.1% O2) conditions 
in an effort to recapitulate the low oxygen environment often found in solid 
HNSCCs [408]. In total, 18,175 genes were silenced using the Dharmacon 
siGENOME library (GE Healthcare) which is broken down into functional classes in 
Table 3.1.  
siRNA Library Class Number of Genes 
Kinase 720 
G-Protein Coupled Receptor 390 
Phosphatase 256 
Ion Channel 352 
Drug Target 4,795 
Protease 480 
Ubiquitin 600 
Rest of Genome 10,582 
Total 18,175 
Table 3.1 Details of the Dharmacon siRNA library. 
 
In the siRNA screen, the positive and negative controls used were All Stars siRNA 
(Qiagen) and non-targeting control siRNA (NTC; Dharmacon On-Target Plus), 
respectively. The cell nuclei counts for the control cells were highly consistent 
within each batch, although normoxic negative controls typically had a higher 
cell count than hypoxic cells, indicating a faster rate of proliferation (Figure 
3.2). The primary method of assessing the quality of the siRNA screen was plate 
z score, which calculates the difference in growth inhibition between the 
positive and negative controls. A z score of > 0.3 is typically deemed acceptable, 




Binning of the results revealed a normal distribution of percentage growth 
inhibition in both oxygen conditions (Figure 3.4), with most of the siRNAs 
yielding a percentage growth inhibition of between 0-20%. A greater percentage 
growth inhibition was observed in the normoxic condition, possibly owing to a 
higher rate of proliferation in these cells. Given this, the percentage growth 
inhibition in the hypoxic condition was mean-normalised to the normoxic 
condition in order to make the results more comparable. The strictly 
standardised mean difference (SSMD) was used as a measure of effect size, with 
more negative values representing a higher percentage growth inhibition (Figure 
3.5). This also allowed the confirmation of the effect of silencing genes that are 
known to be essential for cell viability, such as WEE1 or PLK1. All calculations 
used in the analysis of the siRNA screen can be found in chapter 2. In order to 
identify a greater number of hits, the median growth inhibition was used in the 
initial screen. However, validation experiments utilised the mean growth 
inhibition in order to provide greater stringency.  
 
Figure 3.2 Average nuclei count for control wells throughout the siRNA screen. Values are 
plate averages of non-targeting (NTC) and All Stars control wells. Control outliers were excluded 


















Median Cell Count NTC - Normoxia Median Cell Count NTC - Hypoxia




Figure 3.3 siRNA screen z score values (per plate). Values of ≥ 0.3 (indicated by green line) 
were considered within the acceptable limits. Greater variability was observed in the hypoxic 
condition. Plates that dropped below the 0.3 threshold were repeated. 
 
 
Figure 3.4 Frequency distribution chart of percentage growth inhibition in normoxic and 
hypoxic conditions. A clear shift was observed in the mean percentage growth inhibition of cells 
























































Figure 3.5 SSMD values for all tested siRNAs, relative to NTC, in (A) normoxic and (B) 
hypoxic conditions. SSMD is a measure of effect size - the more negative the value, the higher 
the percentage growth inhibition (or the lower the cell viability). Some known driver genes in 






3.2 Drug-Repurposing Screen 
As an additional method of identifying targetable genes in HNSCC, a drug-
repurposing screen was employed, where the efficacy of 1,351 FDA-approved 
drugs developed for cancer and non-cancer indications were assessed for their 
ability to inhibit the growth of Liv7k cells in vitro. The drug libraries used are 
listed in chapter 2. Drugs chosen for further investigation were required to meet 
three main criteria: (1) result in over 90% growth inhibition; (2) exhibit higher 
efficacy under hypoxia; and (3) exhibit selectivity for Liv7k cells over non-cancer 
cells/other cancer types. The last was included, based on comparisons from 
previous drug screens carried out within the Screening Facility. The results from 
the drug screen are shown in Figure 3.6 in which drugs are coloured based on 
their library of origin. Interestingly, the procollagen C-proteinase inhibitor (UK-
383367) and estradiol valerate were found to have a greater effect on cell 
viability in hypoxia, but this angle was not followed up in this project. 
 
Figure 3.6 Scatter plot showing percentage growth inhibition of Liv7k cell line in response 
to treatment with FDA-approved compounds. A single concentration of 10μM was used for all 
compounds, and growth inhibition values were normalised to DMSO vehicle control. Results are 
the median of three screening replicates. Colours indicate the compound library used: Green, NIH 
Evotec Collection 1; Yellow, NIH Evotec Collection 2; Blue, Developmental Therapeutics Program 
(DTP) FDA-Approved Oncology Set; Red, LOPAC Pfizer (Sigma Aldrich); Orange, Selleck FDA-
Approved Library. Circle size depicts significance according to unpaired t-test (p value). Dashed 




3.3 Screening Analysis 
The results from both screens were analysed and combined with data from a 
number of other sources, including RNA and whole exome sequencing, pathway 
analysis software, in-house screening data and publically available patient 
datasets such as The Cancer Genome Atlas (TCGA). This allowed for the 
selection of the genes most likely to be involved in HNSCC progression. The 
validation approach of genes of interest largely depended on their function 
within the cell (i.e. metabolism, cell movement, epigenetics). Whole exome 
sequencing revealed the presence of a commonly amplified region of 
chromosome three, while a differential susceptibility to gene silencing in 
hypoxia formed the basis of a project centred on triglyceride and ether lipid 
metabolism. Finally, the drug-repurposing screen identified a dependence of 




Chapter 4 Results – Identification of HNSCC 
survival significant genes in the 3q26-29 
amplicon 
Whole exome sequencing of aggressive patient derived oral cancer cell lines 
revealed copy number amplification of a region at the terminal end of 
chromosome three (3q26-29). The region harbours 366 genes, 188 of which are 
protein coding. This chapter presents an analysis of genes within the amplicon, 
supported by transcriptomic data from The Cancer Genome Atlas (TCGA, n = 522 
samples), experimental screening data and pathway analysis. This led to the 
generation of a 6-gene set, which was statistically significant for patient 
survival. Knockdown of these highly expressed genes led to high percentage 
growth inhibition in an oral SCC cell line. Two genes were selected for target 
validation studies. 
Chromosome 3q26-29 is the most frequently amplified region in HNSCC and is a 
negative prognostic factor associated with increased invasive potential and 
decreased overall survival [409]. The region harbours multiple driver genes 
including PIK3CA, which encodes the p110 catalytic subunit of PI3K[410]; SOX2, a 
key regulator of stem cell differentiation[116]; TP63, a relative of TP53 with 
pleiotropic functions[411]; TERC, which encodes the RNA component of 
telomerase[412] and PRKCI, a serine/threonine kinase in the NF-Kβ 
pathway[413]. 
The close proximity of these genes makes an independent assessment of their 
oncogenic potential difficult and this complexity is further compounded by the 
co-amplification of other genes in the region. It is likely that most of the genes 
residing in these regions are passengers experiencing copy number gain in 
parallel with driver genes[414]; however, the presence of yet unidentified driver 




4.1 Amplification of chromosome 3q26-29 in oral SCC 
cell lines 
In order to determine if our patient derived cell lines contained the same 
pattern of copy number alteration as those in the TCGA dataset (see Figure 
1.4), whole exome sequencing (outsourced to Oxford Gene Technology, UK) was 
performed. This revealed copy number gain of 3q26-29 in the Liv7k and KR19 
cell lines but deletion in the Liv37k cell line, when compared to a reference 
human genome HG19 (Figure 4.1). The Liv7k cell line was used for the majority 
of subsequent phenotypic experiments, as they were a good representation of 





Figure 4.1 Copy number analysis of chromosome 3 from whole exome sequencing. Copy 
number plot (chromosome 3), showing amplification of q26-29 region (upper red line) in: (A) Liv7k 
and (B) KR19 and deletion of the region in (C) Liv37k. Each blue dot represents a probe from a 
microarray assay and is plotted vertically based on its fluorescent intensity. The intensity for each 
probe is plotted relative to a reference genome baseline (green line) and provides a copy number 




4.2 Identification of pro-oncogenic factors in 3q26-29 
Chromosome 3 is the third largest chromosome and contains 1078 protein coding 
genes[415]. 3q26-29 amplification is not unique to HNSC - it is a feature of 
squamous cell carcinomas in general, including those of the lung[113], 
cervix[416], oesophagus[417] and skin[418], and is consistently correlated with 
poor prognosis in these cancers. The 3q26-29 amplicon consists of four 
cytogenetic bands and contains 366 genes (188 of which are protein coding). 
TCGA analysis reveals that 117 (62%) of the 366 genes are upregulated at mRNA 
level (z score > 2) in more than 10% of patients with HNSCC (Figure 4.2). 
 
Figure 4.2 Expression profile of genes contained within 3q26-29 amplicon. 3q26-29 contains 
366 gene identities, which are split between four sub-regions. Genes are arranged by 
chromosomal location; the size of the circle depicts the total number of genes within the denoted 
chromosomal locus and inner segments represent the number of genes within that locus with 
mRNA upregulation (defined by a statistical cut-off of z score > 2 in > 10% samples, TCGA HNSCC 
dataset, n = 522 samples). Copy number amplification, mRNA upregulation and mutation 
frequencies are listed for known HNSCC driver genes (red, starred) and genes that we have 




4.3 10 genes are implicated in HNSCC patient survival 
(TCGA) 
In order to determine which of the 188 protein-coding genes were most relevant 
to HNSCC progression, additional criteria were applied. Interrogation of gene 
mRNA expression data in combination with patient survival statistics allowed for 
the identification of oncogenic targets with potential therapeutic significance. 
Using this approach, a total of ten genes (AHSG, EIF5A2, FXR1, IGF2BP2, PSMD2, 
SEC62, ALG3, DNAJC19, IL1RAP and NMD3) were identified as having a negative 
effect on overall and disease free survival when overexpressed at mRNA level in 
HNSCCs (p ≤ 0.05) (Figure 4.3).  
 
Figure 4.3 Survival significant genes are scattered throughout 3q26-29. Correlation plot of 
genes showing the percentage of patients with increased mRNA expression as defined by a z 
score of ≥ 2 versus chromosomal location (TCGA HNSCC dataset, n = 522 samples). Circle size 
and colour denote significance of reduced overall survival. Genes identified as being highly 
significant for patient survival in this analysis and known HNSCC driver genes are labelled. 




These genes are spread over the 3q26-29 amplicon with no obvious clustering. In 
addition, six genes (AHSG, EIF5A2, FXR1, IGF2BP2, PSMD2 and SEC62) have a 
greater cumulative effect on survival when overexpressed simultaneously 
(Figure 4.4a) (overall survival p=2.78x10−06, disease-free survival P=1.63×10−03). 
Although not the most frequently overexpressed gene in the analysis, 
overexpression of IGF2BP2 correlated with most significant decrease in survival. 
Four of the identified genes in the 6-gene set (AHSG, EIF5A2, FXR1 and IGF2BP2) 
encode RNA-binding proteins (RBPs) which regulate the translation of numerous 
gene transcripts and hence influence a wide range of cellular functions. Pathway 
analysis of survival significant genes identified interactions with known 
oncogenes in HSNCC which are also frequently amplified or overexpressed, 




Figure 4.4 Pathway analysis of survival significant genes reveals links to known oncogenes. 
(A) Survival analysis: left: Kaplan–Meier curves showing overall survival of patients with (red) or 
without (blue) overexpression of the 10-gene survival set identified in our analysis; right: table 
showing overall and disease-free survival p-values for overexpression of individual genes and 
concurrent overexpression of the gene set. Survival significance is categorised by log rank value: 
*10−1 **10−2, ***10−3, ****10−4. Survival is based on mRNA upregulation (z score ≥ 2) only. (B) 
Pathway analysis identifies interactions between survival significant genes and a module of core 
genes (PRKCI, SOX2, ECT2 and FXR1) which are known to be significant in HNSCC progression. 
GeneGo MetaCore™ was used to generate the signalling network of gene connections. Published 
in [419].  
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4.4 IGF2BP2 and PSMD2 are required for Liv7k viability in 
vitro and are highly significant for patient survival 
A number of survival-associated genes were found to be significantly upregulated 
at mRNA level in both the Liv7k cell line and TCGA dataset (blue dots, Figure 
1.9). Cross-referencing TCGA data with results from a whole genome siRNA 
screen identifies genes that are important for cell viability in the Liv7k cell line. 
Two genes (IGF2BP2, PSMD2) met all criteria, exhibiting amplified gene copy 
number, mRNA upregulation and significance for survival in patients, in addition 
to being required for Liv7k viability (Figure 4.5 and Figure 4.6). 
 
Figure 4.5 Highly expressed genes are also important for Liv7k cell viability. Scatter plot of 
mRNA expression in TCGA patient data (percentage of patients with a z score ≥ 2, cut-off minimum 
10% patients, red vertical line) and Liv7k siRNA screen (percentage growth inhibition > mean + 
1SD, blue upper horizontal line) identifies genes most substantially upregulated in patient samples 
and required for Liv7k viability. Blue dots represent 22 most highly expressed genes from RNA 
sequencing of Liv7k cell line, while 10 genes identified as significant for patient survival are labelled 





Figure 4.6 IGF2BP2 and PSMD2 overexpression is significantly correlated with reduced 
overall survival in HNSCC patients. mRNA overexpression (z score > 2) of either IGF2BP2 or 
PSMD2 is highly significant for overall survival in patients, as shown in Kaplan-Meier curves (log-
rank test, p < 0.01). Data generated from TCGA HNSCC dataset (n = 522 patients). Percentage of 
deceased patients at time of publication and median survival statistics are presented in graph. 
 
4.5 Discussion 
In this chapter, the process of identifying potential oncogenic driver genes in 
HNSCC is described. First, amplification of a region located at the terminal end 
of chromosome 3q in patient derived cell lines was confirmed. This region is 
amplified in a number of squamous cell carcinomas and is consistently associated 
with a poor prognosis in patients[113]. The region itself contains 188 protein-
coding genes, of which 117 (62%) are overexpressed (z score > 2) in more than 
10% of patients with HNSCC (see Figure 4.5). Additionally, 10 genes in the 
amplicon were found to be statistically correlated with for patient survival (p < 
0.05) in the TCGA HNSCC dataset (AHSG, EIF5A2, FXR1, IGF2BP2, PSMD2, SEC62, 
ALG3, DNAJC19, IL1RAP and NMD3). These genes are spread throughout the 
3q26-29 region, with no obvious clustering. Moreover, six of these genes have a 
greater negative effect on overall survival when overexpressed simultaneously 
(AHSG, EIF5A2, FXR1, IGF2BP2, PSMD2 and SEC62). 
Pathway analysis of the 10-gene set uncovered a number of interactions with 
known HNSCC driver genes, such as the stem cell maintenance gene SOX2 and 
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the protein kinase PRKCI. Of the 117 overexpressed genes, knockdown of 46 
genes (39%) caused a loss of viability greater than mean ±1 SD in a patient 
derived cell line. In the 10-gene set, overexpression of insulin-like growth factor 
2 binding protein 2 (IGF2BP2, 3q27.2) correlated most significantly with 
decreased patient survival, and silencing of the gene in Liv7k cells led to 
significant growth inhibition in a whole genome siRNA screen. Taking all of the 
data into account, IGF2BP2 was the first gene chosen for validation. 
Similarly, overexpression of proteasome 26S subunit, non-ATPase (PSMD2, 
3q27.1) correlates significantly with reduced patient survival. Moreover, 
silencing of the gene led to the highest percentage growth inhibition of survival 
significant genes in the Liv7k cell line. The gene encodes a subunit of the 19S 
regulatory cap, which flanks the 20S catalytic core of the 26S proteasome. 
Rapidly proliferating cells exhibit high rates of protein turnover and thus have an 
increased reliance on proteasomal machinery[420]. Chemical inhibition of the 
proteasome is an approved therapy for multiple myeloma[421], but has failed to 
provide a similar benefit in solid cancers such as HNSCC[422]. This is despite in 
vitro success, where treatment with the proteasomal inhibitor, bortezomib, was 
shown to induce apoptosis synergistically with cisplatin in HNSCC cells[423]. 
Moreover, bortezomib-induced proteasomal inhibition of HPV-positive HNSCC 
cells led to the restoration of functional p53 and the induction of cell cycle 
arrest[424]. In lung cancer, PSMD2 was identified as part of a metastatic gene 
signature, while silencing of the gene resulted in growth inhibition in lung 
adenocarcinoma cells[425, 426]. Given the importance of proteasomal activity in 
cancer and the inhibitory effect of PSMD2 silencing in a patient derived cell line, 
the gene was selected for follow up. 
Although not chosen for validation, previous studies have shown that other genes 
in the set can drive SCC progression and display a striking degree of cooperation 
in doing so. Four genes (AHSG, EIF5A2, FXR1 and IGF2BP2) encode RNA-binding 
proteins (RBPs), which can regulate the translation and stability of a number of 
gene targets and potentially affect a host of signalling pathways. Interestingly, 
HNSCCs have been shown to be enriched for genes encoding RBPs compared to 
matched normal tissue (p < 0.05)[427].  
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In a study of 81 HNSCC tumour samples, increased levels of fragile X-related 
gene 1 (FXR1, 3q26.33) mRNA was correlated with metastasis-free survival[428]. 
The same study also showed that FXR1 binds to and regulates the expression of 
two other 3q26-29 genes, epithelial cell transforming sequence 2 (ECT2) and 
protein kinase C iota (PRKCI), in non-small cell lung carcinoma (NSCLC). ECT2 
was overexpressed in 29% of patient tumour samples in this analysis, and has 
been shown to drive cell proliferation in oral SCC[429]. PRKCI is co-amplified 
with sex determining region Y (SOX2) and both genes cooperate to activate 
hedgehog signalling in lung squamous cell carcinoma (LSCC)[430]. FXR1 has also 
been shown to overcome cellular senescence in HNSCC through its joint 
modulation of p21 and stabilisation of TERC mRNA[431].  
Similarly, increased protein expression of SEC62 (SEC62, 3q26.2) was correlated 
with reduced overall and disease-free survival in 35 pre-treatment biopsies 
taken from patients with locally advanced HNSCC[432]. SEC62, another RBP, was 
identified as a potential oncogenic driver in prostate cancer and silencing of the 
gene significantly reduced the invasive potential of a number of cancer cell 
lines[433, 434]. Additionally, expression of the protein is essential for the 
maintenance of ER stress tolerance in the disease[435]. 
Although not directly studied in HNSCC, eukaryotic translation initiation factor 
5A2 (EIF5A2, 3q26.3) is overexpressed in a number of malignancies, where it is 
correlated with a poor prognosis and/or an aggressive phenotype[436-439]. 
Knockdown of the gene significantly impaired proliferation, migration and 
invasion processes in gastric cancer cell lines and was accompanied by 
downregulation of cyclin D1 (CCND1)[440]. Recent studies have shown that 
EIF5A2 promotes oncogenesis through its upregulation of the metastasis-
associated protein 1 gene (MTA1) in a c-MYC dependent process, which 
positively regulates epithelial to mesenchymal transition (EMT)[438]. Recently, 
it was discovered that functional EIF5A is essential for HIF-1α activation during 
hypoxia[441]. In this way, the 3q26-29 amplicon may promote the adaption of 
HNSCC cells low oxygen environments, thereby driving the selection of cells with 
a more aggressive phenotype. 
The majority of alpha-2-HS-glycoprotein (AHSG, 3q27) is synthesized in the liver 
and secreted into serum where it is involved in bone remodelling[442]. However, 
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the oral cavity is unique in that it can produce endogenous AHSG, which has 
been shown to promote a more invasive phenotype in HNSCC cell lines[443]. In 
support of this role, it has been demonstrated that circulating AHSG can protect 
matrix metalloprotease 9 (MMP9) from autolytic degradation potentially 
enhancing invasion[444]. In vivo studies have shown that AHSG can also promote 
the progression of breast cancer through its modulation of TGFβ signalling[445], 
while AHSG-/- mice show a reduced tumour burden in a Lewis Lung carcinoma 
model[446]. 
Overall, it is clear that the 3q26-29 amplicon contributes to HNSCC progression 
through the overexpression of one of more of its constituent genes. However, 
extricating the network of genes and the role each plays is difficult. Moreover, 
the degree of cooperation between these genes in HNSCC is unknown and makes 
the identification of putative driver genes even more challenging. Some of the 
genes contained within the amplicon are known oncogenes in the disease and a 
small number are targeted by currently available drugs, for example PIK3CA[447] 
and PRKCI[448]. Given the degree of interaction between certain genes, 
combination therapy may be the optimal way forward. However, the fact that 
overexpression of known HNSCC oncogenes (such as the two aforementioned 
genes) did not significantly affect patient survival in the TCGA dataset could 
place a greater importance on as yet undiscovered upstream mediators.  
The PI3K pathway is the most frequently mutated pathway in HNSCC, with a 
third of pathway genes containing driver mutations[57]. However, of the 162 
HNSCC samples overexpressing PIK3CA in this analysis, only 21.5% contain 
activating mutations in the gene. This substantiates the importance of 3q26-29 
amplification in HNSCC. Refinement of existing therapies to improve efficacy is a 
worthwhile venture, however intrinsic heterogeneity of tumours and the 
development of resistance will always be an obstacle to successful treatment. 
The development of novel targeted therapeutics is essential to maximise benefit 
to patients with HSNCC in the long run. There was a strong rationale to follow up 
of a number of 3q26-29 genes as potential therapeutic targets and/or predictive 
biomarkers, but based on patient survival data, two genes (IGF2BP2 and PSMD2) 




Chapter 5 Results – Validation of IGF2BP2 as a 
driver gene in oral squamous cell carcinoma 
5.1 Introduction 
Overexpression of IGF2BP2 had the most significant correlation in terms of 
overall patient survival in an analysis of TCGA data. The gene was also shown to 
be important for viability in a patient derived oral cancer cell line. An RNA-
binding protein (RBP), known to be upregulated in many cancers[177], IGF2BP2 
was selected as one of the targets for further investigation in this body of work. 
A comprehensive summary of what is known about the role of IGF2BP2 is 
provided in chapter 1.5. First, validation of knockdown and the effect on 
growth was carried out using deconvolved siRNA (the same as those used in the 
screen). Next, pathway analysis was performed on computationally predicted 
mRNA targets of IGF2BP2 from a collection of experimentally probed RBP binding 
sites in human transcriptomes[449]. The wider role of IGF signalling components 
was assessed using results from the siRNA screen and RNA sequencing data, 
which were carried out as part of this study. 
Based on the purported role of IGF2BP2 in IGF2-IGF1R-PI3K-AKT signalling[177], a 
major aim of this project was to determine the effect of IGF2BP2 depletion on 
cellular function. To this end, a number of models were created for use in 
phenotypic assays. These included knockdown of IGF2BP2 using siRNA, shRNA 
and CRISPR technologies. Upon validation of effective knockdown, these models 
were employed in proliferation, migration and invasion assays, as well as other 
3D models and metabolic measurements. In addition, western blots were 
performed to determine if IGF2BP2 is involved in oncogenic signalling. 
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5.2 IGF2BP2 expression in a series of oral SCC cell lines 
and validation of growth inhibition 
Gene expression levels of IGF2BP2 were measured in a panel of oral cancer and 
immortalised “normal” control cell lines using qRT-PCR (Figure 5.1). This 
allowed for categorisation of cell lines, which have high and low gene expression 
of IGF2BP2. In the panel, Liv7k cells had the highest expression of the gene, 
while Liv37k cells had the lowest, which corresponded to measured copy 
number. Two immortalised keratinocyte cell lines, OKF4 and OKG4, exhibited 
moderate expression of IGF2BP2. The inhibitory effect on cell growth was 
validated using a deconvolved pool of the screen siRNA set (Figure 5.2A). The 
percentage growth inhibition caused by IGF2BP2 knockdown varied with no 
obvious selectively for carcinoma cell lines over the immortalised cell lines. 
Knockdown efficiency of each deconvolved siRNA is shown in Figure 5.2B, as 
determined by qRT-PCR and western blot. 
 
Figure 5.1 : Bar chart showing mRNA expression of IGF2BP2 in four oral SCC cell lines 
(Liv7k, Liv52k, KR19, Liv52k) and two oral keratinocyte cell lines (OKF4, OKG4). Gene 
expression was measured by qRT-PCR and normalised to ACTB. Data is mean ± SD of three 





























Figure 5.2 Silencing of IGF2BP2 results in growth inhibition in oral SCC and oral 
keratinocyte cell lines. (A) Bar chart showing the effect of IGF2BP2 knockdown on cell growth. 
Results are plotted relative to non-targeting control siRNA (NTC). Data is mean ± SD of three 
technical replicates. (B) qRT-PCR showing reduction in IGF2BP2 gene expression after siRNA 
knockdown in Liv7k cells. IGF2BP2 expression was normalised to ACTB and presented relative to 
NTC. Data is mean ± SD of three biological replicates. Inset: western blot of IGF2BP2 expression 



















































5.3 Predicted Binding Sites of IGF2BP2 
In order to determine a potential role for IGF2BP2 in human cancer, predicted 
binding targets of the protein were acquired from a publically available 
database, (POSTAR, platform for exploring POST-trAnscriptional Regulation 
coordinated by RNA-binding proteins)[449]. These were input into the Reactome 
(http://www.reactome.org)[450] database to determine if IGF2BP2 
preferentially bound genes involved in a particular biological process. The 
POSTAR database contained mRNA targets of the protein in HEK293 cells only, in 
which there were over 100,000 sequence clusters recognised by IGF2BP2, with 
preferential binding to a CAUH (H = A/U/C) consensus sequence[451]. Overall, 
IGF2BP2 binding sequences were present in 3,442 protein coding mRNA 
transcripts (“Piranha” peak-calling, p-value < 0.01)[449]. Analysis of these 
transcripts using the Reactome database revealed significant overrepresentation 
of genes involved in cell cycle progression and metabolism of RNA (Table 5.1) 
[452, 453]. 




Total Ratio P value FDR 
1 R-HSA-69278 Cell Cycle, Mitotic 239 566 0.0418 8.33E-10 1.72E-06 
2 R-HSA-1640170 Cell Cycle 272 680 0.0503 8.08E-09 8.34E-06 






121 254 0.0187 3.91E-08 2.02E-05 
5 R-HSA-72172 mRNA Splicing 97 196 0.0145 1.62E-07 6.69E-05 
6 R-HSA-69620 Cell Cycle Checkpoints 121 279 0.0206 3.75E-06 1.29E-03 
7 R-HSA-8953854 RNA Metabolism 285 782 0.0578 7.35E-06 2.16E-03 
8 R-HSA-453279 Mitotic G1-G1/S phases 80 170 0.0125 1.10E-05 2.83E-03 
9 R-HSA-3247509 Chromatin modification 110 257 0.0190 1.73E-05 3.46E-03 
10 R-HSA-4839726 Chromatin organization 110 257 0.0190 1.73E-05 3.46E-03 
Table 5.1 Reactome analysis reveals predicted IGF2BP2 function. The top 10 biological 
processes of 3,442 protein-coding genes containing IGF2BP2 binding sites in HEK293 cells, as 




All three IGF2BP family members appear to recognise a similar set of target 
transcripts, suggesting a degree overlapping functionality [451]. However, this 
study used exogenously expressed IGF2BP2 and it is been shown that this can 
lead to aberrant sedimentation of RNA, as evidenced by sucrose gradient 
sedimentation[155]. Therefore, further validation is needed to confirm binding 
of IGF2BP2 to its proposed mRNA target.  
5.4 IGF2 is highly expressed in tumour cell lines 
compared to immortalised oral keratinocytes 
In chapter 4, IGF2BP2 was identified as part of an amplified region of 
chromosome 3 in two oral SCC cell lines (Liv7k, KR19). However, several layers 
of regulation exist between genomic DNA and the finished gene transcript. Most 
studies have reported a reasonable correlation between gene copy number (CN) 
and mRNA expression (GE) [454, 455]. As a rule, CN amplification is a stronger 
predictor of increased GE than vice versa. Pollock et al. reported that 40-60% of 
high level CN amplifications in human breast cancer tumours also showed 
elevated GE, while only ~10% of highly expressed genes were amplified[456]. In 
line with this, approximately 36% of patients with amplified IGF2BP2 copy 
number in the TCGA HNSCC database also exhibit overexpression of IGF2BP2 
mRNA. 
Previous studies have shown that IGF2BP2 binds to and stabilises IGF2 mRNA, 
thus regulating its translation[180, 457, 458], making the insulin signalling 
pathway a primary target for functional validation. IGF2 is a growth factor, 
which is most highly expressed in the early developmental stages. To this end, 
RNA sequencing of two patient-derived oral SCC (Liv7k, KR19) and two purchased 
oral keratinocyte cell lines (OKF4, OKG4) revealed mRNA expression levels of 
insulin pathway components (Liv7k comparisons are shown in Figure 5.3 and 
5.4, but KR19 was similar). The mRNA expression level of IGF2 was significantly 
higher in the SCC cell lines compared to oral keratinocyte cell lines, whereas 
IGF2BP2 was similarly expressed in all tested cell lines. Negligible levels of IGF1, 
IGFBP1 and INS and INSR were observed in tested cell lines. Copy number 
analysis of IGF2BP2 in the oral keratinocyte cell lines was not performed, so the 





Figure 5.3 RNA sequencing reveals fold change gene expression of insulin signalling genes 
between Liv7k and OKF/OKG4 cell lines. Scatter plot showing fold change of gene expression 
between Liv7k oral SCC cell line and two immortalised keratinocyte cell lines (OKF4, OKG4). Circle 




Figure 5.4 RNA sequencing reveals gene expression of insulin signalling genes. Mean 
normalised read count of insulin signalling genes in two oral SCC cell lines (Liv7k, KR19) and two 




























5.5 Knockdown of insulin signalling genes results in 
suppression of fitness in Liv7k cell line 
RNA expression of IGF2BP2 and other insulin pathway signalling genes was 
analysed in order to identify components of the pathway, which were 
upregulated in oral cancer cell lines versus immortalised keratinocyte lines. In 
addition, percentage growth inhibition (GI) data from the siRNA screen revealed 
variable dependencies on IGF signalling genes, with knockdown of IGF2BP2 
causing approximately 30% GI (Figure 5.5 and Figure 5.6). Applying a minimum 
cut-off value of 20% GI, genes that are important for survival in the Liv7k oral 
SCC cell line include IGF1, IGF2, IGF2BP2, IGFBP2, IGFBP4, IGFBP6, IGFBP7 and 
INSR.  
The mRNA expression of IGF2BP2 does not change significantly between tumour 
and keratinocyte cell lines. However, it is possible that IGF2BP2 acts on a 
different set of target transcripts in cancer cells compared to normal, or exhibits 
different activities. Interestingly, silencing of IGF2 results in a similar 
percentage growth inhibition as IGF2BP2; possibly suggesting that IGF2BP2 is 
exerting its phenotypic effect through the IGF2 growth factor. 
Despite the negligible expression of IGF1, INS and INSR (shown in Figure 5.4), 
knockdown of these genes using pooled siRNAs resulted in a high percentage 
growth inhibition (Figure 5.6). This suggests that the siRNAs used in the screen 






Figure 5.5 Scatter plot showing percentage growth inhibition in the Liv7k (median) cell line 
versus fold change of gene expression between Liv7k and OKF4 cell line. Thick lines 
represent fold change ≥ 2 for fold change and minimum growth inhibition of 30%, relative to siNTC 
control; colour is percentage growth inhibition upon gene knockdown in Liv7k cell line (green = low, 
red = high). IGF2BP2 is highlighted. 
 
  
Figure 5.6 The effect on Liv7k growth of knockdown of insulin pathway genes in siRNA 
screen. Results are normalised to non-targeting control (NTC) and presented as mean ± SD. 
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5.6 Quantification of IGF2BP2 levels in patient tumour vs 
matched normal tissue 
IGF2BP2 is overexpressed in ~22% of patients with HNSCC, according to the TCGA 
dataset. To determine IGF2BP2 expression in patient derived tumours versus 
normal matched tissue, RNA was isolated from four tumour/normal paired 
samples and converted to cDNA for qRT-PCR analysis (Figure 5.7). Two out of 
four showed increased expression of IGF2BP2 (fold change > 2) while a decrease 
was observed in one sample. Normal as described here refers to a sample taken 
from outside the tumour boundary, and was not histologically defined. IGF2BP2 
copy number was not measured in these tumour samples, but analysis of HNSCC 
(and oral SCC) datasets in Oncomine (www.oncomine.org) reveals consistent 
over-expression of the gene in tumours compared to normal matched tissue[459-
463]. 
 
Figure 5.7 IGF2BP2 mRNA expression was measured in patient tumour and matched normal 
samples. qRT-PCR showing IGF2BP2 gene expression in patient samples. IGF2BP2 expression 
was normalised to ACTB and given as tumour/normal. Data is mean ± SD of three technical 


































5.7 Generation of an shIGF2BP2 knockdown model 
In order to further assess the role of IGF2BP2 in HNSCC, Liv7k and Liv37k cells 
were infected with an inducible shRNA plasmid, which also contained an RFP 
reporter for visual confirmation of induction. After selection, cells were further 
selected by fluorescence-activated cell sorting. Cells were treated for 72 hours 
with doxycycline to induce maximum RFP expression and cells with high RFP 
expression were isolated and cultured independently (Figure 5.8). 
 
 
Figure 5.8 Generation of an inducible shRNA knockdown model. (A) FACS of Liv7k cells into 
high RFP expressing sub-population. (B, C) The efficiency of shRNA knockdown was assessed by 
western blot and RTq-PCR in Liv7k and Liv37k cells. For western blots, cells were treated with 
1µg/mL doxycycline for 72 hours prior to cell lysis. 20µg of protein was loaded per lane. ACTB was 
used as a loading control. RTq-PCR results are the mean ± SD of three biological replicates. 
IGF2BP2 expression was normalised to ACTB reference gene and presented relative to shNTC 






5.8 IGF2BP2 knockdown does not significantly affect oral 
cell line propagation 
Evidence in the literature has suggested that IGF2BP2 can enhance growth and 
survival of cancer cells[177]. To determine the role of IGF2BP2 in promoting an 
aggressive phenotype in oral SCC (based on TNM stage), a series of phenotypic 
assays were performed upon shRNA-mediated knockdown of the gene. The 
Incucyte ZOOM® (Essen BioScience) was used to measure cell propagation, 
migration and invasion, which were quantified using ZOOM software. Two unique 
shRNA sequences (#12532, #164973) were tested in each assay, with identical 
results. Hence, the result for one shRNA only is shown here.  
The result of each knockdown was normalised to a non-targeting control cell 
line. 1µg/mL doxycycline was added 72 hours prior to starting assays to ensure 
complete knockdown at experimental start point. Two cell lines were tested in 
each assay (Liv7k and Liv37k) because of their high and low expression of 
IGF2BP2, respectively. In addition, the Liv37k cell line exhibited a loss of the 
3q26-29 region (Figure 4.1). 
Cell propagation analysis (percentage confluence) revealed no impairment of 
propagation in either cell line. A representative result of shRNA-mediated 
knockdown is shown below (Figure 5.9). Non-doxycycline treated cells serve as 
an additional control showing changes in proliferation rates are not due to 




   
 
Figure 5.9 Cell propagation quantification following silencing of IGF2BP2 in (A) Liv7k and 
(B) Liv37k. Percentage confluence is shown for a non-targeting negative control cell line (shNTC) 
and a stable IGF2BP2 knockdown cell line (sh#12532) for each cell line. Results are plotted as the 























































5.9 IGF2BP2 knockdown does not significantly affect oral 
cell line migration 
The effect of IGF2BP2 knockdown on cell migration (wound healing assay) was 
measured and normalised to the shNTC negative control cell line. The result for 
one representative experiment is shown below (Figure 5.10). Knockdown of 
IGF2BP2 did not significantly impair cell migration following wounding of the 
monolayer. Follow up experiments in which human recombinant insulin and IGF-I 
growth factor were added in addition to knockdown yielded a similar result 
(data not shown). 
 
 
Figure 5.10 Measurement of cell migration following silencing of IGF2BP2 in (A) Liv7k and 
(B) Liv37k cells. Cells were pre-treated with 1µg/mL doxycycline and grown to a confluent 
monolayer over 24h. Following this, a scratch was made. The wound was imaged every two hours 
until complete closure. Relative wound density was calculated by the Incucyte ZOOM software and 
represents the density of the wound at the indicated time points compared to the initial wound. 




























































5.10 IGF2BP2 knockdown does not impair oral cell line 
invasion 
The rate of invasion through matrigel extracellular matrix was measured in Liv7k 
and Liv37k cell lines after IGF2BP2 knockdown. A schematic of the scratch assay 
is shown in Figure 5.11. However, silencing of the gene did not significantly 
slow the rate of invasion in the scratch assay over a 72-hour period (Figure 
5.12). Induction of the shRNA was confirmed by imaging in both brightfield and 
the red channel (representative result shown in Figure 5.13). 
 
Figure 5.11 Schematic representation of scratch assay used to assess oral SCC invasion. 
Briefly, diluted matrigel was used to coat each well of a 96-well plate and incubated overnight. The 
next day, 30,000 cells per well were seeded on top of the matrix layer and allowed to adhere 
overnight at 37°C / 5% CO2. A scratch was made using a Woundmaker™ (Essen Bioscience) and 
concentrated matrigel was added on top of the cell layer. Images were acquired every 2-3 hours for 






Figure 5.12 Cell invasion analysis following IGF2BP2 knockdown in (A) Liv7k and (B) Liv37k 
cells. Knockdown of IGF2BP2 does not impair wound healing through matrigel. Cells were pre-
treated with doxycycline and grown to a monolayer over 24 h. Following this, a scratch was made 
and images were taken every 2 hours for 72 h. Relative wound density was calculated by the 
Incucyte ZOOM software and represents the density of the wound at the indicated time points 
compared to the initial wound. Graph shows results from one representative experiment, mean ± 


























































Figure 5.13 Confirmation of RFP induction in Liv37k cells stably expressing the plasmid.
5.11 The role of IGF2BP2 in epithelial to mesenchymal 
transition (EMT) 
Metastasis to local lymph node is a multistep process involving the detachment 
of transformed cells from tumour tissue and invasion through the extracellular 
membrane. Loss of E-cadherin leads to reduced intracellular adhesion of tumour 
cells and a more mesenchymal phenotype. In addition to directly assessing the 
role of IGF2BP2 in invasion, evidence suggests that IGF2BP2 may promote 
invasion indirectly through its modulation of epithelial to mesenchymal 
transition (EMT)[177].  
Different invasive phenotypes were observed in the Liv7k and Liv37k cell lines, 
which were dyscohesive and non-cohesive, respectively. Expression of common 
markers of EMT (Slug, Snail and E-cadherin) was measured by western blot in the 
Liv7k and Liv37k cell lines. Complete loss of E-cadherin and high expression of 
Slug and Snail were observed in the Liv37ks, suggesting a more invasive 
phenotype in this low-expressing IGF2BP2 cell line. Silencing of IGF2BP2 led to a 
decrease in the expression of Snail, but not Slug in the Liv37k cell line (Figure 
5.14). 
 
Figure 5.14 IGF2BP2 knockdown leads to decreased Snail expression in Liv37k cell line. 
Western blot showing expression of E-cadherin, Slug and Snail in IGF2BP2-knockdown cell lines. 




5.12 IGF2BP2 depletion did not significantly impair 
chemotactic invasion in Liv37k cells 
Based on their enhanced invasiveness and EMT, Liv37k cells were selected for 
another invasion assay, this time involving a chemoattractant. These results 
suggest that IGF2BP2 is not required for chemotactic invasion in oral SCC cells as 
no difference in invasion was observed in a matrigel-containing transwell 
membrane (Figure 5.15). 
 
 
Figure 5.15 Inverse invasion assays were performed on shIGFBP2-induced Liv37k cell line. 
Cells were seeded in media (- EGF) and left to invade upwards toward media (+EGF and 20% 
FBS) for 5 days, when cells were live-cell stained with calcein AM and imaged using confocal 
microscope. Graph shows quantification of calcein AM area as measured by Fiji (ImageJ), mean ± 






























5.13 IGF2BP2 knockdown did not affect spheroid growth 
This project has mainly used in vitro 2D phenotypic assays to assess the role of 
IGF2BP2 in oral cancer progression. However, a 2D monolayer does not 
reproduce the complex architecture of a tumour in vivo, and often creates 
discrepancies in the efficacy of anti-cancer compounds. 3D culturing of cells 
creates a more physiologically relevant environment and represents the early, 
avascular stage of tumour formation. Additional factors such as tumour 
heterogeneity, hypoxia, cell-cell interaction and the remodelling of extracellular 
matrix are recapitulated in a 3D context[464].  
In order to provide a more accurate depiction of the role of IGF2BP2 in vivo, 3D 
spheroid models were formed using three oral SCC cell lines (Liv7k, Liv37k and 
Liv72k) with and without IGF2BP2 knockdown. Silencing of IGF2BP2 did not 
affect spheroid growth in any cell line tested. The results for one experiment 





Figure 5.16 Spheroid formation assay, showing the effect of IGF2BP2 knockdown in the 
Liv7k cell line. 5000 cells/well were seeded in ultra-low attachment round bottomed plates in ECM 
matrix and spun down to form a sphere. After 3 days, concentrated invasion matrix gel was added 
and images of spheroids were taken with 4x objective lens. Image quantification was carried out 








































5.14 The role of IGF2BP2 in mitochondrial metabolism 
Based on previous results published by Janiszewska et al.[179], measurements 
reflecting mitochondrial activity were made in the Liv7k and Liv37k (not shown) 
cell lines. Following stable knockdown of IGF2BP2, oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR), which are indicative of levels 
of oxidative phosphorylation and glycolysis, respectively, were measured (Figure 
5.17). No significant change was detected in either metabolic readout.
 
 
Figure 5.17 The effect of IGF2BP2 depletion on OCR and ECAR in Liv7k cell line. (A) Bar 
chart showing OCR and ECAR normalised to number of nuclei. Values were normalised to post-
measurement nuclei counts (DAPI stained cells read on Operetta) and presented as mean ± SD, 
n=20 wells. One representative experiment of three biological replicates. (B) Extracellular flux 
analysis in Liv7k cell line. OCR was measured under basal conditions followed by the sequential 
addition of oligomycin (1μM), FCCP (1μM), rotenone (1μM)  and antimycin A (1μM). Each data 






















5.15 The role of IGF2BP2 in the regulation of oncogenic 
signalling 
In order to determine if IGF2BP2 is an upstream activator of oncogenic signalling 
pathways, western blots were performed following shRNA-mediated knockdown. 
The results for the Liv7k cell line are shown in Figure 5.18. Human recombinant 
insulin was added to stimulate IGF-1R activation. However, no decrease in the 
phosphorylation of AKT, MAPK or p70 S6 kinase was observed. Similar results 
were obtained for the Liv37k and Liv72k cell lines and for cells treated with IGF1 
growth factor (data not shown). Knockdown of IGF-1R did not decrease IGF2BP2 
expression and silencing of IGF2BP2 did not decrease IGF-1R phosphorylation in 
Liv7k or Liv37k cell lines (data not shown). Given that knockdown of IGF-1R did 
reduce the expression of phospho AKT and MAPK, it appears that IGF2BP2 is not 
acting via this receptor, at least in oral cancer (Figure 5.19). 
 
Figure 5.18 The effect of IGF2BP2 knockdown on oncogenic signalling in the Liv7k cell line. 
Western blot shows expression of phospho and total AKT, phospho and total MAPK, phospho and 
total p70 S6 kinase and PI3K upon IGF2BP2 knockdown. 20µg protein was loaded per well and β-




Figure 5.19 Western blot showing expression of phospho and total IGF1R, IGF2BP2, 
phospho and total AKT and phospho and total MAPK upon IGF1R knockdown in Liv7k cell 
line. Results include cells treated with 100ng/mL IGF-1 for 15 minutes. 20µg protein was loaded 





In this chapter, the role of IGF2BP2 in HNSCC was assessed in a variety of 
phenotypic assays. There was a strong rationale in selecting the gene as a 
potential oncogenic driver in the diseases, based on genomic data and its 
correlation with patient survival. RNA-binding proteins, like IGF2BP2, interact 
with a large number of RNA transcripts throughout the cell and thus have the 
potential to influence a wide range of cellular processes[465]. RNA-
immunoprecipitation experiments have uncovered a host of new binding targets, 
further expanding the possible roles of IGF2BP2[173]. Previous studies have 
shown how IGF2BP2 can control oxidative phosphorylation in primary 
glioblastoma spheroids, and regulate the translation of EMT proteins[179, 213].  
TCGA patient data reveals IGF2BP2 upregulation in ~22% of HNSCC tumour 
samples. However, the same is true of many of genes in the 3q26-29 amplicon. It 
is likely that the majority of genes contained within this region are passengers of 
larger amplification events and have no effect on cell phenotype. For this 
reason, it was necessary to factor in additional selection criteria, such as patient 
survival, to refine the list of genes down to a more manageable set of 10 genes. 
In this set, IGF2BP2 had the highest individual significance on patient survival 
and pathway analysis revealed putative interactions with known oncogenic 
drivers in the disease. Knockdown of the gene also resulted in a high percentage 
loss of viability in the siRNA screen. This stepwise process of elimination allowed 
for the selection of the most likely driver gene candidates in HNSCC progression. 
Insulin signalling represents a key mechanism of HNSCC cell growth and 
survival[466]. IGF1R expression is higher in advanced TNM staged oral SCC 
tumours and is predictive of clinical outcome[120].  Moreover, the receptor can 
be trans-activated with EGFR[467], which also promotes cancer progression, 
metastasis and therapeutic resistance in the disease[468]. A number of small 
molecule inhibitors and monoclonal antibodies to IGF1R have entered clinical 
trials in recent years. Yet, despite a strong rationale, they have failed to show 




Knockdown of IGF2BP2 was achieved by siRNA, shRNA and CRISPR knockout, and 
each system was tested in phenotypic assays. CRISPR knockout cell lines yielded 
similar results to the shRNA models and thus results are not shown. In this study, 
knockdown of IGF2BP2, by any means, did not have a significant effect on the 
proliferation, migration or invasion in a set of oral SCC cell lines. Silencing of 
IGF2BP2 did not impair the growth rate of 3D spheroid models or result in a 
change in oxygen consumption rate. Importantly, knockdown of the gene did 
appear to decrease SNAIL expression in one cell line (Liv37k), but it did not 
translate to a reduced capacity to invade. Moreover, silencing of IGF2BP2 did not 
significantly influence major oncogenic signalling networks in HNSCC. The 
decreased expression of SNAIL in Liv37k cells (which display loss of 3q26-29 and 
have the lowest gene expression of IGF2BP2) is surprising, and may suggest that 
a minimal level of IGF2BP2 activity is required to maintain an aggressive 
phenotype in oral cancer. Overexpression of the gene in this cell line would 
perhaps provide more insight into its cellular function. 
Overall, despite a solid rationale for characterising the role of IGF2BP2 
overexpression, the results here show that it is most likely not a major player in 
HNSCC progression. To date, this is the first functional assessment of IGF2BP2 in 
a head and neck cancer setting. Studies demonstrating an oncogenic role for the 
gene thus far have been performed in other cancer models with potentially very 
different genetic backgrounds. Moreover, the heterogeneity of HNSCC itself may 
explain the inconsistencies in response to IGF2BP2 knockdown in this study. The 
Liv7k and Liv37k cell lines were primarily chosen for their high and low 
expression of IGF2BP2, respectively, and it was hypothesised that these cell lines 
would respond differently to the silencing of the gene. Despite originating from 
primary tumours with nodal involvement, the Liv7k and Liv37k cells displayed 
different invasive phenotypes (dyscohesive and non-cohesive, respectively) 
which may also have influenced their response to IGF2BP2 knockdown. I have 
recently completed an RNA-immunoprecipitation experiment with the Liv7k cell 
line, which is due to be sequenced in the near future. I hope that this will reveal 
novel binding partners of IGF2BP2 and provide further insight into its role in a 
head and neck cancer.  
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Chapter 6 Results – Validation of PSMD2 as a 
driver gene in oral squamous cell carcinoma 
6.1 Introduction 
PSMD2 was the second gene selected for phenotypic validation based on the 
analysis of the 3q26-29 amplicon. The gene, which encodes a subunit of the 26S 
proteasome, is overexpressed in 34% of patients with HNSCC and is significantly 
correlated with reduced overall survival in these patients (Figure 4.3). 
Moreover, silencing of the gene resulted in ~40% growth inhibition of Liv7k cells 
(Figure 4.5). Investigation of the proteasome as a therapeutic target also led to 
the identification of proteasomal subunit genes, which are downregulated in 
patients with HNSCC (compared to normal tissue), such as PSMD6. As proteasome 
activity is essential for cellular function, it was hypothesized that targeting 
genes with partial copy number loss would result in greater loss of viability in 
cancer cells than normal cells. In this chapter, copy number loss of PSMD6 is 
confirmed using Taqman® assays in a series of oral cell lines and the effect of 
siRNA knockdown on cell viability is measured. Dysregulation of the proteasome 
complex is clinically significant in a number of disease pathologies, and can be 
therapeutically exploited in the clinic. 
PSMD2 encodes a non-ATPase subunit (RPN1) of the 19S regulatory cap, which 
exists bound to a 20S catalytic core to form the 26S proteasome (Figure 6.1). 
RPN1 is the largest proteasomal subunit at 110 kDa and coordinates ubiquitin 
processing factors at the boundary between the regulatory and catalytic 
domains[469, 470]. Like PSMD2, PSMD6 encodes a protein in the 19S regulatory 
cap (RPN7) (Figure 6.1). In S. cerevisiae, the protein is essential in the 
maintenance of proteasomal integrity[471], and in human cells it has been 
shown to co-localise with DNA damage foci where it promotes cellular 
senescence following genotoxic insult[472]. Evidence for RPN7’s role in DNA 
damage repair has been strengthened by the finding that it interacts with 
BRCA2[473]. Two other proteasomal subunits, PSMC2 and PSME4, are 
investigated in this chapter based on their copy number alteration status. The 
former encodes RPT1, another essential subunit of the 19S regulatory cap while 
the latter encodes PA200, a regulator of proteasomal activity that stimulates the 
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hydrolysis of small peptides without using ATP[474]. The protein, which is 
primarily localised in the nucleus[475], is required for normal spermatogenesis in 
mice and plays an important role in DNA repair by recruiting proteasomes to 
sites of double stranded breaks[476, 477]. A putative role for PA200 has been 
discovered in a cancer setting where it was shown to regulate tumour cell 
responsiveness to glutamine after exposure to ionising radiation, by enhancing 
postglutamyl proteolytic activity[478, 479]. 
The proteasome represents the end stage of ubiquitin-mediated protein 
degradation and is essential for the maintenance of cellular homeostasis. 
Bortezomib (Velcade®; Millennium Pharmaceuticals Inc., Takeda Oncology, 
Cambridge, MA, USA) specifically targets the β5 subunit of the 20S core, 
inhibiting the chymotrypsin-like activity of the proteasome[480]. Evidence 
suggests that individual subunits play distinct roles in cancer, for example, 
PSMD9 expression has been shown to predict radioresistance in breast cancer 
whereas PSMD10 overexpression can promote cell survival in hepatocellular 
carcinoma[481, 482]. 
 
Figure 6.1 Structure of the 26S proteasome. The 20S catalytic core consists of a barrel of four 
stacked rings (two outer α rings and two inner β rings) and is capped on both ends by 19S 
regulatory particles. RPN1 (PSMD2) is highlighted in red. Bortezomib specifically inhibits the β5 
subunit of the 19S regulatory particle, which is responsible for chymotrypsin-like activity.  
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In addition to residing in a commonly amplified region of chromosome 3 (q26-
29), PSMD2 was identified as part of a metastatic gene signature in lung cancer 
where high expression of the gene correlates with poor prognosis[425]. 
Furthermore, knockdown of the gene significantly reduced proteasomal activity 
and proliferation in a panel of lung adenocarcinoma cell lines[426]. 
Interestingly, the authors of this study observed an increase in the expression of 
p21 (as well as a modest increase in p53 expression) upon silencing of PSMD2. 
Interestingly, a recent study found that a modest reduction of PSMD2 expression 
induced a shift in 20/26S proteasome complex ratios and protected cells against 
proteasomal inhibition by bortezomib[483]. 
Dependence on proteasomal turnover can leave cancer cells vulnerable to the 
silencing of subunit genes. Indeed, Nijhawan et al. recently showed that tumour 
cells harbouring partial loss of the PSMC2 gene are more sensitive to its silencing 
by siRNA/shRNA than non-tumour cells with normal copy number[484]. In a 
similar manner, this study aims to determine if oral cancer cells harbouring 
partial copy number loss of PSMD6 are more sensitive to knockdown of the gene. 
Collectively, these observations highlight the diverse and dynamic roles of 
proteasomal subunit genes in cancer progression. The current project seeks to 
investigate this reliance in two ways: firstly, to determine if overexpression of 
PSMD2 in oral SCC cell lines confers enhanced sensitivity to bortezomib; and 
secondly, to investigate the sensitivity of oral SCC cell lines exhibiting loss of 
copy number of proteasomal subunit genes to further suppression. 
Tumour cells are heavily reliant on proteasomal machinery in order to support 
high rates of proliferation. Since the FDA’s approval of bortezomib for the 
treatment of multiple myeloma in 2003[480], a number of next generation 
proteasome inhibitors have been developed[485]. However, the success of these 
inhibitors in blood-borne cancers has not extended to solid tumours. Bortezomib 
has been trialled in HNSCC in combination with existing chemotherapies, but the 
response rate in patients has been low[422]. The primary aim of this chapter is 
to determine whether targeting specific proteasomal subunit genes, such as 
PSMD2 or PSMD6 could represent a viable therapeutic strategy in HNSCC, or 
improve the efficacy of existing drugs.  
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6.2 PSMD2 is frequently overexpressed in HNSCC patient 
samples 
Using TCGA’s cBioPortal, the mRNA expression of 43 genes encoding proteasomal 
subunits were queried in the HNSCC dataset (n = 522), revealing upregulation of 
PSMD2 gene expression (z score > 2) in 34% of tumour samples (Figure 6.2). 
Moreover, silencing of the gene caused ~40% growth inhibition in the Liv7k cell 
line, possibly because of incomplete knockdown owing to extra gene copies. 
PSMD2 copy number amplification was present in ~20% of these tumour samples, 
a value consistent with other 3q26-29 genes. 
 
Figure 6.2 Genomic profiling of upregulated genes encoding proteasomal subunits. 43 
genes encoding proteasomal subunits were queried in TCGA’s cBioPortal (n = 522 samples). The 
percentage of patients with gene overexpression (z score ≥ 2) is plotted against the percentage 
growth inhibition resulting from gene knockdown in the Liv7k cell line, normalised to a non-targeting 
control siRNA. Dashed lines indicate a minimum cut-off of 30% growth inhibition and 




6.3 Concurrent downregulation of PSMD6 is a common 
event in HNSCC patient samples 
In addition to upregulation of PSMD2, gene expression and viability analysis for 
related proteasomal subunits identified concurrent downregulation of PSMD6. 
Approximately 60% of patient samples with upregulation of PSMD2 gene 
expression (z score > 2) also exhibited downregulation of PSMD6 gene expression 
(z score < -2) (Figure 6.4). PSMD6 is encoded within 3p14.1, a commonly 
deleted region in HNSCC tumours, which is also observed in the Liv7k cell 
line[117].  
Based on a recent study by William Hahn’s group[484], which identified specific 
vulnerabilities as a result of copy number loss, it was hypothesized that partial 
copy number loss of PSMD6 observed in Liv7k cells would render them highly 
dependent on the expression of the remaining copies. Thus, suppression with 
RNAi would have a greater effect in the Liv7k cell line than in other cancer cell 
lines that have diploid PSMD6 copy number.  
RNAi screening revealed a high dependence on genes with frequent copy number 
loss, including PSMD6, where knockdown in the Liv7k cell line caused ~80% 
growth inhibition (Figure 6.3). Furthermore, loss of PSMD6 copy number is 




Figure 6.3 Genomic profiling of downregulated genes encoding proteasomal subunits. 43 
genes encoding proteasomal subunits were queried in TCGA’s cBioPortal (n = 522 samples). The 
percentage of patients with downregulation of gene expression (z score ≤ -2) is plotted against the 
percentage growth inhibition resulting from gene knockdown in the Liv7k cell line, normalised to a 
non-targeting control siRNA. Dashed lines indicate a minimum cut-off of 30% growth inhibition and 





Figure 6.4 Genomic profile of PSMD6 expression in TCGA patient samples. Copy number 
status is given as GISTIC score (-2, deep deletion; -1, shallow deletion; 0, equal to matched normal 
sample; 1, gain; 2, amplification) alongside mRNA expression z score. PSMD6 copy number loss is 
frequently accompanied by downregulation at mRNA level (TCGA, n=522 samples). Red circles 
represent samples with PSMD2 copy number amplification (GISTIC +2).  
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6.4 PSMD6 gene copy number loss renders tumour cells 
more vulnerable to suppression of remaining copies 
RNA sequencing of two oral SCC and two oral keratinocyte cell lines revealed a 
differential expression of proteasomal subunit genes. PSMD2 and PSMD6 
expression sit at opposite ends of this spectrum. Subtracting the mean gene 
expression in the keratinocyte cells lines from the mean gene expression in the 
oral SCC cell lines revealed: (1) overexpression of PSMD2 and (2) downregulation 
of PSMD6 in carcinoma cells versus keratinocytes (Figure 6.5).  
To validate this, mRNA expression and copy number profiles of four differentially 
expressed genes were generated for a panel of cell lines using qRT-PCR (Figure 
6.6 and Figure 6.7). The genes were selected in order to provide a gradient of 
expression, from highly amplified PSMD2 > moderately amplified PSMC2 > 
moderately deleted PSME4 > highly deleted PSMD6. Copy number measurements 
revealed gain of PSMD2 in Liv7k and KR19 OSCC lines and loss of PSMD6 and 
PSME4, compared to normal control lines. Regardless of gene copy number status 
or mRNA expression, protein expression was similar in all tested cell lines 
(Figure 6.8).  
Percentage loss of viability was measured in two cancer and two non-cancer cell 
lines after siRNA knockdown of PSM genes (Figure 6.9A). This revealed a greater 
sensitivity of Liv7k/KR19 to loss of PSME4 and PSMD6 compared to OKG4, but not 
OKF4. Silencing of PSMD6 is particular caused major growth inhibition in three 
out of four cell lines tested. Validation of PSMD2 knockdown was validated using 
qRT-PCR (Figure 6.9B). Validation of protein knockdown also showed on-target 
effect (data not shown). PSMD6 knockdown could not be assessed owing to very 
high growth inhibitory effect on cells.
 Figure 6.5 RNA sequencing analysis reveals differential expression of proteasomal subunit genes in oral SCC cells versus immortalised keratinocytes. 
Each bar represents the difference in expression between oral SCC cells and immortalised keratinocyte cells as denoted in the legend. Expression is given as the 

















Liv7k-OKF4 KR19-OKF4 Liv7k-OKG4 KR19-OKG4
 Figure 6.6 Proteasomal subunit RNA expression profile. RTq-PCR was used to confirm 
proteasomal subunit mRNA expression in oral SCC cells and immortalised keratinocytes. Gene 
expression was normalised to β-actin and presented as mean ± SD of three biological replicates. 
 
 
Figure 6.7 Copy number analysis of PSMD2, PSMC2, PSME4 and PSMD6 using Taqman 
RTq-PCR assays in oral SCC/keratinocyte cell lines. RNaseP was used to normalise genomic 
DNA concentrations and DNA from a cell line known to be diploid (copy number = 2) for each gene 






















































Figure 6.8 Western blot analysis of the expression of the proteins encoded by PSMD2 and 
PSMD6, RPN1 and RPN7 respectively, in two oral SCC and two oral keratinocyte cell lines. 
20µg of whole-cell lysate was loaded per lane. Extracts were quantified and normalised using BSA 





Figure 6.9 Mean growth inhibition after knockdown of proteasomal subunit genes. (A) 
Pooled siRNA targeting selected proteasomal subunit genes were transfected into two oral SCC 
cell lines and two oral keratinocyte cell lines. 72h post-transfection, cells were fixed and stained 
with DAPI for imaging on the Operetta. Results are normalised to non-targeting control siRNA and 
represent the mean ± SD of three technical replicates. (B) RTq-PCR showing reduction in PSMD2 
gene expression after siRNA knockdown in Liv7k cells. PSMD2 expression was normalised to 
ACTB and presented relative to NTC. Data is mean ± SD of three biological replicates. siRNA #4 























































6.5 Copy number amplification of proteasomal subunit 
genes does not predict sensitivity to bortezomib 
Using compound screening data from the Sanger Institute[486], the sensitivity of 
427 authenticated cancer cell lines to bortezomib was plotted (Figure 6.10). 
Based on this, the relative sensitivity of the oral cancer cell lines used in this 
project was ascertained. A bortezomib-resistant breast cancer cell line (BT-474) 
was subjected to a dose response experiment alongside four oral cell lines. This 
cell line was used, as it was the only resistant cell line in frozen storage. The 
results are shown in Figure 6.11. All four oral cell lines had an IC50 value of 
between 0.002-0.006 µM, suggesting that the copy number status of PSM genes 
does not predict bortezomib sensitivity. 
 
Figure 6.10 Bortezomib IC50 values from the Genomics of Drug Sensitivity in Cancer Screen 
(Sanger Institute). IC50 values are presented for cell lines < 0.1 µM, with BT-474 cell line labelled. 





Figure 6.11 Bortezomib dose response curves in BT-474, oral SCC and immortalised 
keratinocyte cell lines. (A) Dose response curves and (B) IC50 values. Bortezomib concentration 
ranges from 0.00001-1µM. Results are normalised to DMSO vehicle control treatment and 





















6.6 Silencing of PSMD2 does not alter the response of 
oral cancer cells to proteasomal inhibition by 
bortezomib 
Based on a recent study by Tsvetkov et al., which showed that reducing the 
expression of 19S subunits protected cancer cells from bortezomib-mediated 
proteasomal inhibition[483], it was hypothesized that knockdown of PSMD2 in 
oral SCC cells may alter their response to bortezomib. To determine if this was 
the case, siRNA targeting the PSMD2 gene was transfected into Liv7k cells 24 
hours prior to the addition of bortezomib. However, no significant difference 
was observed in cells +/- PSMD2 in response to bortezomib (Figure 6.12).  
 
Figure 6.12 Bortezomib dose response curve +/- PSMD2 in Liv7k cell line. Pooled PSMD2 
siRNA was transfected into cells 24 hour prior to addition of bortezomib (concentration range 
0.0003 - 1 μM). Results are presented relative to DMSO vehicle control and are representative of 
the mean ± SD of three technical replicates.  
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6.7 Proteasomal activity is not altered by gene 
expression of PSMD2 (preliminary data) 
In order to determine if different gene expression profiles affected proteasomal 
function, basal proteasomal activity was measured in a panel of oral cell lines 
using the Proteasome-Glo™ chymotrypsin-like assay (Promega #G8660). Relative 
Light Units (RLU) was normalised to the number of nuclei per well and plotted in 
Figure 6.13. In this experiment, Liv7k and OKF4 cell lines had a lower basal 
proteasomal activity than KR19 and OKG4 cells. The effect of bortezomib on 
proteasome activity was also measured in the Liv7k, Liv37k and OKF4 cell lines, 
but no significant difference in IC50 was observed (Figure 6.14). 
 
Figure 6.13 Basal proteasomal activity measured in oral SCC and immortalised keratinocyte 
cell lines. Chymotrypsin-like activity of oral cell lines is ranked from lowest to highest. RLU is 











































Figure 6.14 The effect of bortezomib treatment on proteasome activity. Bortezomib dose 
response curves in Liv7k, Liv37k and OKF4 cell lines showing concentration required to inhibit 
proteasomal activity by 50%. Results are normalised to negative control and represent the mean ± 




PSMD2 encodes a regulatory subunit of the 26S proteasome, which is responsible 
for ATP-dependent degradation of ubiquitinated proteins. Similar to IGF2BP2, 
PSMD2 was shown to be highly upregulated in patient tumour samples and 
amplification of the gene was significantly correlated with reduced survival. 
Highly proliferative cells have a higher proteasomal activity and are thus more 
vulnerable to its depletion than normal cells. Thus, it was hypothesized that 
knockdown of PSMD2 would have a greater effect on the survival of cancer cell 
lines than normal controls.  
Publically available data from the Sanger Institute (Wellcome Trust) presented a 
number of useful control cell lines, previously shown to be sensitive/resistant to 
bortezomib. In a pan-cancer analysis, resistance to bortezomib in these cell lines 
is significantly correlated with a number of genetic alterations (including 
mutation in SOS2), but no alterations in proteasomal subunit genes was detected 
in bortezomib resistant cell lines[486]. To test this theory, I carried out real 
time qPCR on a panel of oral SCC cell lines in order to rank them from highest to 
lowest expression of PSMD2, which I could then relate with their sensitivity to 
bortezomib. To support the mRNA expression, I carried out western blots to 
assess basal protein expression in selected cell lines. No significant difference in 
protein expression was observed. I also generated IC50 curves for bortezomib; 
however, there was no correlation between a higher transcription of the PSMD2 
gene and enhanced sensitivity to bortezomib. A second-generation proteasomal 
inhibitor, carfilzomib, was also tested, but similar results were observed (data 
not shown). However, other factors can also contribute to bortezomib 
sensitivity, including AKT activation status.  
Although there was a higher mRNA expression of the gene in Liv7k cells 
compared to immortalised oral keratinocyte cell lines, protein expression was 
similar in all cell lines tested. In addition, silencing of PSMD2 resulted in a 
similar or greater loss of viability in the normal control cell lines, and did not 
alter the response of Liv7k cells to bortezomib. This, combined with the high 
proteasomal activity in these cell lines, suggests that the immortalised 
keratinocyte cell lines have adapted to growth on a 2D monolayer. This 
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highlights a weakness of this project, which is the lack of control cells that 
accurately represent the situation in normal tissue. Moreover, the tumour cell 
lines may respond differently to loss of proteasomal subunit expression in vivo 
where nutrients and oxygen are limited. 
In addition to upregulation of PSMD2, gene expression and viability analysis for 
related proteasomal subunits identified concurrent downregulation of PSMD6 in 
oral cancer cell lines. Genomic instability of tumours often promotes loss of 
chromosomal regions, which contain tumour suppressor genes, accompanied by 
collateral loss of other genes. Based on a recent study by William Hahn’s 
group[484], which identified specific vulnerabilities resulting from gene copy 
number loss, it was hypothesized that the partial copy number loss of PSMD6 
would render Liv7k cells highly dependent on expression of the remaining copy. 
Thus, suppression with siRNA would have a greater effect in the Liv7k cell line 
than in normal cell lines with diploid copy number. The gene, which is deleted in 
~6% of HNSCCs, is important for cell viability as knockdown of the gene resulted 
in >80% growth inhibition in Liv7k cells. In addition, RNA sequencing revealed 
downregulation of the gene in cancer cell lines compared to oral keratinocytes. 
Knockdown of the gene was only half as effective in the OKG4 cell line. 
However, OKF4 cells did not follow this trend. This inconsistency cannot be 
explained by the expression of PSMD6 in the cell lines, as both OKF4 and OKG4 
showed a relative copy number loss of the gene compared to Liv7k. 
Protein expression of RPN1 (PSMD2) and RPN7 (PSMD6) was equal in all cell lines, 
which might explain the similar response to bortezomib. Gene expression does 
not always correlate with protein expression[487] as many levels of regulation 
exist between gene transcription and production of the final protein[488]. RNA-
binding proteins, such as IGF2BP2, exert a major influence on the stability and 
the rate of translation[489]. However, as previously stated, the environment in 
situ may alter the dynamics of this relationship in such a way as to render the 
expression of PSMD2 or PSMD6 relevant for survival. 
In conclusion, overexpression of PSMD2 could not be correlated to an increased 
dependence on proteasomal machinery in an oral SCC model. Partial copy loss of 
PSMD6 does not appear to render cells more vulnerable to its suppression, and 
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the gene appears to be critical for survival in oral keratinocyte cell lines. The 
activity of the proteasome, and hence its importance in cancer progression, 
relies on a regulatory system more complex than expression of its individual 
components. Based on these results, there is nothing to support that PSMD2 




Chapter 7 Results – The Role of Lipid 
Metabolism Genes in Hypoxia 
7.1 Triglyceride Metabolism 
The mainstay treatment for resectable oral SCC is surgery; however, 
chemo/radiotherapy is used as a primary means of treatment in patients who 
are unable to tolerate such a procedure[490]. External beam radiotherapy 
(EBRT) and conventional chemotherapy can also be used as adjuvants. Hypoxia is 
a defining feature of oral SCC and tumours with poor oxygenation are more 
resistant to chemo/radiotherapy[491, 492]. Hypoxia elicits a range of cellular 
responses, including changes in metabolism, increased angiogenesis and 
enhanced growth and survival. The master regulator of the hypoxic response is 
HIF-1α, which is overexpressed in up to 70% of oral SCCs and is significantly 
correlated with poor survival[493]. Moreover, increased expression of HIF-1α is 
associated with increased rates of metastasis through increased expression of 
matrix metalloproteases and chemokines[494, 495]. 
An increased rate of lipid synthesis is recognised as an important aspect of 
altered metabolism in tumour cells. However, the role that lipids play in cancer 
progression is not clear. Under normal conditions, de novo biosynthesis of fatty 
acids is restricted to particular tissues such as the liver. However, tumours can 
autonomously produce fatty acids and lipid components required for 
growth[272]. Fatty acids are the essential building blocks of lipids and are used 
to build many classes of lipids, which perform a range of functions within the 
cell. A family of transcription factors called sterol regulatory element-binding 
proteins (SREBPS) are master regulators of lipid biosynthesis[496]. Dysregulation 
of SREBPs can stimulate a network of oncogenic signals and promote an 
aggressive phenotype in oral cancer cells[275]. 
7.1.1 Lipid metabolism genes are upregulated in hypoxia 
The aim of this project was to identify genes that provide a growth advantage to 
cells in hypoxia (defined here as 0.1% O2). A data multiplexing approach was 
taken which combined results from a whole genome siRNA screen with RNA 
sequencing analysis. The siRNA screen, which was carried out on the aggressive 
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oral SCC cell line (Liv7k), involved the knockdown of 18,175 genes in normoxic 
(21% O2) and hypoxic (0.1% O2) conditions. In addition, RNA sequencing (RNAseq) 
was carried out to identify changes in gene expression in hypoxia. 
A threshold window of 20% growth inhibition was set between hypoxia and 
normoxia, with a 10% minimum growth inhibition in hypoxia. Of 18,175 genes 
screened, 11% (n=1990) met this criteria (Figure 7.1). However, only 813 genes 
in this subset were deemed significant when a Mann-Whitney t-test was applied 
(p<0.05). Of this filtered set, 127 genes (22%) were also significantly upregulated 
at mRNA level (p<0.05) by ≥ 2-fold. Gene Ontology analysis of this refined gene 
set revealed significant over-representation of genes involved in lipid 
metabolism. 
Enrichment analysis was carried out using Metacore GeneGo™ software in order 
to narrow down specific canonical pathways, which are upregulated in hypoxia 
(Figure 7.2). In this analysis, control of cholesterol and fatty acid biosynthesis 
by SREBP ranked as the second most significant biological pathway (Figure 7.3). 
Sterol regulatory element binding proteins (SREBPs) are a family of transcription 
factors that regulate various aspects of lipid metabolism. SREBP cleavage-
activating protein (SCAP) acts as a chaperone for SREBPs, mediating their 
transport from the endoplasmic reticulum to the Golgi apparatus where they are 
cleaved into active forms. Three isoforms (SREBP1a, SREBP1c and SREBP2) exist 
in mammalian cells and regulate expression of different target genes. SREBP1c 
preferentially regulates genes involved in fatty acid and triglyceride metabolism 
(e.g. FASN), while SREBP2 activates cholesterol synthesis (e.g. HMGCS1). SREBP1 





Figure 7.1 Primary siRNA screen results showing median percentage growth inhibition 
relative to non-targeting control in normoxic and hypoxic conditions. Gene knockdowns that 
are selectively lethal in hypoxia are highlighted in blue. Growth inhibition is normalised to non-
targeting control siRNA. Cut-off was set at 20% difference between hypoxia and normoxia 
(diagonal line) with a minimum growth inhibition of 10% in hypoxia (horizontal line). Circle size is 






Figure 7.2 Metacore GeneGo™ analysis of the hypoxic gene set. Enrichment analysis of 
RNAseq data reveals top 10 upregulated (A) canonical pathways and (B) biological processes in 




Figure 7.3 SREBP-mediated regulation of cholesterol/fatty acid biosynthesis. Pathway 
mapping of “SCAP/SREBP Transcriptional Control of Cholesterol and FA Biosynthesis”, 
highlighting up (red) and downregulated (blue) genes. Image generated by Metacore GeneGo™ 




7.1.2 A subset of triglyceride metabolism genes are important for 
cell survival in hypoxia 
Based on this analysis, a subset of genes that mediate triglyceride metabolism 
(DAGLA, DGAT1, DGAT2, LIPE, MGLL, PNPLA2, SCD) was selected for further 
study based on the differential effect observed upon their knockdown in 
hypoxia. Six of these genes (DGAT1, DGAT2, LIPE, MGLL, PNPLA2, SCD) 
demonstrated an increase in gene expression in hypoxic conditions (Figure 7.4). 
DAGLA gene expression was reduced by > 2 fold in hypoxia (data not shown). 
In addition, data from the siRNA screen indicated that knockdown of 
monoacylglycerol lipase (MGLL) and diacylglyceride acyltransferase 2 (DGAT2) 
resulted in a significantly greater percentage growth inhibition in hypoxia 
compared to normoxia (Figure 7.5). The proteins encoded by these genes work 
in opposing ways, with DGAT2 building triglycerides from fatty acids and MGLL 
breaking them down. This highlights the importance the two genes play in terms 
of energy release vs storage, a vital process for highly proliferative oral cancer 
cells.
 Figure 7.4 Window of percentage growth inhibition versus fold change in gene expression 
between hypoxic and normoxic conditions. Blue circles represent statistical significance in both 
the siRNA screen and the RNAseq dataset, including a window of growth inhibition between 
hypoxia and normoxia of ≥ 20%, a minimum growth inhibition of 10% in the normoxic condition (p < 
0.05) and a fold change in gene expression of > 2 (p < 0.05). Circle size denotes growth inhibition 




Figure 7.5 Mean percentage growth inhibition after knockdown of triglyceride metabolism 
genes (data from siRNA screen). Results are presented as mean ± SD. DGAT2 and MGLL were 

































7.1.3 Validation of differential growth inhibition did not confirm 
screen findings 
In order to validate the differential growth inhibition observed in the siRNA 
screen siRNAs from a different supplier targeting genes of interest were 
transfected into two oral SCC (Liv7k, Liv37k) and two immortalised keratinocyte 
cell lines (OKF4, OKG4). However, under these conditions, MGLL and DGAT2 
knockdown resulted in a similar percentage growth inhibition in both normoxia 
and hypoxia (Figure 7.6). Interestingly, silencing of PNPLA2, which encodes 
adipose triglyceride lipase (ATGL), resulted in a greater differential than that 
measured in the siRNA screen. 
Mean Percentage Growth Inhibition 
Gene Screen (N) Screen (H) Validation (N) Validation (H) 
DAGLA 25.0 13.9 48.54 7.75 
DGAT1 20.9 40.6 68.44 39.55 
DGAT2 5.1 48.8 16.33 -14.90 
LIPE 61.8 68.2 47.24 27.63 
MGLL 13.8 60.3 29.59 24.10 
PNPLA2 24.9 17.0 8.04 31.23 
SCD 88.9 95.1 92.49 55.29 
Table 7.1 Mean percentage growth inhibition after knockdown of triglyceride metabolism 
genes (comparison of data from siRNA screen with validation experiments). Results are 
presented as mean ± SD. 
 
The ATGL enzyme works alongside hormone sensitive lipase (LIPE) to mobilise 
triglycerides and provide cells with energy. A series of recent papers document a 
role for ATGL in cancer. Inhibition of ATGL by the small molecule inhibitor 
atglistatin attenuates the growth of non-small cell lung adenocarcinomas, 
suggesting its enables an aggressive phenotype in tumours[497]. Increased 
expression of the protein was also associated with higher rates of stromal 
proliferation in pancreatic ductal adenocarcinoma, possibly contributing to a 
more invasion phenotype[498]. It has been established that ATGL catalyses the 
rate-limiting step in triglyceride metabolism in adipose tissue, and that its 
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activity increases in parallel with tumour growth[499, 500]. ATGL has also been 
implicated in cachexia in cancer patients, confirming in vivo studies which show 
ATGL null mice to be protected from tumour-induced lipolysis[501]. 
The most lethal knockdown observed in these validation studies was that of 
stearoyl-CoA Desaturase (SCD), possibly reflecting its unique importance in fatty 
acid chain modification. While a degree of redundancy exists in the triglyceride 
storage system with more than one enzyme catalysing similar steps, SCD is the 
only enzyme that can create a double bond in long-chain fatty acids. 
Interestingly, silencing of the gene caused greater growth inhibition in the Liv7k 
cell line compared to the OKG4 keratinocyte cell line. This could possibly 
suggest a vulnerability of highly proliferative cells on the modification of fatty 
acid chains, which are synthesized in greater numbers. However, OKF4 cells 
were as sensitive to SCD silencing as the oral cancer cell lines.
 Figure 7.6 Knockdown of triglyceride metabolism genes leads to growth inhibition in oral cancer cells and immortalised keratinocytes. (A-G) Mean growth 
inhibition was measured in response to gene knockdown and normalised to non-targeting control siRNA in normoxic (red) and hypoxic (blue) conditions. The results 
from pooled siRNA are shown and results are presented as the mean ± SD of three experiments.
7.1.4 Silencing of MGLL leads to a build-up of triglycerides in 
tumour cells 
In order to confirm the mechanism by which silencing of triglyceride metabolism 
genes causes a reduction in cell growth, neutral lipid staining with BODIPY 
493/503 was performed. After treatment with siRNA, cells were fixed and 
stained with DAPI (nuclei), whole cell stain red (cell boundaries) and BODIPY 
493/503 (neutral lipid droplets). Lipid droplet quantifications were generated 
alongside percentage growth inhibition for four cell lines (Liv7k and OKF4 shown 
in Figure 7.7).  
Silencing of MGLL led to a build-up of lipid droplets in both normoxic and 
hypoxic conditions, consistent with its role in breaking down triglycerides into 
fatty acids. Interesting, knockdown of LIPE resulted in a marked difference in 
the levels of lipid droplets between hypoxia and normoxia. Silencing of DGAT2 
led to a small reduction numbers of lipid droplets in the Liv7k cell line. While 
the effect of MGLL knockdown was consistent in all cell lines tested, knockdown 
of LIPE and DGAT2 also caused an increase in the number of droplets in other 
lines. It is possible a degree of overlap exists between DGAT2 and its family 
gene, DGAT1, which could be elucidated by dual knockdown. 
If oral cancer cells are more dependent on fatty acids for energy in hypoxia, it 
would be expected that knockdown of triglyceride lipase genes (DAGLA, MGLL, 
PNPLA2, LIPE) would have a greater effect on cell growth in this condition. In 
the Liv7k cell line, knockdown of MGLL and LIPE led to a build-up of lipid 
droplets in normoxia only (> 1.5 fold). This may suggest a greater activity of 
other lipases in hypoxia, which are able to compensate for the silencing of one 
gene. Interestingly, PNPLA2 knockdown had the opposite effect, showing a 
hypoxia-specific increase in lipid droplets.
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Figure 7.7 Quantification of neutral lipid droplets in oral cell lines. (A-G) BODIPY 493/503 neutral lipid stain was used to stain neutral lipid droplets (mostly 
triglycerides) in normoxia (red) and hypoxia (blue) upon knockdown of triglyceride metabolism genes. Lipid droplets were counted using Harmony software (Perkin 
Elmer) and normalised to non-targeting control siRNA. Fold change is the mean ± SD of three experiments. (H) Representative image of Liv7k cells treated with non-
targeting control and MGLL siRNA, with magnified inset.
H 
7.2 Ether Lipid Metabolism 
Reprogramming of metabolism is an important hallmark of cancer and 
dysregulated lipid metabolism plays a major role in tumour development[502, 
503]. Fatty acids support the rapid proliferation of tumour cells by acting as a 
substrate for energy production, building blocks for cell membranes and lipid 
signalling molecules. Ether lipids make up approximately 20% of total 
phospholipid mass[504], and data from the siRNA screen, in combination with 
pathway analysis suggests that ether lipid metabolism can selectively support 
cell viability in a hypoxic environment.  
Tumour cells possess elevated levels of ether lipids (such as plasmalogens), 
which are characterised by one or more ether linkages on the glycerol backbone, 
in place of the more common ester linkage[505-507]. This alternative structure 
has important implications for the roles of ether lipids within the cell, including 
membrane fusion, vesicle formation and lipid-mediated signalling. A key enzyme 
involved in ether lipid biosynthesis, alkylglycerone phosphate synthase (AGPS), is 
overexpressed in a number of aggressive cancer types, including breast and 
melanoma[268]. By mobilising free fatty acids from neutral lipid stores, AGPS 
intensifies de novo generation of lipid signalling molecules such as 
lysophosphatidic acid (LPA), and enhances tumourigenicity[508]. However, the 
specific role of AGPS and ether lipids in a low oxygen setting is unknown. An 




Figure 7.8 Overview of Ether Lipid Synthesis. AGPS, alkylglycerone phosphate synthase; FAR, 
fatty Acyl-CoA Reductase; GNPAT, glycerone-phosphate O-Acyltransferase; e: lysophosphatidic 
acid-ether. 
 
AGPS catalyses the rate limiting step in ether lipid synthesis but the process also 
involves Fatty Acyl-CoA Reductase 1 and 2 (FAR1/2) and Glycerone-phosphate O-
Acyltransferase (GNPAT)[509]. All three enzymes reside and act within 
peroxisomes where FAR1 and FAR2 provide substrate for GNPAT and AGPS to 
synthesize ether lipids by reducing fatty acids to fatty alcohols. GNPAT catalyses 
the acylation of dihydroxyacetonephosphate (DHAP) to acyl-DHAP, which is 
subsequently acted on by AGPS to exchange the acyl for an alkyl group[510]. 
Genetic deficiencies in AGPS, GNPAT or FAR1 severely impair the formation of 
etherphospholipids, and have been linked to cataract formation in humans and 
mice[511-514]. At the time of writing, only AGPS has been shown to have a role 




7.2.1 A subset of genes involved in ether lipid synthesis are 
essential for cell viability in hypoxia 
Analysis of the ether lipid synthesis pathway revealed a number of ether lipid-
related genes that when silenced in the Liv7k cell line had an effect on viability 
in hypoxia (Table 7.2). Analysis of the TCGA HNSCC dataset reveals altered gene 
expression of ether lipid biosynthesis genes in 5-10% of cases, confirming the 
importance of this pathway (Figure 7.9). Alterations in the expression of AGPS 
tend toward a reduction in patient survival, according to the TCGA HNSCC 
dataset (not significant). A small percentage of patient samples contain mutually 
exclusive alterations in ether lipid biosynthesis genes, but no further reduction 
in patient survival is observed. 
 Mean % Growth Inhibition  
Gene Normoxia Hypoxia Fold Change P value 
AGPS 19.22 69.06 3.59 0.006 
FAR1 24.27 32.41 1.34 0.619 
FAR2 3.52 34.56 9.80 0.015 
GNPAT 14.74 24.02 1.63 0.398 
Table 7.2 siRNA screen results showing percentage growth inhibition for ether lipid 
biosynthesis genes in Liv7k cell line. Fold change values are given for hypoxia and normoxia 





Figure 7.9 Gene expression of major ether lipid pathway components from TCGA HNSCC 
dataset. Box plot shows the percentage of 522 patients with altered expression (red, z score > 2; 




7.2.2 Validation of AGPS knockdown in oral SCC cell lines 
Knockdown with deconvolved siRNAs (same sequence as in screen) to ether lipid 
genes validated the high percentage growth inhibition from the siRNA screen; 
however, the differential between hypoxia and normoxia could not be repeated 
in 3/4 oligos (Figure 7.10). The efficiency of AGPS knockdown was assessed by 
qRT-PCR showed ≥ 90% loss of gene expression compared to non-targeting 
control (data not shown). A significant reduction is protein expression was also 
observed in response to AGPS knockdown (Figure 7.11). However, AGPS is also 
essential for the viability of normal cell lines, as evidenced by the high 
percentage growth inhibition in OKF4 (data not shown). 
 
Figure 7.10 Validation of growth inhibition upon silencing of ether lipid genes in Liv7k cell 
line. Cells transfected with four individual and pooled siRNA sequences were normalised to non-


























Figure 7.11 Validation of AGPS knockdown in Liv7k cell line. Western blotting of treated cells 
confirmed reduction in AGPS protein expression in response to silencing with siRNA targeting the 
gene. Knockdown was observed in all deconvolved sequences (#1-4). 20µg of protein was loaded 




7.2.3 Lipid profiling of AGPS knockdown cells in hypoxia 
Ether lipids are present at higher levels in tumour cells, but their function 
therein is unclear. AGPS catalyses a critical step in the production of ether lipids 
and is upregulated in HNSCC. So far, I have shown that AGPS and other related 
pathway components are required for oral cell viability under both normoxia and 
hypoxia. To unravel the dependence of oral cells on ether lipid species, a series 
of LCMS experiments were performed. In addition, the impact of low oxygen on 
levels of ether lipid species was assessed. 
LCMS profiling of Liv7k cells following AGPS knockdown in normoxia and hypoxia 
revealed alterations in multiple ether lipid metabolites, including 
phosphocholines (PC), phosphoethanolamines (PE), phosphoinositols (PI), 
phosphoserines (PS) and lysophosphatidylcholines (LPC) (diacylglycerols and 
triacylglycerols were not included in this analysis). These lipids carry out a range 
of functions, including formation of the cell membrane, energy storage, and cell 
signalling.  
Gillian Mackay (CRUK Beatson Institute) carried out LC-MS analysis in which Liv7k 
cells were treated with a non-targeting control siRNA and compared to four 
unique siRNAs targeting AGPS in normoxia and hypoxia. In addition to internal 
standards (pos, PC 170/170; neg, PE 170/170), the concentration of lipid species 
was measured and normalised to cellular RNA content. In total, 68 ether lipid 
species were detected. Species detected by positive (n=29) and negative (n=39) 
ion mode were combined for this analysis. MetaboAnalyst 3.0 software 
(http://www.metaboanalyst.ca) was used to analyse mass spectrometry data in 
this project[515]. The first step was to normalise and transform the data (Figure 
7.12). Data was mean-centred and divided by the standard deviation in order to 
make individual species more comparable. Following this, the data was logged in 





Figure 7.12 Pre-processing of LC-MS Data. Data was pre-normalised to internal lipid control 
species (pos, PC 170/170; neg, PE 170/170). Prior to analysis, normalised data was log 
transformed and mean-centred in order to make individual values comparable in magnitude to each 
other. The left panel shows a box and whisker plot of the data before normalisation while the right 




7.2.4 Hypoxia alters levels of ether lipid species 
Unsupervised principal component analysis (PCA) was performed on the non-
targeting groups only to assess the changes in the lipid profile in hypoxic 
conditions. A 2D PCA scores plot describes a set of observations based on a large 
number of variables in a two dimensional graph. PC1 and PC2 represent the 
principal components, which in this case, describe the concentration of lipid 
species spanning the most and the second most variation between hypoxia and 
normoxia, respectively. The levels of lipid metabolites varied depending on 
oxygen condition (Figure 7.13). The expression of 36 metabolites decreased in 
hypoxia while 32 increased (Figure 7.14). However, significant downregulation 
of ether lipids (log2FC > 1.5, p < 0.05) was observed for 5/36 lipids, and only 
1/32 metabolites significantly increased. 
 
Figure 7.13 Principal Component Analysis (PCA) plot of ether lipid species in hypoxia and 
normoxia. PC1 explains 65.8% of variation in the concentration of ether lipid species, while PC2 
explains 20.4%; together PC1 and PC2 account for 86.2% of variation. Non-targeting control 
groups only are shown. Lipid concentrations were normalised and auto-scaled prior to analysis, 




Figure 7.14 Hypoxia significantly altered levels of certain ether lipids. (A) Heat map showing 
differential lipid profiles in hypoxia and normoxia (siNTC); (B) Significantly altered lipids in the 
dataset (log2FC > 1.5, p < 0.05). PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, 





7.2.5 AGPS knockdown selectively decreases ether lipid species 
in hypoxia 
Principal component analysis of all tested groups shows the distribution of 
expression changes. The NTC condition in hypoxia is distant from other groups, 
but an outlier replicate (hypoxia replicate #2) maintains a connection with them 
(Figure 7.15). Knockdown of AGPS in hypoxia decreases ether lipid production in 
the Liv7k cell line (Figure 7.16A). Decreases were observed in the levels of 
ether lipids upon pooled knockdown of the gene in hypoxia (Figure 7.16B). 
Three ether lipids were significantly downregulated: PE(160p/203), 
PE(160p/223), PE(181p/225). 
 
Figure 7.15 PCA plot showing distribution of correlations between groups. The 
Hyp_AGPS_N group has an outlying data point (red asterisk), which affects the significance of 





Figure 7.16 Heat map and hierarchical clustering of ether lipid metabolites upon knockdown 
of AGPS in hypoxia and normoxia. (A) Expression of lipid metabolites in Liv7k cells in normoxia 
and hypoxia, after transfection with four unique AGPS siRNAs, compared to non-targeting control 
siRNA (n=3). (B) Significant changes in levels of ether lipid metabolites were assessed by unpaired 
t-test upon AGPS knockdown in hypoxia (FClog2 < 1.5, p < 0.05). PE, phosphatidylethanolamine; 








Hypoxia is a critical modulator of gene expression in solid tumour cells and 
promotes a resistant phenotype associated with reduced survival[250]. However, 
the mechanism of hypoxic tumour progression is not fully understood. The 
extent of hypoxia fluctuates throughout the tumour mass, giving rise to a 
heterogeneous population of cells with varying physiological 
characteristics[516]. Nutrient and oxygen stress leads to the activation of a 
hypoxic transcriptome, which stimulates a network of signalling pathways 
involved in cell growth and survival. This hostile environment also necessitates 
changes to cellular metabolism to utilise limited resources more efficiently[517]. 
Whole genome siRNA screening was combined with RNA sequencing of patient-
derived oral SCC cell lines to identify genes that are equally essential for cell 
growth and viability in hypoxia and normoxia. As a result, lipid metabolism 
pathways pertaining to fatty acid/triglyceride metabolism and ether lipid 
synthesis were selected for follow up. 
SREBP-mediated fatty acid metabolism was identified as a selectively essential 
process in hypoxic conditions. Activation of SREBP1 has been also shown to 
promote survival through an EGFR-AKT signalling axis in glioblastoma, which, like 
HNSCC exhibits a high percentage of EGFR amplification[518, 519]. It has 
previously been shown that loss of SREBP activity leads to growth inhibition in 
cancer cells by preventing SCD1-mediated fatty acid desaturation[520]. SCD1 
was identified in the siRNA screen as being upregulated in hypoxia (Figure 7.3) 
and knockdown of the gene led to a significant inhibition of growth in oral SCC 
cell lines (Figure 7.6). However, in validation experiments, no difference in 
growth inhibition was observed between normoxic and hypoxic conditions. 
Further investigation is merited to confirm the decreased effect of SCD1 
knockdown in OKG4 keratinocyte cell line, in order to see if tumour and normal 
cells rely on the activity of the enzyme to different extents. 
MGLL and DGAT2, which control the catabolism and anabolism of triglycerides to 
fatty acids, respectively, were identified as selectively essential for cell viability 
in the siRNA screen (p < 0.01). However, this differential could not be 
reproduced in validation experiments. The enzymes encoded by these genes 
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catalyse the breakdown and build-up of triglyceride molecules into neutral lipid 
droplets, respectively (Figure 1.8). Despite the inconsistency of results between 
hypoxia and normoxia, the effect on growth inhibition pointed toward the 
importance of dynamic lipid storage for oral SCC growth and survival. To this 
end, the abundance of lipid droplets was measured in response to gene 
knockdown in hypoxia. This revealed a build-up of lipid droplets in MGLL 
knockdown cells, confirming its role in the breakdown of triglyceride molecules 
to free fatty acids. In contrast, silencing of DGAT2 led to a reduction in lipid 
droplet number. The average number of lipid droplets per cell was similar in 
normoxic and hypoxic conditions (data not shown). However, upon silencing of 
MGLL in the Liv7k cell line, a greater increase in the number of lipid droplets 
was observed in the normoxic condition, suggesting that under hypoxic 
conditions, other enzymes may have a more active role in the breakdown of 
triglycerides. Alternatively, it may suggest that under hypoxia, DGAT2 does not 
act to generate triglycerides as efficiently. Cells with knockdown of LIPE (which 
cooperates with MGLL to hydrolyse triglyceride stores) displayed a similar 
change in lipid droplet levels. 
Tumours favour de novo lipid synthesis and it is well documented that hypoxia 
leads to triglyceride accumulation in cancer cells[521]. However, in this study, 
similar levels of LDs were observed under both oxygen conditions. It is possible 
that this is a result of using serum-free media, as it has been shown that lipid 
droplet accumulation in hypoxia is mainly due to fatty acid uptake from 
serum[328]. Bensaad et al. reported that lipid droplet accumulation was due to 
induction of the membrane-associated protein adipophilin (PLIN2) [328] in 
contrast to the SREBP mechanism reported in other cancer models[522]. 
However, PLIN2 gene expression was barely detectable in RNA sequencing of the 
Liv7k cell line in either oxygen condition (data not shown). The size of lipids 
droplets was not analysed in this study, but could perhaps shed more light on the 
impact of hypoxia on lipid storage. 
The greater impact of MGLL knockdown on lipid droplet number in normoxia was 
also unexpected, given that the gene was upregulated (albeit not significantly) 
in hypoxia. In addition, treatment of Liv7k cells with the MGLL inhibitor, JZL-
184, resulted in ~30% growth inhibition in normoxia but had no effect in hypoxia 
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(data not shown). The function of MGLL extends beyond that of lipid 
metabolism - in addition to its role in lipid mobilisation, MGLL is the major 
enzyme responsible for the hydrolysis of 2-arachidonoylglycerol (2-AG), an 
endogenous ligand of the endocannabinoid system[523]. This system is involved 
in a number of physiological responses, including pain, appetite, mood and 
memory[524]. The product of 2-AG hydrolysis, arachidonic acid, is the precursor 
molecule for eicosanoid biosynthesis, which act to promote inflammation (see 
also chapter 8)[525]. Blockage of MGLL reduces the available pool of 
arachidonic acid, thus diminishing the damaging inflammatory response that 
occurs in hepatic ischemia reperfusion (I/R) injury[526]. The pleiotropic actions 
of MGLL may explain the inconsistencies observed in response to its knockdown 
in this project. 
On the other hand, PNPLA2 (which encodes adipose triglyceride lipase, 
ATGL[527]) was not identified as selectively essential in hypoxia in the siRNA 
screen but caused greater growth inhibition in follow up experiments (Figure 
7.6). Moreover, the gene was ~6-fold upregulated in hypoxia and siRNA-
mediated knockdown led to a build-up of lipid droplets in hypoxia in Liv7k cells 
(Figure 7.7). The efficacy of a small molecule ATGL inhibitor, atglistatin, was 
tested in high and low oxygen, but failed to result in loss of viability in either 
condition at concentrations up to 10µM (Liv7k cells, data not shown). Increased 
ATGL activity has been observed in obese breast cancer patients[528] and has 
been implicated in cancer-associated cachexia[500]. Moreover, high ATGL 
expression led to increased rates of tumour stromal proliferation in pancreatic 
ductal adenocarcinoma[498], whereas inhibition of the protein was shown to 
attenuate the growth of lung cancer cells[497]. 
In addition to genes involved in fatty acid and triglyceride metabolism, a subset 
of genes involved in the synthesis of ether lipids was identified as essential in 
oral cells. The finding here reflects that of another study which showed hypoxia 
increasing levels of ether phosphatidylethanolamines (ePEs) in a leukaemia cell 
line, independently of HIF-1α[529]. Ether lipids constitute ~15-20% of 
phospholipids in cell membranes[504]. 
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Plasmalogens are a lesser-studied species of phospholipid which contain a cis 
double bond adjacent to this ether-linked alkyl chain at the first carbon of 
glycerol[530]. This “vinyl-ether” linkage renders plasmalogens uniquely sensitive 
to reactive oxygen species and as such, they act as effective scavengers of 
ROS[531]. Indeed, plasmalogens have repeatedly been shown to act as 
endogenous antioxidants in mammalian cells[532, 533]. Accordingly, 
plasmalogens have been shown to protect pulmonary artery endothelial cells 
from mitochondrial-derived ROS generated in the initial period of hypoxia, as 
cells adjust their rate of respiration[534]. 
TCGA analysis revealed upregulation of genes involved in ether lipid synthesis in 
~5-10% of HNSCC patients. The rate-limited step of ether lipid biosynthesis is 
catalysed by alkylglyceronephosphate synthase (AGPS), which was recently 
shown to be upregulated in aggressive human cancer and drive an oncogenic 
lipid-signalling network[268]. Moreover, small molecule inhibition of the protein 
impaired cancer migration and invasion[535].  
At the time of writing, a direct role of AGPS in hypoxia had not been studied. In 
this project, RNA sequencing of Liv7k cells revealed a slight downregulation of 
all four ether-lipid synthesizing genes (AGPS, FAR1, FAR2 and GNPAT) in hypoxia 
(data not shown). This project was discontinued after a failure to reproduce the 
hypoxia differential observed in the siRNA screen upon AGPS knockdown (Figure 
7.10), despite showing an efficient reduction of protein expression (Figure 
7.11).  
A direct assessment of the role of AGPS in oral SCC came from the measurement 
of ether lipids upon gene knockdown. As shown in Figure 7.14, hypoxia 
significantly altered ether lipid/plasmalogen levels in Liv7k cells. Knockdown of 
AGPS appeared to reduce ether lipids in the hypoxic condition; however, an 
outlier in the NTC condition meant that only three phosphatidyl ethanolamine-
plasmalogen (PEp) species were significantly downregulated according to 
unpaired t-test (p < 0.05). Further work is required to determine the functional 
impact of AGPS-induced ether lipid reduction in an oral cancer setting. CRIPSR 
knockout cell lines have been generated, but a phenotypic assessment has yet to 
184 
 
be completed. Until then, it is difficult to speculate on a role for the gene in 
oral SCC progression or in fact, what the downstream lipids do. 
The absence of clinically applicable methods for measuring tumour oxygenation 
has fuelled the development of hypoxic gene signatures, with the potential to 
predict therapeutic response[536], and the ability to accurately reproduce 
tumour hypoxia in vivo using xenograft models has facilitated this goal[537]. This 
study sought to improve on gene expression studies by identifying genes, which 
are essential for viability in hypoxic conditions. However, the differential effect 
observed between hypoxia and normoxia in the siRNA screen could not be 
reproduced in small scale validation studies. A follow up siRNA screen targeting 
the ~10% of genes which were selectively essential in the hypoxic condition has 
since been completed. This second screen used On-Target Plus siRNA instead of 
the siGENOME set used in the primary screen, which should provide a greater 
knockdown specificity and thus a more robust result. It will be interesting to 
compare the two and identify additional targets to investigate. 
Lipid metabolism is a complex system that is highly dependent on cellular 
context and the surrounding microenvironment. Blocking individual processes in 
a 2D setting is of questionable relevance when it comes to addressing the 
situation in vivo[538]. To this end, the development of high-throughput 3D 
screening methods may help bridge the gap between in vitro and in vivo success. 
Moreover, different tools to tease out the effect of individual lipids in cells and 
the phenotypic effects resulting from fluctuations in lipid biosynthesis would 




Chapter 8 Results – In vivo significance of 
cysteinyl leukotrienes in oral SCC 
8.1 Introduction 
The tumour microenvironment is a dynamic structure that influences tumour cell 
survival and mobility. It consists of a variety of cell types, including those of the 
immune system, tumour vasculature, and the extracellular matrix[539]. 
Cysteinyl leukotrienes are a class of inflammatory mediators, which are 
produced mainly by white blood cells in response to inflammatory stimuli[540]. 
They exert their effect through two G-coupled protein receptors, CysLT1R and 
CysLT2R. The former is the main receptor subtype in the inflammatory response 
and is expressed on the surface of nasal mucosa interstitial cells, endothelial 
and smooth muscle cells, and a variety of inflammatory cells[541-543]. Although 
the receptor is not normally expressed on the surface of epithelial cells (such as 
those in the oral cavity), some epithelial cells are capable of producing CysLT 
ligands[544]. Moreover, overexpression of CysLT1R has been detected in various 
tumours[378, 379]. 
Leukotrienes are a class of biologically active lipids called eicosanoids, which 
have previously been implicated in tumour progression. The leukotriene pathway 
branches off at LTRA4 to generate either LTB4 or LTC4, via LTRA4 hydrolase and 
LTC4 synthase, respectively (Figure 8.1). LTB4 which is elevated in colorectal 
and prostate cancer[545, 546], stimulates a distinct pair of receptors and is not 
discussed here. LTC4 is exported to the extracellular environment and further 
metabolised to LTD4 and LTE4[354]. LTD4 binds the CysLT1R with the highest 
affinity, making it the most potent stimulator of receptor activity[368]. In the 
intestine, LTD4 has been shown to promote proliferation, survival and migration 
through PKC-Raf-Erk, GSK3β-βcatenin and PI3K-Akt-Rac pathways, 
respectively[362-364]. Moreover, CysLT1R is overexpressed in colorectal cancer 




Figure 8.1 Overview of cysteinyl leukotriene metabolism. CysLT1R has been shown to activate 
downstream pathways including PI3K[362], ERK[363] and GSK3β[364]. Inhibitors act on various 
points in this pathway (purple boxes). LTRA4, C4, D4, leukotriene A4, C4, D4; FLAP, 5-
lipoxygenase-activating protein; 5-LO, 5-lipoxygenase; 5-HPETE, 5-hydroperoxyeicosatetraenoic 
acid; GSK3β, glycogen synthase kinase 3 beta; PI3K, phosphoinositide 3-kinase; PKCα, protein 
kinase C α; ERK, extracellular signal-related kinase; MEK, mitogen-activated protein kinase kinase; 
cPLA2, cytosolic phospholipase A2. 
 
Non-steroidal anti-inflammatory drugs are significantly associated with a 
reduced risk of metastasis development[547]. Montelukast, zafirlukast and 
pranlukast belong to a family of NSAIDs that selectively antagonise CysLT1R, and 
evidence suggests they may be effective in a cancer setting[548]. Zafirlukast was 
found to slow the progression of lung adenomas induced by treatment with vinyl 
carbamate[549]. Similarly, montelukast reduced tumour growth in a colorectal 
xenograft model by slowing proliferation and inducing apoptosis[394]. This 
chapter presents data from experiments designed to assess the effect of 
montelukast in aggressive oral cancer cell lines. This project was performed in 
collaboration with Karen Blyth’s lab (CRUK Beatson Institute) and in vivo 
experiments were carried out by Susan Mason.  
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8.2 Cysteinyl leukotriene pathway inhibitors inhibit 
growth of oral SCC cells in a drug screen 
To complement the results of the siRNA screen, Liv7k cells were treated with 
1,351 FDA-approved drugs for cancer and non-cancer indications. This revealed a 
striking dependence on a subset of genes involved in the cysteinyl leukotriene 
inflammatory pathway (Figure 8.2). Given the resistance often seen in hypoxic 
tumours in response to drug treatment, a 90% growth inhibition minimum was 
set in both normoxic and hypoxic conditions, in order to ensure selection of 
drugs effective in cells in a hypoxic environment. 
 
Figure 8.2 Scatter plot showing percentage growth inhibition of the Liv7k cell line in a drug-
repurposing screen. 1,351 compounds were added to Liv7k cells at a fixed concentration of 10µM 
for 72h. Results are normalised to DMSO control and represent the median of three screening 
replicates in normoxic and hypoxic conditions. Dashed lines represent 0% growth inhibition cut-off 
in normoxia and hypoxia. Circle size and colour is indicative of significance according to unpaired t 




Three compounds (montelukast, zafirlukast and MK-886) used for the treatment 
of asthma and inflammatory conditions, caused >90% growth inhibition of Liv7k 
cells, while having little or no effect on non-oral cancer cell lines previously 
tested within the BICR screening facility (Figure 8.3). All three target 
components of the CysLT pathway: MK-886 is an inhibitor of 5-lipoxygenase-
activating protein (FLAP), while montelukast and zafirlukast are CysLT1R 
antagonists (Figure 8.1). 
 
Figure 8.3 Bar chart showing percentage growth inhibition in a panel of cancer cell lines 
treated with CysLT1R antagonists. A fixed concentration of at 10µM was used and the 
experiment end point was 72h post drug-addition. Results are normalised to DMSO control and 

















































































8.3 Serum-containing media protects cells from 
leukotriene pathway inhibition 
By testing a panel of oral cell lines, it was found that serum-containing media 
negated the growth inhibition caused by leukotriene receptor antagonists 
(LTRAs) and an upstream FLAP inhibitor. Figure 8.4A shows the effect of LTRAs 
in cell lines grown in keratinocyte serum-free media, but testing of seven 
additional oral cancer cell lines grown in serum-containing media showed no 
effect up to 10μM (not shown). However, it is unclear how serum provides a 
survival benefit to cells treated with LTRAs. To validate this effect, Liv7k cells 
were adapted to grow in DMEM containing 10% serum and treated with 
montelukast (Figure 8.4B). The growth inhibition observed in cells grown in 
serum-free media was lost. Comparable IC50 values were observed for two 
immortalised keratinocyte cell lines (OKF4, OKG4) in this analysis. 
  Pan-kinase FLAP CysLT1R 

















Liv7k 0.0044 0.7129 0.7506 0.4928 
Liv37k 0.0142 0.7954 0.3608 1.0813 
KR19 0.0070 0.6617 0.5324 0.8695 
OKG4 0.0032 0.6333 0.8644 0.3345 
OKF4 0.0020 0.5203 0.6700 0.4884 
scc9 0.0089 0.6771 0.8431 0.9784 
 
 
Figure 8.4 Percentage growth inhibition (IC50 values) of leukotriene pathway antagonists in a 
series of oral cell lines. (A) IC50 values (μM) in a series of oral cell lines, grown in keratinocyte 
serum-free media. OKF4 and OKG4 are immortalised keratinocytes. MK 886, montelukast and 
zafirlukast were tested. (B) Montelukast dose-response curve in the Liv7k cell line with a 
concentration range of 0.005-10µM. Results are normalised to DMSO control and represent the 





8.4 Montelukast is a selective antagonist of CysLT1R 
Despite the lack of effect in serum-containing media, it was reasoned that 
keratinocyte serum free media contained growth factors at more physiologically 
relevant concentrations than that of serum containing media. STITCH ‘Search 
Tool for InteracTions of CHemicals’[550] reveals known interactors of 
montelukast (Figure 8.5). The strongest interaction occurs between montelukast 
and CysLT1R, the primary binding partner of LTD4. Confidence scores are 
presented in the table, with interacting proteins ranked from highest to lowest 
probability. Montelukast binds to CysLT1R with an IC50 of less than 5nM in human 
HEK-293 cells stably expressing the receptor[551]. 
 
Figure 8.5 Molecular structure of montelukast and its known interactions. Thick lines 
represent stronger associations, which are based on the probability of the interaction being non-
random. Protein-protein interactions are shown in grey, chemical-protein interactions in green and 
interactions between chemicals in red. Small nodes depict proteins of unknown 3D structure; large 
nodes depict proteins where some 3D structure is known. Table shows association probability 




8.5 Knockdown of CysLT1R causes growth inhibition in 
Liv7k cell line 
The efficacy of leukotriene inhibitors is paralleled by the knockdown of CysLT1R, 
which results in > 60% growth inhibition in both normoxic and hypoxic conditions 
in Liv7k cells (Figure 8.6). Screening data also shows a high percentage growth 
inhibition in response to knockdown of genes that are predicted to interact with 
montelukast (Figure 8.5): ALOX5, IL13, CYSLTR2R, LTB4R and LTB4R2. This data 
validated the importance of leukotriene signalling pathways, centred around 
CysLT1R, in oral SCC.
 
Figure 8.6 Bar chart showing percentage growth inhibition upon knockdown of montelukast 
target genes in the Liv7k cell line. Results are normalised to non-targeting control and represent 





























8.6 Montelukast induces cell death in the Liv7k cell line 
To determine if montelukast was cytostatic or cytotoxic, Liv7k cells were 
treated with a range of montelukast concentrations in the presence of Sytox 
Green™ (Thermo Fisher). Higher concentrations (> 1µM) of montelukast resulted 
in cell death after 16 hours, while DMSO control cells remained viable (Figure 
8.7). Lower concentrations of montelukast (≤ 1µM) did not appear to induce cell 
death, but still reduced total cell number.  
 
 
Figure 8.7 Liv7k cells were treated for 16 h with montelukast (0.75-10μM). (A) Cell death was 
quantified using an Incucyte Zoom imager, measuring SYTOX Green uptake. Green cell count was 
normalised to total confluence and is presented relative to DMSO negative control. Results are 
mean ± SD of three experiments. (B) Representative phase and fluorescent images taken of 10µM 







































8.7 Preliminary data shows montelukast slows growth in 
a 3D culture model 
The effect of montelukast was assessed in a 3D spheroid model as a proof of 
principle experiment for in vivo efficacy. 3D culturing of cells creates a more 
physiologically relevant environment in which additional factors such as tumour 
heterogeneity, hypoxia, cell-cell interaction and extracellular matrix 
remodelling are recapitulated. Results from the single experiment performed 
showed a slight decrease in the rate of spheroid growth in cells treated with 
montelukast at 1 and 10µM (Figure 8.8). 
 
Figure 8.8 Rate of spheroid growth in a 3D spheroid model (preliminary data). Liv7k cells 
were cultured into 3D spheroids and treated with montelukast at 1µM and 10µM. 1µM 
staurosporine and 0.1% DMSO were used as positive and negative controls, respectively. Results 































p > 0.05 
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8.8 Montelukast tends toward reduced tumour volume in 
Liv7k xenograft model 
Given the success of montelukast in other xenograft models and the results of in 
vitro experiments in this project, its efficacy in vivo was assessed. Prior to drug 
treatment, the ability of Liv7k cells to form tumours in mice was evaluated, and 
showed that tumours formed in 5/5 mice injected (data not shown). Following 
this, twenty NOD/SCID mice were subcutaneously injected with 5x106 Liv7k 
cells. Mice were split into treatment or control groups by cage assignment (n=10 
per group). Montelukast (5 mg/kg) or vehicle control were administered daily by 
oral gavage once tumours were palpable and had reached a predetermined size 
(5mm x 5mm). Thereafter, measurements were taken using calipers three times 
weekly until tumour endpoint had been reached, as per licence conditions 
(15mm x 15mm). Results show that average tumour volume in the control group 
began to separate from the treated group as the experiment progressed. An 
unpaired t-test revealed statistical significance at day 61 post-treatment; 
however, fewer control mice were alive at this point having reached clinical 
endpoint before this time (Figure 8.9). A breakdown of measured tumour 
volumes for each mouse is shown in Figure 8.10. 
 
Figure 8.9 Tumour size as a percentage of start volume for montelukast (n=10) and vehicle 
control groups (n=10). Average tumour volume was normalised to start volume and is presented 
as the mean ± SD of each treatment group. Significance was assessed by unpaired t-test at each 
time point. At day 61, five treated mice were being compared to three control mice. The lower table 
shows number of mice alive at each time point.
 
Figure 8.10 Tumour size as a percentage of start volume for individual montelukast and vehicle control mice. 0 days is the start of treatment at which time all 
mice had palpable tumours.  Vehicle (blue) and montelukast treated (red) cohorts are shown. Mice still alive at 100 days are labelled with unique IDs.
8.9 Montelukast does not significantly delay time to 
tumour endpoint 
Mice were taken when tumour size reached 15mm in any direction (as per 
licence conditions) and survival curves were plotted. However, treatment with 
montelukast did not significantly delay time to tumour endpoint (Figure 8.11). 
Moreover, the survival curves crossed, indicating that the hazard ratio was not 
proportional in the two groups. Three mice in the montelukast group survived 
beyond 100 days, at which point treatment was stopped (# 2, #6 and #7, see 
Figure 8.10). The tumour in one of these mice had regressed by this point (#6, 
while the other two tumours (#2 and #7) gradually increased in size after 
treatment cessation, suggesting that treatment had constrained tumour growth. 
 
Figure 8.11 Survival curve of montelukast (n=10) versus vehicle control (n=10) mice, up to 
100 days since the start of treatment. The difference in survival is not statistically significant, 





8.10 Montelukast does not affect the proliferation of Liv7k 
xenograft cells 
Xenograft sections were stained with Ki67 to determine if montelukast 
treatment had an effect on proliferation. Human lymphocyte antigen staining 
was used to confirm the presence of human cells (data not shown). Halo® 
software (Indica Labs) was used to quantify staining intensity of Ki67 in human 
squamous epithelial cells only (Figure 8.12). However, there was no significant 
difference in staining intensity between the two groups (unpaired t-test, p > 
0.05). The intensity of phospho AKT, phospho MTOR, phospho ERK and total ERK 
was also quantified but no significant differences were observed (data not 
shown).  
Given that mice were taken after tumours reached end point, it is perhaps not 
surprising that there was little difference in proliferation. A cross sectional study 
measuring markers of proliferation and survival at a number of earlier time 
points, when tumours are actively expanding, may yield a more significant 
difference in staining intensity. LTD4 is the most potent activator of CysLT1R but 
free LTD4 is rapidly metabolised into LTE4, which is rapidly eliminated from 
blood plasma (plasma half-life ~7 minutes)[552]. However, LTE4 can be readily 
detected in urine at a concentration of between 10-60 pg/ml in humans (higher 
in asthma sufferers)[552]. The level of LTE4 was measured in mouse urine but no 
meaningful difference was found between control and treated mice, owing to 






Figure 8.12 Ki67 histological staining. (A) Scatter plot showing percentage Ki67 positive cells in 
Liv7k xenograft sections. The differences in the treated (n=6) and control (n=10) groups was shown 
not to be statistically significant when assessed by unpaired t-test. (B) Representative images of 






8.11 Montelukast treatment did not significantly alter the 
innate immune response to tumour cells 
Given that montelukast is an anti-inflammatory drug, it was hypothesized that it 
may reduce the inflammatory immune response in treated mice. Neutrophils are 
one of the first responders to inflammatory insult, migrating through dilated 
blood vessels to phagocytose foreign cells and release pro-inflammatory 
cytokines[553]. Similarly, monocytes flood to the site of inflammation and 
differentiate into mature macrophages. The levels of neutrophils (NIMP) and 
macrophages (F4/80) were determined histologically in Liv7k xenograft sections, 
but revealed no obvious difference in the intensity of staining between the 





Figure 8.13 H&E, macrophage (F4/80) and neutrophil (NIMP) histological staining. 
Representative images of stained sections are shown. Ten control tumours and six treated tumours 





In this chapter, the role of cysteinyl leukotrienes in oral SCC has been addressed 
in a series of in vitro and in vivo experiments. Treatment with the FLAP 
inhibitor, MK-886 and two leukotriene receptor antagonists (LTRAs), montelukast 
and zafirlukast, resulted in near-complete growth inhibition of a patient-derived 
oral SCC cell line in a drug-repurposing screen. In terms of growth inhibition in 
normoxia, the compounds ranked 2nd, 10th and 41st, respectively. LTRAs are 
approved for the maintenance treatment of asthma, where they block the action 
of CysLT1R, thus relaxing airway constriction and reduce inflammation and 
mucus build-up in the lungs[554]. Encouragingly, use of LTRAs was shown to 
decrease cancer risk in a meta-analysis of ~25,000 adults with asthma diagnosed 
between 2001 and 2011[555]. 
Moreover, the effect appeared to be specific to the oral cancer cell line, as no 
effect of montelukast was shown in previous drug screens, carried out on cells 
lines derived from other cancer types by the screening facility. It was later 
discovered that the effect was dependent on the presence of foetal bovine 
serum (FBS) in the culture media, as was the case for the eight breast cancer 
lines and one glioblastoma line screened previously. Many cell lines require FBS 
supplementation for proper growth and proliferation. FBS contains a multitude 
of growth factors, transport proteins, essential amino acids and other small 
molecules such as sugars and lipids[556]. 
A possible explanation for this unusual finding is that LTRAs are bound by serum 
proteins such as human serum albumin (HSA) and alpha-1 acid glycoprotein 
(AGP). In humans, montelukast is rapidly absorbed following administration, and 
has a half-life of 2.7-5.5 hours[557]. Importantly, montelukast has a highly 
lipophilic structure that causes 99% of the molecule to become bound to plasma 
proteins, leaving a limited unbound fraction to have a biological effect[558]. A 
drug-drug interaction study found that montelukast possessed the strongest AGP 
binding affinity in a series of cystic fibrosis drugs[559]. Another possibility is that 
FBS supplementation maintains the activity of oncogenic signalling pathways in 
the absence of CysLT1R activation, through the stimulation of other receptors 
such as IGF1R[560]. However, it is reasonable to assume that keratinocyte serum 
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free media contains more physiologically relevant concentrations of growth 
factors and nutrients than serum-containing media. 
Previous in vitro data supports the potential anti-cancer role of montelukast. 
The major mediator of leukotriene action, LTD4, has been shown to increase cell 
proliferation and survival in intestinal epithelial cells[383]. In addition, LTD4 
significantly reduced apoptosis by preventing the activation of caspase-8[561]. 
Addition of LTD4 to intestinal epithelial cells activated PI3K signalling and 
increased translocation of β-catenin to the nucleus[396]. 
To date, three in vivo studies have shown efficacy of LTRAs as cancer 
therapeutics[393, 394, 549], however their potential role in oral SCC had yet to 
be evaluated. In this study, daily treatment of mice with 5 mg/kg montelukast 
did not significantly reduce tumour volume compared to the control group; 
however, there was a trend for smaller tumour size. No significant difference in 
time to tumour endpoint was observed; albeit a tantalising tail of responders 
was seen in the survival graph (Figure 8.11). In light of these results, it was not 
unexpected to find no significant difference in Ki67 staining intensity between 
the two groups. This is in contrast to findings by Savari et al., who found that 
average tumour weight was significantly reduced in the montelukast group in a 
colorectal xenograft model[394].  
However, there were some important differences between the two studies. This 
study used immunocompromised NOD/SCID mice, while Savari’s study was 
performed on athymic balb/c nude mice in which HCT-116 colorectal cells were 
pre-treated with montelukast prior to injection. In addition, montelukast was 
given by intraperitoneal injection in their study. Reassuringly, no significant 
reduction in Ki67 positive cells was observed in Savari’s study, which suggests 
that the drug may be exerting its anti-tumour effects through other pathways 
(cell death was observed in Figure 8.7). To this end, the authors showed 
montelukast treatment led to significantly increased expression of p21WAF/Cip1 
and decreased levels of VEGF in xenograft samples, indicating roles in cell cycle 
arrest and suppression of angiogenesis. Additional studies performed by the 
group showed montelukast treatment promoted apoptosis through cleavage of 
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caspase-3. The preliminary results in our study have not merited investigation of 
these pathways, although cross-sectional studies in the future may be pursued. 
Future in vivo experiments should have increased numbers of mice to provide 
greater confidence in the results. Moreover, a more thorough characterisation of 
cell lines used in these experiments would likely elucidate the differential 
response to montelukast. This would allow for the categorisation into high and 
low CysLT1R-expressing cell lines, which could be compared in further studies. 
Given that montelukast induced cell death in Liv7k cells, the mode of cell death 
needs to be determined. Cell cycle analysis by flow cytometry will reveal the 
effect of montelukast on cell growth, while western blotting for cleaved caspase 
3 and cleaved PARP will determine if montelukast induces apoptosis in oral SCC 
cell lines. It was hypothesized that blocking the CysLT1R would lead to a build-
up of leukotrienes in the extracellular space. Given that excess leukotriene 
metabolites are excreted in the urine, the concentration of these metabolites 
was measured in treated and control mice by ELISA. However, the results of this 
experiment were extremely variable. Another approach would have been to 
measure the concentration of excreted drug in the urine to provide an idea of its 
bioavailability in this in vivo model. 
In summary, although previous evidence has shown that LTRAs such as 
montelukast can prevent cancer progression, no significant reduction in tumour 
growth was observed in this study, albeit this may be due to limitations in the 
current study design. It is clear from in vitro data that inhibition of CysLT1R is 
effective at inhibiting the growth of oral SCC cells, but this did not translate into 
success in vivo. It is likely that tumour heterogeneity plays an important role in 
the efficacy of leukotriene inhibitors. The patient-derived Liv7k cell line was 
used in these experiments at a low passage, and possibly more heterogeneous 
than the established HCT-116 cell line used in the Savari study. Moreover, the 
basal expression of CYSTL1R in the primary tumour may be predictive of LTRA 
response. High expression of the parallel COX pathway is also predictive of a 
poor prognosis, and may negate the benefit of LTRAs. Therefore, dual inhibition 
of the COX and LOX pathways would be a logical avenue of investigation in 
further studies.  
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Chapter 9 Concluding Remarks 
For many years, the standard treatment options for patients diagnosed with oral 
cancer have been surgery and radio-therapy, and it was only in 2006 that the 
FDA approved chemotherapeutic agents for use in treating HNSCC.  The first of 
these, cetuximab, targets the EGF Receptor, which is expressed in >90% of 
HNSCC tumours[562]. However, recent clinical trials have shown disappointing 
results, and failure to prolong patient survival[563]. The failure of the 
humanised monoclonal antibody to significantly prolong patient survival is 
primarily due to the heterogeneity of the disease, which contributes to intrinsic 
and acquired resistance[564]. While cetuximab undoubtedly has a place in 
HNSCC treatment, it does not provide benefit to a substantial proportion of the 
patient population[565], and indeed, despite the availability of 
chemotherapeutics approved for HNSCC, only one in two patients diagnosed with 
advanced oral cancer in the UK survive for five years after diagnosis[2]. 
Resistance to currently available therapeutics will continue to contribute to high 
rates of recurrence and metastases, necessitating the pursuit of novel 
therapeutic strategies which are based on the identification of driver genes with 
key roles in HNSCC progression. 
Recent advances in the genomic characterisation of cancer have allowed 
tumours to be classified based on molecular subtype[35], which in turn has 
opened the door to personalised treatment strategies with maximal patient 
benefit. This body of work sought to identify novel driver genes in oral SCC, 
which may have potential clinical relevance. In doing so, three major themes 
emerged: (1) the clinical relevance of an amplicon found on chromosome three; 
(2) the role of hypoxia in lipid metabolism; and (3) tumour promoting 
inflammation.  
Analysis of a commonly amplified region of chromosome 3 led to the selection of 
two genes for further investigation, IGF2BP2 and PSMD2, both of which displayed 
amplified copy number, overexpression at mRNA level and significant correlation 
with HNSCC patient survival, in addition to being required for Liv7k cell line 
viability. Potential mechanisms of oncogenic progression in oral SCC were 
explored based on putative roles in the literature. IGF2BP2 was hypothesized to 
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contribute to a more aggressive phenotype through its modulation of the insulin 
signalling pathway. However, silencing of IGF2BP2 did not lead to significant 
abrogation of IGF1R phosphorylation or downstream signalling nodes, such as 
AKT and ERK. Moreover, knockdown of IGF2BP2 did not significantly impair 
proliferation, migration, or invasion, in oral SCC cell lines. This does not 
necessarily rule out a role for the gene in HNSCC/oral cancer, but a better 
understanding of its targets in HNSCC cancer cells, as are expected imminently 
from the results of an RNA immunoprecipitation experiment, will help guide 
further investigations of this molecule and the phenotypic effects of 
amplification and over expression.  
The second gene investigated was PSMD2, which encodes a subunit of the 
proteasome. PSMD2 was found to be over-expressed in >30% of HNSCC tumours, 
with over-expression correlated with reduced overall survival of patients.   
Silencing of the gene resulted in ~40% growth inhibition in the Liv7k cell line. 
The fact that PSMD2 silencing led to the selective induction of p21 in lung 
adenocarcinoma cell lines (but not human dermal fibroblasts) suggested that 
modulation of individual proteasomal subunits could lower the apoptotic 
threshold in cancer cells[426]. However, this did not appear to be the case for 
oral cancer, as equal or greater growth inhibition was observed in response to 
PSMD2 knockdown in immortalised keratinocyte cell lines.  
PSMD6, another proteasomal subunit, was found to be down-regulated in ~6% of 
tumours in the TCGA HNSCC dataset, leading to the hypothesis that the affected 
cancer cells may exhibit a greater dependence on PSMD6 activity than diploid 
oral keratinocytes.  This was borne out by the silencing of the gene, which 
resulted in reduced growth inhibition in a keratinocyte cell line compared to two 
oral SCC cell lines. The resistance to PSMD6 silencing needs to be confirmed in a 
wider range of non-cancer cell lines in order to establish its selectivity in HNSCC. 
A number of proteasomal subunits were identified as being altered in these 
studies and others, giving credence to the use of proteasomal inhibitors in the 
treatment of HNSCC.  In vitro experiments have demonstrated that proteasomal 
inhibition is an effective method of killing HNSCC cells in vitro through the 
stimulation of apoptosis, inhibition of the NF-kB pathway and generation of 
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reactive oxygen species[423, 566, 567]. In clinical trials however, bortezomib 
(which targets the β5 subunit of the 20S proteolytic core), has resulted in high 
rates of resistance and toxicity[422]. Second-generation proteasomal inhibitors 
such as carfilzomib, which exhibit greater specificity than bortezomib, have 
been effective at overcoming resistance to proteasomal inhibitors in vitro and 
inhibiting the growth of HNSCC xenografts[568, 569]. However, the efficacy of 
these agents is limited by the fact that proteasomal inhibitors also stimulate 
survival signals in HNSCC cells[570, 571]. Bortezomib was demonstrated to 
antagonise the action of the EGFR inhibitor cetuximab in a phase I clinical trial, 
resulting in unexpected early progression of HNSCC tumours[572]. This highlights 
the need for a more targeted strategy to inhibit proteasomal activity with 
enhanced specificity and higher tolerability. 
A major aim of this project was to uncover novel processes through which 
hypoxia influences the progression of oral SCC. To this end, an oxygen 
differential was employed in both the siRNA screen and RNA sequencing 
experiments in order to select for genes which, when silenced, resulted in a 
greater percentage growth inhibition in hypoxia than normoxia. Tumour hypoxia 
is an important prognostic factor in HNSCC, and is associated with therapeutic 
resistance and reduced overall survival[47]. A hypoxic tumour microenvironment 
drives phenotypic diversity within the tumour and selects for cells that best 
adapt to nutrient stress[573]. This includes alterations in energy metabolism 
such as increased glycolysis, reduced oxidative phosphorylation and increased de 
novo fatty acid synthesis. In this study, pathway analysis carried out on genes 
upregulated and essential for survival in hypoxia identified a subset of genes 
involved in triglyceride metabolism. 
One of these genes, MGLL, had previously been shown to regulate a fatty acid 
network that promotes cancer pathogenesis[312]. Although the triglyceride 
hydrolysis aspect of MGLL action was confirmed in this study, the selective 
growth inhibition observed in our initial screen could not be reproduced in 
follow up experiments. The gene is involved in additional catalytic processes and 
has even been purported as a tumour suppressor gene in colorectal cancer[319]. 
The pleotropic roles of MGLL in different cancer types may have contributed to 
the inconsistencies observed upon its silencing, but more work is needed to 
207 
 
investigate its relevance in HNSCC. Knockdown of another gene responsible for 
triglyceride breakdown, PNPLA2, did show a hypoxia specific effect in follow up 
experiments, but treatment with a small molecule inhibitor of the protein did 
not result in a loss of viability in high or low oxygen. Analysis of data from a re-
screen carried out as part of this project with stricter statistical thresholds, and 
utilising a more specific set of siRNAs, may uncover targets with greater 
significance in hypoxia. 
Similarly, a subset of genes involved in the synthesis of a structural class of lipid 
known as ether lipids were initially found to be essential for viability in hypoxia, 
but this could not be validated upon further experimentation. AGPS, which 
catalyses the rate limiting step in this process, has previously been shown to fuel 
an aggressive phenotype ion cancer cells through its modulation of ether lipid 
signalling molecules[268]. This study found that silencing of AGPS in the Liv7k 
cell line resulted in a hypoxia-selective reduction of ether lipids, supporting the 
original hypothesis. This may suggest the AGPS is required in this condition to 
maintain the structural integrity of rapidly proliferating oral cancer cells. 
Although an outlying replicate affected the overall significance of the result, a 
small number of ether lipid species were altered upon knockdown of AGPS. It is 
possible that these lipids are involved in oncogenic signalling pathways in oral 
cancer, thus contributing to enhanced proliferation and survival. Additional work 
is required to determine if the gene can modulate oncogenic signalling networks 
in HNSCC and effect phenotypic change.  
Finally, a drug-repurposing experiment, carried out to complement the results of 
the siRNA screen, revealed a selective sensitivity of oral cells grown in serum-
free media to a family of leukotriene pathway antagonists. Leukotrienes are 
important pro-inflammatory mediators, which have been identified in a number 
of disease processes, including cancer[574]. Montelukast, an antagonist of the 
primary cysteinyl leukotriene receptor, CysLT1R, resulted in an IC50 of 670 nM in 
oral cancer cells, but showed no effect up to 10 µM in cell lines grown in serum-
containing media. Serum-free media likely recapitulates the limited nutrient 
environment available to tumour cells lacking adequate vasculature, making it 
more physiologically relevant. However, immortalised keratinocyte cells were 
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equally sensitive to montelukast treatment, indicating a process not specific to 
cancer cells is being targeted. 
Treatment of nude mice with montelukast did tend toward reduced tumour 
volume of Liv7k xenografts, but did not significantly delay time to tumour 
endpoint, although there was a tendency toward prolonged survival. Histological 
staining of xenograft sections revealed no decrease in proliferation as measured 
by Ki67 staining intensity, perhaps not unexpectedly given that tissues were only 
collected at end-point. Interestingly, one tumour did begin to grow slowly upon 
treatment cessation at 100 days, after remaining static while on treatment. 
Staining of these sections may shed some light on its apparent sensitivity to 
montelukast.  
In addition, treatment of cells within an extracellular matrix containing cancer-
associated fibroblasts may elicit a more realistic response to montelukast 
treatment, which better reproduces the cross-talk between oral SCC cells and 
the microenvironment, indicating that patient-derived xenografts, or xenografts 
with and without co-cultured fibroblasts may be required to better tease out the 
potential benefits of montelukast or similar cysteinyl leukotriene receptor 
inhibitors.  Similarly, performing cross-sectional studies, and taking animals at 
particular time points post treatment initiation may reveal differences in tumour 
dynamics, immune cell infiltration, and stromal response. 
Survival rates for patients with advanced HNSCC have not improved since the 
licensing of cisplatin as an antineoplastic agent in the late 1970s[575]. 
Cetuximab represented the first targeted therapeutic agent to be employed in 
the disease, and yet has failed to provide a survival benefit commensurate with 
the extent of EGFR expression in HNSCCs[576]. Equally as important as better 
therapeutic options are the development of biomarkers to predict disease 
behaviour and allow for the stratification of patients into personalised 
therapeutic regimes, because, at present, no such biomarker exists to stratify 
patients into likely effective treatment groups.  
The work described herein sought to combine both the comprehensive genomic 
characterization of cancer genomes available in publicly available datasets such 
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as the TCGA and ICGC, and the power of high-throughput screening, to identify 
potential novel therapeutic targets in HNSCC.  Furthermore, by utilising 
physiologically relevant criteria, such as differential efficacy between hypoxic 
and normoxic conditions, we hoped to generate a set of targets which could be 
used to benefit a substantial portion of the population diagnosed with HNSCC.  In 
summary, this study has provided an analysis of potential driver genes in oral 
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